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Abstract  
Type 2 diabetes (T2D) is a progressive chronic condition requiring timely 
treatment intensification to prevent/delay the development of long-term 
complications associated with prolonged hyperglycaemia. Despite the proven 
efficacy of insulin therapy in reducing hyperglycaemia (and international guidelines 
recommending early initiation), insulin uptake and intensification are commonly 
delayed in practice. Several barriers exist at the systemic and healthcare professional 
levels, while people with T2D may also be reluctant to intensify treatment.  
The aim of this thesis was to investigate attitudes to insulin therapy among 
adults with T2D, focusing on the constructs of ‘psychological insulin resistance’ 
(PIR) and ‘receptiveness’. This program of doctoral research was designed to 
generate new knowledge in relation to: a) the measurement of these constructs; b) the 
occurrence of, and factors associated with, PIR and receptiveness to insulin 
initiation; c) the demographic, clinical and psychological predictors of actual insulin 
uptake; and d) attitudes toward insulin post-initiation, perceptions of benefits and 
consequences of insulin, and attitudes to further treatment intensification.  
A mixed methods approach was taken, using data from three studies: 1) a 
national cross-sectional survey of adults with T2D, 2) a two-armed, 12-month, 
cluster randomised controlled trial (RCT) in a primary care setting, testing a new 
model of care designed to facilitate timely insulin initiation among adults with T2D 
for whom insulin is clinical indicated, 3) an exploratory qualitative interview study 
with adults with insulin-treated T2D. This thesis presents the findings of those 
studies in six empirical reports. 
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The Insulin Treatment Appraisal Scale (ITAS) is a widely used measure of 
insulin appraisals. Data from the national survey (Study 1a; paper 1) confirmed its 
psychometric properties in an Australian population, separately for insulin-treated 
and non-insulin-treated sub-samples. The scale was acceptable and psychometrically 
sound in both groups but the use of the subscale (ITAS Negative and Positive) scores 
is recommended in preference to the Total scale.  
Factors associated with ITAS Negative scores among adults with non-insulin-
treated T2D were examined (Study 1b; paper 2). Negative insulin appraisals were 
associated with the emotional burden of diabetes (diabetes-related distress) and 
concerns about current diabetes medications (i.e. oral hypoglycaemic agents). This 
suggests that identifying and addressing these issues may help to improve 
receptiveness to future treatment intensification.  
PIR/receptiveness has commonly been quantified as ‘hypothetical willingness’, 
or intention, to begin insulin – but the validity of this measure in predicting actual 
insulin uptake has never been tested. At baseline, 19% of RCT participants were 
‘very willing’ to begin insulin therapy, if recommended, and this was associated with 
higher socioeconomic status, less negative and more positive insulin appraisals 
(Study 2a; paper 3). Controlling for study arm allocation, greater intention and higher 
HbA1c independently predicted insulin initiation at 12 months (Study 2b; paper 4). 
Thus, interventions to promote timely insulin initiation should aim to reduce PIR and 
improve receptiveness among people with T2D. 
Change in negative, but not positive, insulin appraisals at 12 months was 
associated with insulin uptake among RCT participants, corroborating previous 
research. However, experience with insulin alone may not mitigate the negative 
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impact of insulin therapy universally. In the national survey, adults with insulin-
treated T2D reporting higher ITAS Negative scores were more likely to report worse 
general and diabetes-specific emotional wellbeing, and lower diabetes-specific self-
efficacy and satisfaction with blood glucose, than those with less negative insulin 
appraisals (Study 1c; paper 5). In the final qualitative study (Study 3; paper 6), in 
addition to the perceived benefits of using insulin (e.g. improved blood glucose 
levels), adults with insulin-treated T2D also identified disadvantages, some of which 
are not captured within the ITAS. Further, while most participants reported 
receptiveness to insulin intensification, the perceived inconvenience of additional 
insulin injections and concerns about more intensive insulin regimens were barriers 
for some. These findings highlight the impact of PIR and receptiveness beyond 
insulin uptake and the need to identify and address ongoing, or new, concerns 
throughout treatment progression.  
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Outline of Thesis 
The aim of this research was to examine attitudes toward insulin therapy, or 
psychological insulin resistance (PIR) and receptiveness, among adults with type 2 
diabetes (T2D) in Australia. This program of the research was designed to contribute 
to our understanding of a) the measurement and b) the occurrence of, and factors 
associated with, PIR and receptiveness among Australians with non-insulin-treated 
T2D, c) the demographic, clinical and psychological predictors of actual insulin 
uptake, d) attitudes toward insulin post-initiation, perceptions of benefits and 
consequences of insulin, and attitudes to further treatment intensification.  
This thesis consists of 10 chapters, including six independent but related 
empirical papers, (Chapters 4-9), reporting on data collected from three research 
studies (1) Diabetes MILES – Australia, a national cross-sectional survey, 2) 
Stepping Up, a cluster randomised controlled trial (RCT), and 3) Insulin Appraisals, 
a qualitative study). Figure 1 provides a schematic representation of the research 
aims of this thesis, the study in which relevant data were collected, and the resulting 
empirical paper(s). 
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Figure 1. Schematic representation of research studies, research aims and empirical 
papers  
 
Chapter 1 (Introduction) describes the condition, management, and prevalence 
of T2D as well as the problem of delayed insulin intensification. In Chapter 2 
(Literature Review), the concepts of PIR and receptiveness are defined and barriers 
to as well as facilitators of insulin initiation, ongoing use, and intensification are 
examined. Chapter 3 (Methodology) summaries the methods used, and the research 
Study 1 
Diabetes MILES– 
Australia 
(national survey) 
 
Study 2 
Stepping Up 
(cluster RCT) 
Study 3 
Insulin Appraisals 
(qualitative study) 
 
a) Scale psychometric 
validation in Australia 
(Paper 1, Study 1) 
b) Cross-sectional examination of insulin 
appraisals among adults with non-insulin treated 
T2D in a national (Paper 2, Study 1) and clinical 
sample (Paper 3, Study 2) 
c) Longitudinal study 
of predictors of 
insulin uptake (Paper 
4, Study 2) 
d) Longitudinal investigation of change in attitudes towards insulin (Paper 4, 
Study 2), quantitative assessment of factors associated with negative attitudes 
towards insulin (Paper 5, Study 1), qualitative investigation of impact of insulin 
use and attitudes towards intensification (Paper 6, Study 3), following insulin 
initiation. 
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questions asked of, the three broad research studies. A detailed description of the 
methods is provided in Appendix C.  
The first empirical study (Chapter 4, Paper 1: Further investigation of the 
psychometric properties of the insulin treatment appraisal scale among insulin-using 
and non-insulin-using adults with type 2 diabetes: Results from Diabetes MILES – 
Australia) uses cross-sectional data (Study 1: Diabetes MILES – Australia) to 
undertake psychometric validation of an existing measure of insulin therapy 
appraisals within an Australian sample. Chapters 5 and 6 both examine attitudes 
towards insulin and associated factors among adults with non-insulin-treated T2D. In 
Chapter 5 (Paper 2: Explaining psychological insulin resistance in adults with non-
insulin-treated type 2 diabetes: The roles of diabetes distress and current medication 
concerns. Results from Diabetes MILES – Australia), negative attitudes towards 
insulin therapy are examined among those not yet using insulin at a national level, 
drawing upon data from Study 1 (Diabetes MILES – Australia). The relationship 
between negative attitudes towards insulin and general and diabetes-specific 
wellbeing and beliefs about medications is examined. In Chapter 6 (Paper 3: 
Willingness to initiate insulin among adults with type 2 diabetes in Australian 
primary care: Results from the Stepping Up study), attitudes towards insulin and 
hypothetical insulin uptake are examined among a clinical sample (Study 2: Stepping 
Up RCT) of adults with T2D for whom insulin has been clinically indicated. In this 
paper, clinical, demographic and psychological factors associated with hypothetical 
willingness to begin insulin were identified. 
Chapter 7 (Paper 4: Predictors of insulin uptake among adults with type 2 
diabetes in the Stepping Up study) presents longitudinal data (baseline and 12-month 
  
xx 
 
follow-up) gathered in the Stepping Up RCT. Paper 4 examines 1) demographic, 
clinical and psychological predictors of actual insulin uptake, controlling for the 
Stepping Up intervention, and 2) change in attitudes towards insulin as a function of 
the intervention and insulin uptake.  
In Chapters 8 and 9 (Papers 5 and 6), the research focus moves to the 
exploration of insulin appraisals among those already using insulin. Chapter 8 (Paper 
5: Negative appraisals of insulin therapy are common among adults with type 2 
diabetes using insulin: Results from Diabetes MILES – Australia cross-sectional 
survey), using data from Study 1 (Diabetes MILES – Australia), examines whether 
negative insulin appraisals are common among adults with T2D already using insulin 
therapy and identifies demographic, clinical, self-management and psychosocial 
outcomes that differ for those with more and less negative insulin appraisals. Chapter 
9 (Paper 6: The impact of insulin therapy and attitudes towards insulin intensification 
among adults with type 2 diabetes: A qualitative study) reports on qualitative 
findings of an interview study (Study 3: Insulin Appraisals) involving adults with 
T2D who have initiated insulin use within the past four years. This paper aims to 
identify positive and negative consequences of insulin use, post-initiation, and 
attitudes to ongoing use and insulin intensification. 
Finally, Chapter 10 (General Discussion) presents an integrated synthesis of 
the thesis. In this chapter, the findings of the empirical papers are summarised and 
discussed in relation to the literature reviewed in Chapter 2. Strengths and limitations 
of the empirical studies are discussed, as well as clinical and research implications, 
and recommendations for future research. 
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Chapter 1: Introduction  
This chapter describes T2D, its prevalence, and management. The problem of 
delayed insulin initiation and intensification is introduced.  
1.1. What is Type 2 Diabetes? 
T2D is a chronic condition characterised by the inability of the pancreatic beta 
cells to produce sufficient or effective insulin (insulin deficiency) or the body to use 
it effectively (insulin resistance). Insulin is required for the body to convert glucose 
into energy. T2D is a progressive condition, with complete beta cell failure generally 
occurring within 10 years of onset for most individuals (U.K. Prospective Diabetes 
Study Group, 1995). Loss of beta cell function causes an increase of glucose 
circulating in the blood stream, otherwise known as hyperglycaemia. The body reacts 
to hyperglycaemia by secreting more insulin, resulting in exhaustion of the beta cells 
and, eventually, less production of insulin and/or insulin resistance. Prolonged, 
untreated hyperglycaemia increases the risk of developing micro-vascular 
complications (e.g. neuropathy, nephropathy, retinopathy) and macro-vascular 
complications (e.g. peripheral vascular diseases, heart disease) (Adler et al., 2002; 
Stratton et al., 2000).  
Symptoms of hyperglycaemia include lethargy, increased thirst and frequent 
urination, blurred vision, loss of sensation, poor wound healing and increased fungal 
or bacterial infections. However, in its early stages T2D may be asymptomatic and 
go undiagnosed for several years (American Diabetes Association, 2004). The Royal 
Australian College of General Practitioners’ (RACGP (2014)) clinical guidelines for 
the management of T2D indicate that clinical testing should be conducted if a person 
is experiencing the above symptoms, has risk factors for T2D, or exhibits clinical 
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signs of insulin resistance. T2D may be diagnosed through measurement of fasting or 
random blood glucose, oral glucose tolerance testing, or glycated haemoglobin 
(HbA1c), a measure of the average amount of glucose in the bloodstream over an 8-
12 week period. Specifically, diagnostic criteria include, on two separate occasions: 
HbA1c ≥6.5% (48 mmol/mol), fasting blood glucose of ≥7.0 mmol/L or a two-hour 
post-prandial oral glucose of ≥11.0 mmol/L. 
1.2. Causes of Type 2 Diabetes 
The exact cause of T2D is unknown but risk factors are well established. Risk 
factors may be non-modifiable (i.e. genetic predisposition, family history, age) or 
potentially modifiable (i.e. overweight or obesity, poor nutrition and physical 
inactivity). As T2D most commonly develops in adults over the age of 40 years, 
clinical guidelines suggest that all individuals be screened for T2D every three years 
from this age (The Royal Australian College of General Practitioners and Diabetes 
Australia, 2014). However, T2D is increasing among people of younger ages, 
including adolescents (Dunstan et al., 2002; Lammi et al., 2007; Pinhas-Hamiel & 
Zeitler, 2005; SEARCH for Diabetes in Youth Study Group et al., 2006), largely 
associated with modifiable risk factors.  
Landmark studies have demonstrated that T2D can be prevented in up to 58% 
of cases through lifestyle modifications (Lindström et al., 2006; Tuomilehto et al., 
2001). Indeed, physical activity and dietary modifications are recommended in 
diabetes care guidelines (The Royal Australian College of General Practitioners and 
Diabetes Australia, 2014). However, personal efforts at undertaking lifestyle 
modifications and reducing weight may be hampered by the so-called ‘obesogenic’ 
environment (e.g. lack of public space, availability of energy dense/low cost foods, 
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large portion sizes) (Egger & Swinburn, 1997; Swinburn et al., 2011). A singular 
focus on the modifiable risks alone, ignoring the non-modifiable risks and the role of 
environment, may lead to unintended consequences (Browne, Zimmet, & Speight, 
2011). The perception of T2D as a ‘lifestyle disease’ may create or reinforce stigma 
around diabetes and obesity (Browne, Ventura, Mosely, & Speight, 2013; Kalra & 
Baruah, 2015; Schabert, Browne, Mosely, & Speight, 2012). Recent Australian and 
international research has highlighted that adults with T2D experience diabetes-
related stigma, including feeling blamed for bringing the condition on themselves 
(Browne et al., 2013; Stuckey et al., 2014).  
1.3. Prevalence of Type 2 Diabetes Globally and in Australia 
T2D is a global emergency with over 400 million adults currently living with 
the condition and this number is expected to rise to 642 million by 2040 
(International Diabetes Federation, 2015). Approximately 1.2 million Australians are 
registered with the National Diabetes Services Scheme (NDSS)1, of which 86% have 
T2D (National Diabetes Services Scheme, 2016a), and it is estimated that for every 
four adult Australians with diagnosed T2D, another lives with the condition 
undiagnosed (Australian Bureau of Statistics, 2013).  
T2D was the sixth leading cause of death in Australia in 2011, accounting for 
10% of all deaths (Australian Institute of Health and Welfare, 2014), and diabetes is 
expected to be the leading cause of disease burden by 2023 for males and the second 
leading cause for females (Australian Institute of Health and Welfare, 2010). The 
                                               
1Australians with diabetes are eligible to register with the National Diabetes Services 
Scheme (NDSS) to access a large range of subsidised diabetes self-management 
products and services. The NDSS is an initiative of the Australian Government and is 
administered with the assistance of Diabetes Australia. 
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indirect cost of diabetes to the Australian community is nearly $15 billion annually 
and this is expected to double by 2025 (Australian Government Department of 
Health, 2015)  
1.4. Management of Type 2 Diabetes 
While there is no known cure for T2D, lifestyle modifications, such as 
increased physical activity, weight loss and healthy eating, and a range of 
pharmacological treatments can be effective in managing hyperglycaemia. 
Guidelines recommend a staged pharmacological management plan with increasing 
intensification of treatment from lifestyle modifications, to the introduction of oral 
hypoglycaemic agents (OHAs), glucagon-like-peptide-1 (GLP1) receptor agonists 
and insulin therapy (Gunton, Cheung, Davis, Zoungas, & Colagiuri, 2014; 
International Diabetes Federation, 2012; Inzucchi et al., 2015; Nathan et al., 2009). 
The efficacy of pharmacological therapies is determined largely by their 
impact on blood glucose levels, which is clinically assessed in terms of HbA1c. The 
standard recommended target HbA1c for people with T2D is <7% (<53 mmol/mol) 
(International Diabetes Federation, 2012), though individualisation of targets is 
recommended. The American Diabetes Association and the European Association 
for the Study of Diabetes position statement on the management of hyperglycaemia 
in T2D highlights the need to consider both non-modifiable clinical characteristics 
(i.e. disease duration, life expectancy, established comorbidities, medication side 
effects) as well as potentially modifiable characteristics (i.e. access to resources and 
support systems, and attitudes, ability and desire to undertake the treatment change) 
to determine the optimal HbA1c target for each presenting individual with T2D 
(Inzucchi et al., 2015). Timely intensification of treatment and achieving, and 
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maintaining, optimal HbA1c is associated with significantly reduced risk of the 
development or progression of micro-vascular complications (U.K. Prospective 
Diabetes Study Group, 1998). HbA1c should be assessed every 3-6 months (The 
Royal Australian College of General Practitioners and Diabetes Australia, 2014). 
Blood glucose may be assessed through self-monitoring, which typically 
involves the use of a lancet device to finger prick, adding a drop of blood onto a 
blood testing strip, and finally inserting the strip into a blood glucose meter, which 
displays the blood glucose reading in terms of millimols per litre of blood (mmol/L). 
Self-monitoring of blood glucose (SMBG) can be used, for example, to identify, and 
inform treatment of, hyperglycaemia or hypoglycaemia (defined as a low blood 
glucose reading <3.5 mmol/L (Frier, 2009)), and, to reflect on glucose patterns. The 
recommended target blood glucose range for a person with diabetes is 6-8 mmol/L 
pre-prandial (pre-meal) and 6-10 mmol/L two hours postprandial (post-meal) 
(Colagiuri, Dickinson, Girgis, & Colagiuri, 2009). Use and frequency of SMBG 
depends on the individual’s circumstances and therapeutic aims. Among adults with 
non-insulin-treated T2D, SMBG has been found to provide limited clinical benefits 
in terms of glycaemia improvements (Malanda et al., 2012). Consequently, in July 
2016, the Australian Federal Government implemented a new policy to restrict the 
access to subsidised test strips for people with non-insulin-treated T2D. Access will 
now be provided only in cases where an authorised healthcare professional (HCP) 
‘considers it clinically necessary’ (Australian Government Depatment of Health, 
2016). SMBG remains recommended for people with T2D using insulin therapy. 
Other ‘clinically necessary’ cases may include during pregnancy or when changes in 
treatment, lifestyle or health require monitoring of blood glucose patterns (The Royal 
Australian College of General Practitioners and Diabetes Australia, 2014).  
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While there is little evidence for the effectiveness of the routine 
recommendation of ‘unstructured’ SMBG (Malanda et al., 2012), a ‘structured’ 
approach to SMBG, for example, a three-day period of intensive monitoring and 
recording at specific times in the week prior to a HCP consultation, has demonstrated 
clinical benefit (Speight, Browne, & Furler, 2013). Trials of structured SMBG 
among adults with non-insulin-treated T2D have demonstrated effectiveness in terms 
of reduced HbA1c, as well as offering benefits for emotional wellbeing (Polonsky et 
al., 2011) and confidence in diabetes self-care (Fisher et al., 2012). Thus, it has been 
argued that the government restriction is short-sighted (Speight, Browne, & Furler, 
2015), and should instead advocate for a focused, structured approach to SMBG 
among those not using insulin to inform T2D management.  
1.4.1. Insulin therapy 
Insulin therapy is the only diabetes management option that can maintain 
optimal blood glucose levels throughout the progression of beta cell failure. Through 
the prevention of diabetes-related complications, insulin use can contribute indirectly 
to maintaining both quantity and quality of life (Pouwer & Hermanns, 2009). 
International guidelines emphasise the early consideration and initiation of insulin 
therapy among people with T2D for whom target glycaemic outcomes are not 
achieved with maximum OHAs (Inzucchi et al., 2015; Nathan et al., 2009).  
Insulin must be injected through the skin subcutaneously. Less invasive modes 
of administration are the focus of much research, including, for example, inhaled, 
oral and nasal insulins (Shah, Patel, Maahs, & Shah, 2016). However, to date, no 
alternatives to subcutaneously-injected insulin are approved for use in Australia. 
Insulin injections may be delivered either using a syringe and vial, a preloaded or 
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reloadable insulin ‘pen’ injector, or an insulin pump. An insulin pump is a small 
programmable device worn outside the body that delivers insulin through a plastic 
tube connected to a fine needle inserted under the skin. Insulin syringes and pen 
needles are freely available from the NDSS for Australians with T2D using insulin 
therapy. However, insulin pump consumables (tubing and needles) are not currently 
subsidised by the NDSS for people with insulin-treated T2D.  
In addition to the invasive nature of insulin injections, there are two main side 
effects of insulin therapy: hypoglycaemia and weight gain. Hypoglycaemia, a blood 
glucose level <3.5 mmol/L (Frier, 2009), is caused by a relative excess of insulin in 
the body. This may be due to too much insulin injected or ‘on-board’, increased 
physical activity, or consuming less carbohydrates (glucose) than required. Early 
symptoms of hypoglycaemia vary but can include shaking, sweating, light-
headedness, confusions, and mood change. If the individual is awake and able to 
swallow, hypoglycaemia can be treated with consumption of a quick-acting glucose 
(e.g. juice, jellybeans), followed by SMBG and additional long-acting carbohydrate 
(e.g. toast) if required. If hypoglycaemia is not treated early, and blood glucose 
continues to drop, the person may experience an episode of severe hypoglycaemia, 
characterised by the inability to self-treat, and require the assistance of another 
person for recovery (Strachan & Frier, 2013). The other key side effect of insulin is 
weight gain: an increase (approximately 2-4 kilograms) is commonly reported after 
insulin initiation (Holman et al., 2007; Pontiroli, Miele, & Morabito, 2011; U.K. 
Prospective Diabetes Study Group, 1998). Reasons for weight gain include the 
reduction in calorie loss due to the body’s improved ability to absorb glucose and an 
increase in calorie intake to feed insulin doses and/or combat hypoglycaemia 
(Strachan & Frier, 2013). 
  
8 
 
There are five categories of insulin available, differing in terms of how quickly 
they begin working and how long they last, which informs how many times they 
should be taken per day and at what times of day (e.g. once-daily injections, 30 
minutes before a meal) (NPS MedicineWise, 2016). For people with T2D, the 
RACGP and Diabetes Australia (2014) recommend that the initiation of insulin 
involve the prescription of either a once-daily injection of basal insulin (long-acting 
insulin, lasts up to 24 hours) or a once-daily injection of pre-mixed insulin 
(combination of both intermediate acting insulin, lasting 16-24 hours, and either 
short or rapid fast-acting insulins) injection taken prior to the largest meal of the day. 
The insulin dosage may then be adjusted in the short term in response to changes in 
glucose levels. If HbA1c is not within target after three months or more following 
initiation of once-daily insulin injections, insulin intensification may be required. 
Insulin intensification may include an increased dose or additional injections (e.g. a 
single additional injection or several meal-related injections per day), which may 
require changes in the type of insulin used (e.g. addition of pre-prandial short-acting 
insulin or pre-mixed insulin injections). 
1.4.2. Healthcare professional(s) and self-care roles  
Clinical guidelines for the management of diabetes highlight the need for 
person-centred (or patient-centred) care (Inzucchi et al., 2012; The Royal Australian 
College of General Practitioners and Diabetes Australia, 2014). Person-centred care 
is “respectful of and responsive to individual patient preferences, needs, and values, 
and ensuring that patient values guide all clinical decisions” (Institute of Medicine 
Committee on Quality of Health Care in America, 2001). The role of the HCP in the 
management of T2D is to assess the health of the person with T2D and provide 
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timely recommendations for treatment (such as insulin initiation) in the context of 
the person’s needs, priorities and abilities. Ongoing diabetes education (both directly 
and through referral to specialists and structured diabetes education programs as 
necessary) is needed to provide the person with diabetes with adequate 
understanding with which to make informed treatment decisions and undertake 
optimal daily diabetes self-management (e.g. SMBG, monitor/adjust (multiple) daily 
injections, manage food intake and physical activity in relation to glucose levels). 
T2D self-management is a life-long, and daily, responsibility for a person living with 
the condition, and is often complicated by the need to concurrently manage one or 
more additional chronic condition (i.e. multimorbidity) (Luijks et al., 2012; Struijs, 
Baan, Schellevis, Westert, & van den Bos, 2006; Teljeur, Smith, Paul, Kelly, & 
O’Dowd, 2013). While the role of the HCP is prescription and communication, it is 
the person with T2D, not the HCP, who must perform the daily management of 
diabetes and live with the consequences of their decisions (Anderson, 1985).  
1.5. The Problem: Delayed Insulin Initiation or Intensification and Insulin 
Omission 
Despite the proven efficacy of insulin in reducing hyperglycaemia and 
delaying/slowing progression of diabetes-related complications (U.K. Prospective 
Diabetes Study Group, 1998), there exists a mismatch between the number of people 
with T2D using insulin and the number who have a HbA1c and diabetes history 
suggestive of the need to initiate insulin (S. Khunti, Davies, & Khunti, 2015). For 
example, in the Australian ‘Fremantle Study’, transition to insulin occurred at a 
median diabetes duration of eight years and a median HbA1c of 9.4% (79mmol/mol) 
(Davis, Davis, & Bruce, 2006). This is corroborated by more recent data indicating 
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that only 24% of Australians with T2D (approximately 250,000 people) are using 
insulin to manage their diabetes (National Diabetes Services Scheme, 2016b), despite 
reports that mean HbA1c is above target (8%, 64 mmol/mol) (National Association 
of Diabetes Centres, 2009; Swerissen, Duckett, & Wright, 2016). A recent review of 
chronic disease management in Australian primary care reported that 40% of adults 
with T2D did not have blood glucose data recorded, and of those with recorded data 
only one in four had within target HbA1c (≤7.0%, ≤53 mmol/mol) (Swerissen et al., 
2016). Similar results have been found internationally. In Canada, the mean diabetes 
duration and HbA1c prior to insulin initiation is nine years and 9.5% (80mmol/mol) 
respectively (Harris, Kapor, Lank, Willan, & Houston, 2010); in the USA (Curtis & 
Lage, 2014) and the UK (Blak, Smith, Hards, Maguire, & Gimeno, 2012), mean 
HbA1c at insulin initiation was 8.6% (70mmol/mol) and 9.3% (78mmol/mol) 
respectively; and a multi-country primary care study reported a mean of 8.9% 
(74mmol/mol) (K. Khunti, Damci, Meneghini, Pan, & Yale, 2012). In a South 
London prospective observational cohort study of newly diagnosed adults with T2D 
(N=1,335), one-third of the 7% who had initiated insulin at follow-up had 
experienced an insulin initiation delay according to clinical guidelines and the 
authors ascertained that a further 10% of the overall sample required insulin therapy 
but had not yet commenced (Keij, Ismail, & Winkley, 2016).  
Beyond insulin initiation, delayed intensification and insulin omission (i.e. 
purposefully or mistakenly skipping an insulin injection, or taking less insulin than 
required) may cause prolonged hyperglycaemia among people with T2D already 
using insulin. Among those already using insulin, recent studies have explored time 
until, and HbA1c at the time of, insulin intensification, suggesting a mismatch 
between clinical practice and clinical guidelines (Fulcher, Roberts, Sinha, & Proietto, 
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2015; Grant, Buse, & Meigs, 2005; K. Khunti et al., 2016; Polinski et al., 2014). 
Rates of insulin omission vary across studies (Davies et al., 2013). For example, a 
previous US study reported that 20% of adults using insulin therapy skip their 
injections often or some of the time (Rubin, Peyrot, Kruger, & Travis, 2009), while 
in a more recent US study, 46% of participants reported ‘non-adherence’ to their 
insulin regimen over the two weeks prior (Osborn & Gonzalez, 2016).  
The delay in insulin initiation and intensification may be, in part, due to a lack 
of recommendation/prescription by the HCP known as clinical inertia (which is 
discussed elsewhere: Shaefer, 2006). It may also be due to a phenomenon known as 
‘psychological insulin resistance’ (PIR), negative attitudes to insulin therapy 
experienced by a person with T2D which may lead to reluctance to commence or 
intensify insulin therapy (Leslie, Satin-Rapaport, Matheson, Stone, & Enfield, 1994). 
In contrast, positive attitudes, or receptiveness, to insulin therapy may be associated 
with insulin uptake. The focus of this thesis is on understanding PIR and 
receptiveness to insulin therapy initiation, use, and intensification among Australian 
adults with T2D throughout treatment progression.   
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Chapter 2: Literature Review: Understanding Attitudes towards 
Insulin among Adults with Type 2 Diabetes 
 The Literature Review in Context 
In this chapter, the terms ‘psychological insulin resistance’ (PIR) and insulin 
‘receptiveness’ are defined and a synthesis of existing research exploring attitudes to 
insulin therapy among adults with T2D is presented. In addition, quantitative 
measures of PIR and receptiveness and associated concepts are explored. 
Throughout, gaps in the existing literature are identified, serving to provide a 
rationale for the research undertaken.  
The program of research described in this thesis commenced in 2012, and since 
that time, research examining PIR has developed considerably, with new 
publications focused on PIR including: systematic reviews (S. Khunti, Davies, & 
Khunti, 2015; Ng, Lai, Lee, Azmi, & Teo, 2015), qualitative studies (e.g. Hu, 
Amirehsani, Wallace, & Letvak, 2013; Y. K. Lee, Low, Lee, & Ng, 2015; Patel, 
Stone, McDonough, et al., 2015) and cross-sectional quantitative studies (Fu, Wong, 
Chin, & Luk, 2016; Gherman & Alionescu, 2015; Machinani, Bazargan-Hejazi, & 
Hsia, 2012). Prior to 2012, no interventions to reduce PIR had been developed or 
evaluated, but recent years have seen the publication of intervention pilots to 
improve attitudes toward or education about insulin therapy (e.g.Patel, Stone, 
Hadjiconstantinou, et al., 2015). Until recently, a major limitation of PIR research 
was the lack of longitudinal research assessing change in insulin appraisals and 
predictors of insulin uptake. This, too, is changing with the inclusion of measures of 
insulin appraisals in recent longitudinal multi-centre studies (Keij, Ismail, & 
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Winkley, 2016; Odawara, Ishii, Tajima, & Iwamoto, 2016) and trials (Hermanns et 
al., 2015; Liebl et al., 2013). Finally, the inclusion of insulin omission and/or 
reluctance to intensify insulin therapy in the conceptual understanding of PIR was 
uncommon at the commencement of this program of research. A recent systematic 
review has highlighted the need for additional research in this area (Polinski et al., 
2012). The study chapters, which were submitted for publication from 2013 to 2016, 
may draw attention to gaps in the literature that no longer exist, and exclude 
references to more recent literature. However, important research conducted after 
2012 is incorporated within this chapter, with reference to its recency.  
 Defining Psychological Insulin Resistance and Receptiveness 
Diabetes self-management typically requires a multitude of daily decisions and 
behaviours, for example: undertaking, and possibly recording and responding to, 
SMBG; dietary modifications and increased physical activity (for weight 
management and/or in response to glucose levels); as well as, administration of 
medications throughout the day. A key determinant of undertaking a health 
behaviour, for example: insulin use, is an individual’s attitudes or beliefs about the 
behaviour and its intended outcome (Michie, Johnston, Francis, Hardeman, & 
Eccles, 2008). Negative perceptions of the physical or psychological impact of 
insulin use may lead to a reluctance to initiate insulin therapy.  
PIR has been conceptualised as negative attitudes toward insulin which may 
lead to a reluctance to use insulin therapy among people with T2D, typically 
referring to initiation of insulin rather than ongoing use. Although this concept first 
appeared in the field 20 years ago (Leslie & Satin-Rapaport, 1995; Leslie, Satin-
Rapaport, Matheson, Stone, & Enfield, 1994), research has grown significantly over 
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the past decade. Systematic reviews provide an overview of the definitions and 
components of PIR, its impact on diabetes management, as well as a synthesis of the 
measures and predictors of, and proposed interventions to reduce, PIR (Brod, 
Kongsø, Lessard, & Christensen, 2009; Gherman et al., 2011; Ng et al., 2015; Wang 
& Yeh, 2012). Receptiveness has been quantified as a lack of PIR, exhibited through 
willingness to initiate insulin (Jenkins, Hallowell, Farmer, Holman, & Lawton, 2010; 
Polonsky, Hajos, Dain, & Snoek, 2011). In this thesis, receptiveness is 
conceptualised as positive attitudes toward insulin therapy.  
In addition to being relevant to the initiation of insulin, PIR and receptiveness 
are likely to have explanatory value in relation to ongoing use of insulin therapy (e.g. 
the omission of insulin in those already using insulin) and treatment intensification 
(e.g. receptiveness to additional injections per day and/or changes in insulin types). 
However, few researchers include the omission of insulin or avoidance of treatment 
intensification in their definitions or discussion of these constructs. In the current 
thesis, PIR and receptiveness are discussed, and explored, in relation to both insulin 
initiation (incorporating attitudes to, and barriers and facilitators of, insulin initiation) 
and ongoing use of insulin therapy and insulin intensification.  
 Attitudes towards Insulin Therapy: Evidence from Qualitative Studies  
Understanding attitudes toward insulin therapy among people with T2D, and 
how they develop, has been the aim of a vast body of qualitative research. In 
addition, a number of studies exploring ‘illness perceptions’ or ‘medication beliefs’ 
more broadly among adults with T2D, have contributed to the study of the PIR and 
receptiveness. Qualitative examination of attitudes to insulin therapy have been 
conducted across the globe, including studies examining the attitudes of specific 
  
25 
 
subgroups (e.g. Chinese Canadians (Ho & James, 2006), the Bangladeshi population 
living in East London (Khan, Lasker, & Chowdhury, 2008)).  
Qualitative studies of PIR have employed focus groups, interviews or a 
combination of both, including people with non-insulin-treated and/or insulin-treated 
T2D. Research including those already using insulin typically focuses on perceived 
barriers to insulin initiation rather than the experience of using insulin post-initiation. 
Further, few studies have examined attitudes to insulin intensification among those 
already using insulin therapy. 
In some studies, both people with T2D and HCP participants are included. 
HCPs are asked to reflect on their own beliefs about insulin, systemic barriers and 
enablers of insulin initiation, as well as their beliefs about the attitudes held by 
people with T2D (Furler, Spitzer, Young, & Best, 2011; Jenkins et al., 2010; Tan et 
al., 2011). To date, only one qualitative study of PIR has been undertaken in 
Australia (Furler et al., 2011). That study included people with T2D (N=14) and HCP 
(N=12) participants, but reported mainly on HCP attitudes towards insulin initiation 
within primary care and HCP roles in the initiation and education of insulin therapy 
(Furler et al., 2011).  
The following is a synthesis of the negative and positive attitudes to, or 
consequences of, insulin therapy identified in previous qualitative research of adults 
with T2D, discussed in relation to: a) the perceived necessity of insulin initiation; b) 
perceived or real negative consequences of insulin initiation; c) perceived benefits of 
insulin initiation; and d) the formation of attitudes towards insulin.  
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2.3.1. The perceived necessity of insulin initiation 
People with T2D not yet using insulin commonly believe or assert insulin to be 
unnecessary for achieving optimal blood glucose control. They discredit the efficacy 
of insulin (K. W. Chen, Tseng, Huang, & Chuang, 2012; Tapu-Ta'ala, 2011), assert 
that they are able to improve their blood glucose levels without insulin (Bogatean & 
Hâncu, 2004; Guimarães et al., 2010; Hunt, Valenzuela, & Pugh, 1997; Khan et al., 
2008; Noakes, 2010; Tan et al., 2011), and indicate a preference for alternative 
therapies, such as herbs or dried fruit (K. Brown, Avis, & Hubbard, 2007; Ho & 
James, 2006; Mull, Nguyen, & Mull, 2001). In one study, participants described 
insulin as “(in) fashion these day”, a personal preference of the HCP rather than a 
therapeutic necessity (Bogatean & Hâncu, 2004).  
Concerns about the necessity of insulin are particularly common in studies 
including participants of non-Western ethnic heritage. In these studies, barriers to 
insulin initiation include the perception that insulin is an unnatural or chemical 
substance that causes an imbalance in the body (K. Brown et al., 2007; Mull et al., 
2001). HCPs report patients’ distrust of Western doctors or medications as a barrier 
to insulin initiation (Haque, Emerson, Dennison, Navsa, & Levitt, 2005; Y. K. Lee, 
P. Y. Lee, & C. J. Ng, 2012; Patel, Stone, Chauhan, Davies, & Khunti, 2012). 
Religious beliefs are also cited by some respondents with T2D as a barrier to insulin 
initiation (Khan et al., 2008; Noakes, 2010); HCPs in Malaysia note that their 
patients of Muslim religion remain concerned about the origin2 of insulin (Y. K. Lee 
et al., 2012). In addition to the perception that insulin is an unnatural product, some 
                                               
2Up until the 1980s, insulin was derived from animal sources, including bovine, 
equine and porcine. Under the Muslim faith, the consumption or use of animal 
products must comply with strict religious standards in order to be considered lawful. 
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perceived the actual task of injecting, and being dependent on, a foreign substance 
into one’s body as unnatural or not ‘normal’ (Morris, Povey, & Street, 2005).  
Conversely, two studies have suggested that people with T2D may not be as 
psychologically resistant as previously documented (Jeavons, Hungin, & Cornford, 
2006), with PIR being greatly over-emphasised and, in fact, receptiveness being a 
more common experience (Jenkins et al., 2010). Indeed, with few exceptions (Khan 
et al., 2008), prior qualitative research does not focus exclusively on participants 
who have refused insulin initiation and the qualitative examination of barriers of 
insulin therapy frequently includes people with T2D who were already using insulin. 
Thus suggesting that even those reporting negative attitudes or barriers to insulin 
therapy may be receptive to insulin therapy. In an interview following participation 
in the Treat To Target in Type 2 Diabetes (4-T) trial, people with T2D reported being 
upset or disappointed when recommended insulin but quickly accepting insulin 
initiation in response to observing the reduced effectiveness of oral medications and 
recognising that their diabetes had progressed (Jenkins et al., 2010). Other studies 
have also reported that a person’s perception of discomfort caused by diabetes 
symptoms may influence his/her likelihood of viewing insulin initiation as necessary. 
For example, those who feel the acute discomfort of hyperglycaemia are more likely 
to acknowledge a need for insulin or express a desire to progress to the next phase of 
treatment (Bogatean & Hâncu, 2004). Similarly, diabetes nurse specialists report that 
patients who felt unwell were more willing to convert to insulin (Phillips, 2007b), 
and older African Americans with more symptomatic T2D or severe complications 
report following their medical regimen more aggressively (Chin, Polonsky, Thomas, 
& Nerney, 2000). Similarly, in a recent interview study of adults with T2D living in 
the UK the necessity of insulin was determined by participants in two different ways: 
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some participants relied on their HbA1c results to alert them of the inability of OHAs 
to maintain glucose control, while others reported that insulin would be required 
when diabetes-related complications had developed (Patel, Stone, McDonough, et 
al., 2015). However, T2D may be experienced as asymptomatic, with no symptoms 
of prolonged hyperglycaemia recognised as out of the ordinary, and those not yet 
using insulin may not be encouraged to monitor, or understand, their blood glucose 
levels (Speight, Browne, & Furler, 2015). Thus, with no physical signs of the sub-
optimal management of the condition, people with T2D may not perceive treatment 
intensification as necessary. Further, negative consequences of insulin therapy may 
outweigh possible positive consequences and/or the perceived necessity of the 
insulin use (Patel, Stone, McDonough, et al., 2015). 
2.3.2. Perceived or real negative consequences of insulin initiation 
Research exploring attitudes towards insulin has typically focused on 
identifying barriers to insulin initiation among adults with non-insulin-treated T2D or 
attitudes held prior to initiation among those already using insulin. Thus, there is a 
vast literature revealing the perceived negative aspects of insulin initiation. While 
diabetes duration and primary treatment (i.e. insulin injections, OHAs, lifestyle 
modifications) are commonly provided, studies including people with insulin-treated 
T2D only occasionally describe the average number of years participants have been 
using insulin, and rarely specify any eligibility inclusion criteria for this. In some 
cases, participants may be asked to reflect on their experience of, and attitudes held 
prior to, insulin initiation years after the actual event. For example, in a study that 
aimed to identify barriers to insulin initiation among Chinese people with T2D living 
in Canada, the sample of five participants had been using insulin for between one 
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and 11 years (Ho & James, 2006). Thus, it is unclear whether the identified attitudes 
did, in fact, form prior to or after initiation, whether these attitudes changed over 
time, or whether they are accurately remembered. Furthermore, despite the frequent 
inclusion of adults with insulin-treated T2D, only a minority of studies have sought 
to understand ongoing barriers to, or consequences of, insulin therapy use after 
initiation (Morris et al., 2005; Phillips, 2007a), or negative attitudes to insulin 
intensification (Jenkins, Hallowell, Farmer, Holman, & Lawton, 2011).  
The following section provides a summary of the negative consequences of 
insulin therapy, which may be a barrier to insulin uptake, or an experienced 
consequence post insulin initiation. People with T2D report the most important 
aspect of a given diabetes treatment is its impact on blood glucose control 
(Guimarães et al., 2009), but satisfaction with treatment goes beyond its 
effectiveness, incorporating experience also (e.g. convenience/flexibility and side 
effects). Potential negative experiences of insulin that are frequently raised as 
barriers to insulin initiation include: physical consequences; lifestyle consequences; 
and the implied meaning or symbolism of insulin use and consequences for self-
identity.   
2.3.2.1. Physical consequences  
One of the most common themes to emerge from the literature concerns insulin 
injection anxieties. People with T2D perceive insulin injections as an invasive and 
painful treatment (e.g. Guimarães et al., 2010; Ho & James, 2006; Tan et al., 2011) 
and a preference for non-injectable insulin treatments has been identified (e.g. 
Guimarães et al., 2010; Hayes, Bowman, Monahan, Marrero, & McHorney, 2006). 
In addition to a fear of needles, insulin therapy is also perceived to be a more 
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complex treatment regimen. Worry and disbelief in one’s ability to self-inject or 
adjust insulin doses, and concerns about the negative consequences of injecting 
incorrectly, are frequently raised (e.g. Bogatean & Hâncu, 2004; K. W. Chen et al., 
2012; Hassali et al., 2013; Morris et al., 2005).  
People with T2D, regardless of whether they currently use insulin, commonly 
report concerns about the side effects of insulin. Most commonly, these side effects 
include hypoglycaemia, weight gain (e.g. Guimarães et al., 2010; Tan et al., 2011), 
and bruising from injection sites (Hayes et al., 2006). Hypoglycaemia is a concern 
among those already using insulin who express avoidance of increasing their insulin 
dose so as not to increase the likelihood of experiencing hypoglycaemia (Simon, 
Gude, Holleman, Hoekstra, & Peek, 2014; Tong, Vethakkan, & Ng, 2015). In a 
comparison of beliefs about insulin held by Brazilians and Canadians, Guimarães et 
al. (2010) noted that, while both groups expressed insulin anxiety and a preference 
for non-injectable treatments, Brazilians were more concerned about hypoglycaemia 
and the cost of insulin, while Canadian participants were most concerned about 
weight gain as well as the convenience of injections and their timing. The cost of 
insulin, injection devices and consumables is also reported elsewhere as a barrier to 
insulin treatment for people with T2D, most commonly in ethnic minority participant 
groups (Guimarães et al., 2010; Hayes et al., 2006; Hunt et al., 1997; Khan et al., 
2008; Noakes, 2010). 
2.3.2.2. Lifestyle and social consequences 
Insulin therapy is generally perceived to be an intensive and burdensome self-
management activity. For some individuals, the burden of self-injecting and 
adjusting insulin doses is something they do not feel able to manage, thus increasing 
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their dependence on family members and HCPs to support them in these activities 
(K. W. Chen et al., 2012; Guimarães et al., 2010; Khan et al., 2008; Tan et al., 2011). 
However, the inconvenience of insulin and the hassle it places on eating times and 
restrictions surrounding daily activities are more commonly reported negative 
consequences (Abu Hassan et al., 2013; Singh, Cinnirella, & Bradley, 2012). Further, 
after integrating insulin therapy into one’s lifestyle, the addition of more injections 
per day may again be cause for concern. For example, in the few qualitative studies 
exploring attitudes towards insulin intensification, participants reported concerns 
about the need to juggle their daily routine to make time for additional injections and 
wishing to avoid injecting in public (Jenkins et al. 2011), as well as a preference for 
fewer injections per day (Simon et al., 2014). 
The potential for needing to inject insulin in a public space and the 
consequential social embarrassment is a concern (Abu Hassan et al., 2013; Shiu, 
Kwan, & Wong, 2003). Chinese participants report feeling that if they inject in 
public, others may perceive them as drug addicts or it may draw negative attention to 
them as the public feel the condition is self-induced (Shiu et al., 2003). Social stigma 
surrounding diabetes has been an overlooked and potentially underestimated 
phenomenon, the occurrence and impact of which is only now coming to the fore 
(Browne, Ventura, Mosely, & Speight, 2013; Kalra & Baruah, 2015; Schabert, 
Browne, Mosely, & Speight, 2012). Fears about injecting in public have 
consequences for optimal diabetes self-management with reports of missing or 
delaying insulin doses due to social embarrassment (Jenkins et al., 2011; Shiu et al., 
2003). Further, Bangladeshi people living in London report that the stigma 
associated with insulin has negative implications for relationships and marriage 
prospects (Khan et al., 2008).  
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2.3.2.3. Symbolic consequences 
A commonly reported belief is that needing insulin indicates an increase in the 
severity of the condition. In an Australian study, participants rated T2D as being 
‘mild’ if managed with dietary modifications, more serious if requiring oral 
hypoglycaemic agents, and more serious again if diabetes-related complications had 
occurred, but most severe if managed with insulin (Dunning & Martin, 1997). The 
belief that insulin indicates a more serious stage of diabetes relates also to the 
erroneous beliefs held by people with T2D that insulin is the cause of serious 
diabetes complications, such as blindness and amputations, or even death (e.g. K. W. 
Chen et al., 2012; Hu, Amirehsani, Wallace, & Letvak, 2012); insulin is an end-stage 
treatment or last resort treatment (e.g. Brod, Alolga, & Meneghini, 2014; Hassali et 
al., 2013; Hayes et al., 2006; Hu et al., 2012); and insulin is a punishment for 
‘failing’ to self-manage their diabetes previously (e.g. Bogatean & Hâncu, 2004; 
Hayes et al., 2006). For example, some report feeling shocked when insulin therapy 
is finally prescribed, previously considering it only to be a threat, and anger that they 
are being unfairly punished for sub-optimal diabetes management (Morris et al., 
2005). For some people with T2D, the recommendation of insulin initiation felt like 
a loss of control of their body (Vermeire, Van Royen, Coenen, Wens, & Denekens, 
2003), or led to a sense of powerlessness and a feeling that they are being controlled 
by their condition and medications (Hayes et al., 2006; Morris et al., 2005). 
 Perceived benefits of insulin initiation 
Understanding negative beliefs about, and barriers to, insulin use has been the 
primary focus of qualitative research, with benefits or positive aspects of insulin 
therapy infrequently reported. When positive aspects of insulin are reported, they are 
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generally concentrated on the positive physiological consequences of insulin and 
reported mainly by those already using insulin. Prior to insulin initiation, 
understanding that insulin is an effective treatment, which may lower blood glucose 
levels and, therefore, reduce the risk of developing diabetes-related complications, 
acts as a facilitator of insulin acceptance (Abu Hassan et al., 2013). Post-insulin 
initiation, participants identify that insulin is more effective at lowering blood 
glucose levels than other medications, in addition to delaying complications and 
enabling them to live longer (Guimarães et al., 2010; Morris et al., 2005; Vinter-
Repalust, Petriček, & Katić, 2004). Further, many participants view using insulin as 
a positive step in their treatment, which has led to increased understanding of their 
diabetes and its treatment, improved diabetes, as well as increased personal control 
over the management of their condition.   
A small-scale interview study investigating attitudes towards insulin therapy 
before and after a HCP-led educational intervention about insulin, concluded that 
after receiving education, participants were more accepting of insulin therapy and 
reported that injecting insulin therapy seemed much easier than expected (Hassali et 
al., 2013). Similarly, a general relief felt after injecting insulin for the first time is 
commonly reported by both HCPs and people with T2D (Furler et al., 2011; Hayes et 
al., 2006; Jenkins et al., 2010; Morris et al., 2005; Noakes, 2010; Phillips, 2007a, 
2007b; Tapu-Ta'ala, 2011), and insulin pens and devices are reportedly much easier 
to use than expected (Hu et al., 2012; Jenkins et al., 2010; Phillips, 2007a; Tan et al., 
2011; Vinter-Repalust et al., 2004). Similarly, Vijan et al. (2005) reported the 
perceived burden of injections tends to decrease following insulin use, while 
Ratzmann (1991) reported that negative perceptions of insulin diminished four 
months after initiation, except for the perception that insulin means diabetes has 
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reached a more serious stage. Morris et al. (2005) reported that for those participants 
whose resistance to insulin had lessened after insulin initiation, a realisation that 
insulin was actually helping, rather than hindering, was common. This suggests that 
the initiation of insulin itself may attenuate negative insulin appraisals.   
 Formation of attitudes towards insulin therapy 
Understanding what influences the development of attitudes toward insulin and 
how they change over time can assist in the development of strategies and 
interventions to increase receptiveness to insulin therapy among those with T2D, 
and, in turn, improve the timely initiation of insulin therapy. The in-depth qualitative 
investigation of attitudes held by those with T2D either before or after insulin 
initiation provides insights into how these attitudes may have developed and what 
may have influenced resistance or receptiveness towards insulin. Hunt et al. (1997) 
proposed that the formation of attitudes towards insulin is grounded within three 
sources: self-experience, experience of others, and relationships with their HCPs. 
These are discussed below in reference to more recent literature.  
2.3.4.1. Self-experience  
As discussed earlier (Section 2.3.1.), perceiving insulin initiation as necessary 
may be influenced by a person’s experience of symptom discomfort caused by 
prolonged hyperglycaemia or their understanding of their own diabetes progression. 
For example, the provision of information and tools required to understand changes 
in blood glucose patterns and recognise symptoms of hyperglycaemia may allow the 
person with T2D to recognise the inefficacy of their current treatment and take 
personal responsibility for the management of their condition (Fisher et al., 2012). 
Self-experience as a potential enabler of psychological insulin receptiveness is also 
  
35 
 
evidenced through the relief commonly reported after injecting insulin for the first 
time (Furler et al., 2011; Hayes et al., 2006; Jenkins et al., 2010; Morris et al., 2005; 
Noakes, 2010; Phillips, 2007a, 2007b; Tapu-Ta'ala, 2011), whereby this experience 
may increase self-confidence and autonomy in the management of their diabetes 
(Fisher et al., 2012) and provide a sense of power over one’s body (Furler et al., 
2011; Morris et al., 2005; Vinter-Repalust et al., 2004). Similarly, for some who are 
already injecting insulin, additional injections per day is of little concern due to 
already being familiar with the requirements of the treatment, while for others new 
injection experiences (such as additional injections during the day, perhaps in public) 
may cause greater concern (Jenkins et al., 2011). In addition to injection 
administration, self-experience of insulin therapy side effects plays a role in optimal 
insulin use after initiation. People with T2D report not fully understanding 
hypoglycaemia until they have actually experienced it (Nair, Levine, Lohfeld, & 
Gerstein, 2007). Hunt et al. (1997) noted that participants who described 
experiencing negative side effects of insulin therapy, such as hypoglycaemia, 
perceived insulin to be more harmful and felt discouraged to continue taking their 
insulin therapy.  
2.3.4.2. Influence of others  
Wolffenbuttel et al. (1993) proposed that the most important determinant of 
intention to initiate insulin is the ‘subjective norm’, defined as the opinion of 
‘significant others’ (e.g. usual HCPs, family and friends). Amongst a Mexican 
American sample, Hunt et al. (1997) reported observations of others’ experience 
with insulin as well as conversations with those using insulin as an important 
contributor to the development of beliefs about insulin therapy. Observing family 
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members use insulin therapy successfully has been reported as a facilitator of insulin 
initiation among people with T2D (Abu Hassan et al., 2013; Patel, Stone, 
McDonough, et al., 2015), and family history of insulin use has been associated with 
less negative attitudes towards insulin (K. P. Lee, 2015). However, people with T2D 
frequently report discussions or experiences with family members and friends about 
the negative aspects of insulin use which may heighten concern about insulin therapy 
initiation (Ho & James, 2006; Hu et al., 2012; e.g.Khan et al., 2008; Patel, Stone, 
McDonough, et al., 2015). For example, in a study exploring the meaning of insulin 
use to a group of Hispanic Americans with T2D and their families, family 
misconceptions about insulin and lack of support was a barrier to optimal diabetes 
management (Hu et al., 2012). Families and friends may perceive insulin, rather than 
the possible several years of prolonged hyperglycaemia, as causing deterioration in 
health (e.g. Bogatean & Hâncu, 2004; Hu et al., 2012; Hu et al., 2013). HCPs also 
report the negative influence of family and friends on the initiation of insulin, 
particularly among those with non-Western cultural heritage (Jeavons et al., 2006; Y. 
K. Lee et al., 2012; Patel et al., 2012). Lee et al. (2015) suggested that the role of the 
family in the decision to initiate insulin varies according to the family dynamic, from 
the family playing an active role in helping to gather information and attend clinic to 
avoiding sharing personal health information. Both HCPs and people with T2D have 
discussed the inclusion of families in diabetes education (e.g. clarifying family 
member roles in the individual’s health care) (Hu et al., 2012; Patel et al., 2012) and 
peer group education (Bogatean & Hâncu, 2004; Noakes, 2010; Patel et al., 2012; 
Phillips, 2007a, 2007b; Vinter-Repalust et al., 2004) as possible enablers of insulin 
initiation. 
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2.3.4.3. Relationship with healthcare professionals 
HCPs commonly report patients’ beliefs and cultural or familial barriers as 
influencing the decision to initiate insulin, but rarely discuss their own influence on 
their patients. The impact of interactions between HCPs and people with T2D, and 
how insulin appraisals might be shared through these interactions, is a potential 
enabler, or barrier, to both the timely recommendation and the initiation of insulin. 
For example, Karter et al. (2010) have found that people with T2D who do versus do 
not fill their initial prescription of insulin therapy differ according to their 
interactions with their HCP. Those who report not filling their prescription were 
significantly more likely to report that the risks and benefits of insulin therapy were 
not well explained to them and were significantly less likely to have received insulin 
training from a doctor, nurse or education class, compared to those who filled their 
insulin prescription. People with T2D identify early discussion of insulin within care 
and good rapport with their HCP as potential facilitators of insulin receptiveness 
(Abu Hassan et al., 2013; Bogatean & Hâncu, 2004; Jenkins et al., 2010; Noakes, 
2010; Patel, Stone, McDonough, et al., 2015; Phillips, 2007a; Tan et al., 2011; 
Vinter-Repalust et al., 2004), and HCPs highlight the importance of early education 
and discussion about diabetes and its treatment (J. B. Brown et al., 2002). However, 
HCPs attempts to engage people with T2D in their diabetes self-management often 
include inaccurate and harmful language use which may, in effect, delay insulin 
initiation (Speight, Conn, Dunning, & Skinner, 2012). For example, HCPs may use 
the need for insulin as a veiled threat to improve self-management long prior to the 
need to initiate insulin, which reinforces among people with T2D the idea of insulin 
as a ‘last resort’ option and as a punishment for suboptimal medical outcomes 
(Morris et al., 2005; Phillips, 2007a; Tan et al., 2011). Struggling to reach treatment 
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goals can be frustrating and promote feelings of failure and self-blame (Beverly et 
al., 2012; Krall et al., 2014), and contribute to the negative and emotional reactions 
to insulin recommendation commonly reported (Jeavons et al., 2006; Morris et al., 
2005; Phillips, 2007b).  
Studies exploring HCPs’ attitudes suggest that they have preconceived ideas 
about patients’ willingness to initiate insulin or their likelihood of taking insulin as 
recommended (Haque et al., 2005; Y. K. Lee et al., 2012; Patel et al., 2012; Tan et 
al., 2011). They report their expectation of patients’ emotional reactions to insulin as 
a barrier to insulin recommendation (Furler et al., 2011; Jeavons et al., 2006; Jenkins 
et al., 2010; Y. K. Lee et al., 2012; Phillips, 2007b; Tan et al., 2011). The assumption 
that patients will be distressed by the idea of insulin may influence HCP-patient 
communications and, perhaps, discourage HCPs from introducing insulin therapy in 
earlier consultations (K. W. Chen et al., 2012; Noakes, 2010; Tan et al., 2011), or 
encourage HCPs’ preference to discuss the benefits of insulin therapy and downplay 
or ignore possible risks or barriers to insulin (Y. K. Lee, Lee, & Ng, 2013). 
HCPs report a number of barriers, beyond those expressed by the person with 
T2D, which contribute to the delayed recommendation of insulin therapy, or clinical 
inertia. These barriers may delay or prevent early education about and discussion of 
insulin within care, thus not adequately assisting people with T2D to formulate an 
understanding of, or positive attitudes, about treatment intensification. First, HCPs 
may hold beliefs about insulin that are incorrect or inconsistent with optimal care. 
For example, some HCPs report avoiding insulin initiation in people who are obese, 
‘non-adherent’, have diabetes-related co-morbidities, or due to the increased risk of 
hypoglycaemia (Haque et al., 2005; Hayes, Fitzgerald, & Jacober, 2008; 
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Ratanawongsa et al., 2012). HCPs who have lower belief in the efficacy of insulin, 
and non-specialist HCPs report a higher preference to delay insulin initiation until 
absolutely necessary (Peyrot et al., 2005). Second, HCPs have varying levels of 
experience and knowledge of initiating insulin in people with T2D and they report 
feeling that they require further education in insulin initiation, including clear 
practice guidelines, hands-on experience and supervision (Greaves et al., 2003). 
Hence, a number of HCPs report anxiety and lack confidence in their knowledge and 
abilities to initiate insulin and may be overwhelmed by the specifics of initiating 
insulin (Furler et al., 2011; Tan et al., 2011). Lacking diabetes-specific education and 
confidence may reduce motivation to discuss or initiate insulin and a preference to 
refer patients to specialists (Haque et al., 2005; P. Y. Lee, Y. K. Lee, & C. J. Ng, 
2012; Y. K. Lee et al., 2012; Tan et al., 2011).  
Finally, the logistical limitations of health consultations are frequently raised 
by HCPs as a barrier to insulin initiation. These include language barriers (Haque et 
al., 2005; Jeavons et al., 2006; P. Y. Lee et al., 2012; Y. K. Lee et al., 2012; Patel et 
al., 2012); restricted consultation times (e.g. Furler et al., 2011; Greaves et al., 2003; 
P. Y. Lee et al., 2012; Patel et al., 2012); and a lack of continuity of care (e.g. 
Greaves et al., 2003; Haque et al., 2005; P. Y. Lee et al., 2012; Tan et al., 2011). The 
perceived lack of time and ease of communication has led some HCPs to report that 
the ability to educate patients about insulin devices, algorithms and injecting is too 
difficult and may be avoided, and some report deferring initiation until the next 
appointment or for another HCP to handle (Y. K. Lee et al., 2012; Tan et al., 2011). 
Given HCPs also report consultation times and the complexity of insulin therapy 
being barriers to insulin recommendation, it is not surprising then that people with 
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T2D who may be naïve to insulin therapy commonly perceive insulin therapy as 
complex and difficult. 
 Summary of qualitative research identifying attitudes to insulin  
A vast body of exploratory qualitative research has been conducted with the 
aim of identifying attitudes towards insulin among people with T2D to better 
understand how these attitudes form and why people with T2D may choose to delay 
insulin initiation. An extensive list of attitudes towards, and potential barriers and 
facilitators of, insulin initiation is synthesised above. To date, one qualitative study 
of PIR has been undertaken in Australia, which focused largely on HCP perceptions 
of insulin initiation (Furler et al., 2011). While we may expect to find similar results 
among Australian adults with T2D, as found elsewhere, further research is required 
to corroborate this assumption.  
While many qualitative studies include adults with insulin-treated T2D, most 
focus on understanding attitudes towards insulin prior to, or at the time of, initiation. 
With a few exceptions, little research has examined the experience of actual insulin 
use, including ongoing barriers to optimal insulin use (Morris et al., 2005; Phillips, 
2007a), or attitudes toward the intensification of insulin therapy (Jenkins et al., 2011; 
Simon et al., 2014). To advance the field of knowledge, additional research including 
people already using insulin needs to explore possible ongoing, or unforeseen, 
positive or negative consequences of insulin use and how these consequences might 
impact on participants’ diabetes self-management (i.e. insulin omission) and attitudes 
toward insulin intensification. Further qualitative research is needed to explore 
ongoing facilitators and barriers of optimal insulin use and drivers of willingness to 
intensify insulin in the real world.  
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 Quantifying Psychological Insulin Resistance and Receptiveness and 
Associated Factors 
In accordance with the traditional focus of PIR research (identifying barriers to 
insulin initiation), insulin refusal rates among people with T2D may provide a useful 
quantification of the rate of PIR. Similarly, the reverse may also be true, in that rates 
of insulin initiation at the time of recommendation may be helpful in quantifying 
receptiveness to insulin therapy. Many studies have explored delay of insulin 
initiation from a clinical perspective, e.g. time to and proportion of insulin uptake 
among those with T2D who clinically require insulin (for example: Keij et al., 2016; 
K. Khunti, Damci, Meneghini, Pan, & Yale, 2012). However, it is unclear what 
proportion of the delayed insulin initiation is due clinical inertia (i.e. lack of 
prescription/recommendation of insulin by the HCP), and what proportion is due to 
insulin refusal or delay by the person with diabetes who has PIR. Limited data are 
available on the proportion of people with T2D recommended insulin who refuse, 
delay or immediately initiate insulin.  
The landmark UK Prospective Diabetes Study (UKPDS), a 20-year multicentre 
trial of glycaemic therapies among newly diagnosed adults with T2D, provided early 
insight into the proportion of people with T2D who refuse insulin therapy. Eligible 
newly diagnosed participants referred between 1977 and 1987 (N=2,520) were 
allocated to receive diet alone, or diet plus one of four pharmacological treatments 
(including insulin therapy) (U.K. Prospective Diabetes Study Group, 1995). Of those 
allocated to receive insulin (N=676), 27% refused this form of therapy (U.K. 
Prospective Diabetes Study Group, 1995). In comparison, less than half as many 
participants refused prescribed OHA medications. In a single clinic study exploring 
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PIR among a UK Bangladeshi population, 58% of those recommended insulin 
therapy (N=212) immediately commenced insulin (Khan et al., 2008). A further 22% 
initiated insulin within three months. However, one in five participants remained 
unwilling to commence insulin regardless of receiving two counselling sessions 
(Khan et al., 2008). In a recently published multi-centre longitudinal study 
undertaken in Japan, 57% of adults with T2D who were recommended insulin 
therapy (N=130) had commenced insulin within four months (Odawara et al., 2016). 
This proportion significantly differed according to the qualification of the 
participant’s primary HCP, whereby those receiving care from a Japan Diabetes 
Society accredited specialist were less likely to refuse insulin (30%) than those 
receiving care from general practitioners (68%). However, data collection took place 
over a decade prior to publication. 
The above studies suggest that insulin refusal rates, a behavioural consequence 
of PIR, may range from 20% to 43% of those recommended insulin, depending on 
the support received, the study setting (i.e. clinical trial, real-word cohort study) and 
population. Further research is required to better understand real-world, cross-
country insulin refusal rates. PIR and receptiveness have been more commonly 
measured quantitatively in two main ways: through the assessment of 1) hypothetical 
intention to commence insulin therapy, and 2) attitudes towards insulin, or insulin 
appraisals. These methods of measuring PIR and receptiveness are described below.   
2.4.1. Hypothetical insulin refusal and acceptance 
The proportion of people with T2D who may be receptive to insulin or 
reluctant when prescribed is commonly inferred through the proportion of people 
who report being hypothetically willing/unwilling to initiate insulin. This is generally 
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assessed using a single item, e.g. “If your doctor recommended that you start insulin, 
how willing would you be to take it?” (Polonsky et al., 2011). This wording, or 
similar, has been used internationally (Gherman & Alionescu, 2015; Larkin et al., 
2008; K. P. Lee, 2015; Nur Azmiah, Zulkarnain, & Tahir, 2011; Polonsky, Fisher, 
Dowe, & Edelman, 2003; Polonsky, Fisher, Guzman, Villa-Caballero, & Edelman, 
2005; Polonsky et al., 2011; Wong et al., 2011; Woudenberg, Lucas, Latour, & 
Scholte op Reimer, 2012). Rates of ‘unwillingness’ vary considerably across 
samples. For example, in a recent multi-national study, the reported proportion of 
people with T2D ‘not at all willing’ to initiate insulin differed between countries, 
from 6% (Spain) to 37% (Italy), with an average of 17% (Polonsky et al., 2011). In 
contrast, the average proportion of participants who reported being receptive, i.e. 
moderately or very willing, to insulin initiation across countries was 48%, with a 
further 35% ambivalent. In Singaporean and Malaysian samples of adults with T2D, 
rates of ‘unwillingness’ have been reported as high as 71% (Wong et al., 2011) and 
51% (Nur Azmiah et al., 2011), respectively. The proportion of Australians with 
T2D (un)willing to begin insulin is unknown.   
To date, research exploring willingness to commence insulin has most often 
been conducted using convenience or clinical samples of people at various stages of 
diabetes progressions, not only among those for whom insulin has been clinically 
indicated (e.g. prolonged hyperglycaemia on maximum OHA dosage). Thus, studies 
quantifying ‘willingness’ to begin insulin may include a substantial proportion of 
people who report being ‘unwilling’, not only because they display PIR, but because 
they are aware that insulin would be an inappropriate or unnecessary treatment 
progression at this stage of their diabetes. Further, these single items do not capture 
any information about why a person is willing or unwilling to initiate insulin. Thus, 
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the item is often accompanied by other single items or scales that explore the positive 
and/or negative attitudes toward insulin which contribute to PIR/receptiveness. 
2.4.2. Insulin appraisals among adults with non-insulin-treated T2D 
Questionnaires may be used to measure positive or negative insulin appraisals 
(attitudes), which may contribute to PIR or receptiveness. Study-specific items have 
been used to quantify prevalence of negative attitudes towards insulin within certain 
populations (e.g. Ahmed et al., 2010; Wong et al., 2011), predictors of such attitudes 
(e.g. Peyrot et al., 2005), how such attitudes differ by hypothetical willingness to 
begin insulin (Polonsky et al., 2011), and actual insulin uptake (Odawara et al., 
2016). However, such items are commonly unvalidated, with little description 
provided of the item wording or development, and scale brevity is often prioritised 
over comprehensiveness, validity, or reliability. As such, it is unclear whether these 
items have comprehensively assessed the range of attitudes towards insulin among a 
specific group and whether these items, and the study findings, are generalisable 
across T2D population groups, and indeed whether they would be sensitive to change 
in attitudes. 
In 2007, the development and validation of three PIR scales were published: 
the ‘Barriers to Insulin Treatment’ (BIT) questionnaire developed in Germany for 
people with non-insulin-treated T2D (Petrak et al., 2007); the ‘Insulin Treatment 
Appraisal Scale’ (ITAS), developed in the USA, measuring PIR in people with T2D, 
both insulin-treated and non-insulin-treated (Snoek, Skovlund, & Pouwer, 2007); and 
the ‘Study the Hurdles of Insulin Prescription’ (SHIP) questionnaire for use with 
people with type 1 diabetes or T2D (Martinez et al., 2007). All three measures 
include both positive and negative aspects of insulin initiation. SHIP is not specific 
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to T2D, is not easily accessible and has not been widely used, thus it is not discussed 
further. The BIT questionnaire, which was designed for people with T2D not yet 
using insulin, and the ITAS, designed for both non-insulin-users and insulin-users, 
are both discussed in detail in the following section. More recently, the 13-item 
Chinese Attitudes to Starting Insulin Questionnaire (Ch-ASIQ) has been published 
(Fu et al., 2013). Ch-ASIQ was developed specifically for Chinese primary care 
patients with non-insulin-treated T2D, with a focus on the concerns of older adults. 
This scale has been used only once since its validation (Fu et al., 2016). In addition 
to these questionnaires, developed specifically to assess PIR in people with T2D, a 
number of others are relevant, but not specific, to PIR. For example: a measure of 
fear of self-injecting or self-testing (Snoek, Mollema, Heine, Bouter, & Van Der 
Ploeg, 1997), insulin-specific treatment satisfaction (e.g. Anderson et al., 2004), and 
concerns about hypoglycaemia (Polonsky, Fisher, Hessler, & Edelman, 2015). 
However, these measures either focus too specifically on a single issue that might 
affect willingness to use insulin, or they assess satisfaction with insulin without 
identifying factors influencing satisfaction. Furthermore, these scales may not be 
developed specifically for people with T2D and therefore they may not fully capture 
the concerns specific to this population.  
2.4.2.1. Barriers to Insulin Treatment questionnaire 
The development of the BIT questionnaire involved the compilation of a pool 
of 35-items by an expert panel of diabetes HCPs based on clinical experience, 
interviews with people with T2D and literature review (Petrak et al., 2007). This pool 
of items was then tested in a survey of 488 German adults with non-insulin-treated 
T2D, followed by item reduction analysis. The resulting final items were then 
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validated in a different sample of 449 adults with non-insulin-treated T2D who were 
categorised as receiving ‘insufficient’ diabetes pharmacological treatment, defined as 
an Hba1c ≥7.5% (58mmol/mol). The BIT questionnaire was developed and validated 
for people with T2D who were not currently using insulin therapy. However, the 
scale has been used, although not validated, among participants already using insulin 
therapy (Bahrmann et al., 2014; Hermanns et al., 2015). Following statistical 
validation, the German questionnaire was translated into English, which involved a 
vigorous validation process, including: forward and backward translations, item 
review by HCPs, and cognitive debriefing with English-speaking adults with T2D.  
The BIT questionnaire includes 14 items comprising five subscales: fear of 
injection and self-testing; expected positive insulin-related outcomes; expected 
hardship from insulin treatment; stigmatisation by insulin injections; and fear of 
hypoglycaemia (Petrak et al., 2007). Each item is presented as a statement about 
insulin therapy with response options on a ten point scale from ‘completely disagree’ 
(0) to ‘completely agree’ (10). Authors suggest total and subscale scores can be 
calculated by taking a mean of item scores. The total scale and subscales show 
satisfactory internal reliability (Cronbach’s α=0.62-0.85) (Petrak et al., 2007). 
Items included in the BIT questionnaire refer more commonly to the physical 
aspects of insulin use or technical concerns, such as side effects and pain, compared 
to the meaning of insulin, e.g. feelings of failure/self-blame or increased diabetes 
severity. In the validation sample, the most highly endorsed subscales related to 
expectations about positive insulin-related outcomes and fear of hypoglycaemia 
(Petrak et al., 2007), which has been replicated in more recent studies using the BIT 
questionnaire (Bahrmann et al., 2014; Nam, Chesla, Stotts, Kroon, & Janson, 2010; 
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Petrak, Herpertz, Stridde, & Pfützner, 2013).The two-item fear of hypoglycaemia 
subscale is preceded by a statement indicating that insulin can lead to low blood 
glucose. Such ‘scene-setting’ does not feature elsewhere in the questionnaire and 
likely increases endorsement of these items among those with T2D who may be 
otherwise unaware of the increased possibility of experiencing hypoglycaemia as a 
side effect of insulin therapy.   
2.4.2.2. Insulin Treatment Appraisal Scale 
The ITAS is a commonly used measure of PIR, and Chinese and Romanian 
versions have been validated (Chang, Huang, Li, Liao, & Chen, 2010; Gherman & 
Alionescu, 2015). The ITAS was developed with the aim of capturing current insulin 
appraisals among those with T2D, regardless of insulin use (Snoek et al., 2007). Item 
generation was informed by literature review, discussion with HCPs and clinical 
experience with people with insulin-treated and non-insulin-treated T2D. Authors 
proposed a 20-item scale, including 16 statements referring to the negative aspects of 
insulin use and four referring to the positive aspects of insulin. Items include positive 
aspects of insulin use as well as potential physical, social and symbolic consequences 
of insulin use. Response options range, on a 5-point Likert scale, from ‘strongly 
disagree’ (1) to ‘strongly agree’ (5). The ITAS was conceptualised as a two-
dimensional scale (positive and negative) with a single underlying construct: insulin 
therapy appraisals. Consistent with this, exploratory factor analyses reveal a two-
factor structure. Subscales are calculated by taking a sum of relevant items and the 
total score is calculated by summing all 20 items after reverse scoring the positively 
worded items. Higher scores indicate more negative insulin appraisals for the total 
ITAS score (Cronbach’s α=0.89) and negative subscale score (Cronbach’s α=0.90), 
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while for the positive subscale score, higher scores indicate less negative insulin 
appraisals (Cronbach’s α=0.64) (Snoek et al., 2007). Consistent with findings from 
the BIT questionnaire, in the majority of studies employing the ITAS, the positively-
worded statements are highly endorsed (agreed or strongly agreed with) by those not 
yet using insulin therapy (C. C. Chen et al., 2011; Larkin et al., 2008; Snoek et al., 
2007; Woudenberg et al., 2012). However, the item referring to the increased risk of 
hypoglycaemia is not endorsed as commonly as would be expected given the results 
of the BIT questionnaire.  
Unlike the BIT questionnaire, the ITAS (Snoek et al., 2007) was developed for 
use with people with T2D regardless of insulin use, which enables assessment of 
insulin appraisals between treatment groups, and before and after insulin initiation. 
However, factor analysis and internal reliability assessments were conducted on the 
sample as a whole, across treatment groups. Thus, statistical validity should be re-
assessed separately for each treatment group to ensure the 20 items, and total and 
subscale scores, perform consistently between groups.  
2.4.3. The role of hypothetical willingness and insulin appraisals in the 
prediction of actual insulin uptake 
The discriminatory power of the BIT questionnaire and the ITAS has been 
assessed in relation to a hypothetical choice made by adults with non-insulin-treated 
T2D about whether to begin insulin therapy. Using the BIT questionnaire in a cross-
sectional study, the attitudes of participants who hypothetically chose to initiate 
insulin were significantly less negative and endorsement of expectations about 
positive insulin-related outcomes was significantly greater compared to those who 
choose not to initiate injectable insulin therapy (Petrak et al., 2013; Petrak et al., 
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2007), although the positive insulin-related outcomes subscale was the most highly 
endorsed regardless of hypothetical choice. This suggests that even those participants 
who hold strong negative appraisals of insulin therapy may be commonly aware of 
the positive aspects of insulin therapy, perhaps due to HCPs’ tendency to prefer 
comprehensive education about the benefits of insulin therapy over the risks or 
barriers (Y. K. Lee et al., 2013). In addition, Woudenberg et al. (2012) and Larkin et 
al. (2008) both reported in cross-sectional studies that participants who were 
‘willing’ to initiate insulin if recommended display lower, less negative, total ITAS 
scores than those who are ‘unwilling’. However, assessment of willingness is 
hypothetical and items have never been validated to determine their discriminant 
validity, i.e. their ability to identify actual refusals versus those showing initial or 
hypothetical reluctance but initiating insulin.  
 In the first longitudinal study employing the ITAS, 73 adults with non-insulin-
treated T2D, who required treatment intensification, completed the ITAS at baseline 
and at three months follow-up (Hermanns, Mahr, Kulzer, Skovlund, & Haak, 2010). 
In this time, 44 participants switched to insulin therapy and 29 remained on OHAs. 
Those who transferred from oral treatment to insulin displayed slightly lower ITAS 
scores (less negative insulin appraisals) at baseline than those remaining on OHAs, 
suggesting that they were more receptive to the prospect of initiating insulin 
(Hermanns et al., 2010). Further, a cohort study comparing attitudes about insulin 
(measured using study-specific non-validated items) among a purposively selected 
sample of people with T2D who did and did not fill their prescription for insulin 
initiation found that those who did not fill their initial prescription displayed 
significantly more negative attitudes towards insulin (Karter et al., 2010).  
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At the time of undertaking the current program of research, no further evidence 
in support of the relationship between insulin appraisals and insulin uptake was 
available. More recently, Odawara et al. (2016) reported that in a longitudinal study 
of Japanese adults with T2D for whom insulin was recommended (N=130), those 
who initiated insulin (57%) reported significantly less negative, and more positive, 
insulin appraisals, at baseline, compared with those who remained on OHAs. Insulin 
appraisals were measured using a study-specific questionnaire. Elsewhere, the BIT 
questionnaire has been shown to be predictive of time to insulin initiation, whereby 
more negative appraisals among adults with newly diagnosed T2D were associated 
with a longer time to insulin initiation after accounting for diabetes-related emotional 
distress (Keij et al., 2016). However, these studies have not investigated this 
association in the context of other known correlates (see Section 2.4.5) of PIR and 
insulin uptake. Prospective research is needed, using validated measures of attitudes 
towards insulin, as well as accounting for the effect of other known or potential 
correlates of PIR, to corroborate the finding that attitudes towards insulin are 
predictive of willingness to begin insulin and, indeed, actual insulin uptake.  
2.4.4. Psychological insulin resistance and receptiveness in people with 
T2D using insulin 
Most research into PIR has focused on gauging willingness to, or attitudes 
towards, insulin initiation among those who have not yet commenced insulin. Once 
insulin has been initiated the concept of PIR might be considered of less relevant. 
Consistent with this, adults with insulin-treated T2D report less negative Total ITAS 
scores compared to those using OHAs (Bahrmann et al., 2014; C. C. Chen et al., 
2011; Hermanns et al., 2010; Snoek et al., 2007). This may be due to one, or both, of 
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the two following reasons: 1) those who commence insulin display less negative 
attitudes towards insulin prior to insulin initiation (as discussed above); and 2) 
insulin experience may attenuate negative insulin appraisals. Indeed, when assessing 
hypothetical treatment preferences, adults with T2D using insulin place significantly 
less importance on treatment administration type (oral versus injection) (Casciano, 
Malangone, Ramachandran, & Gagliardino, 2011) and significantly greater 
importance on glucose control, in comparison to the frequency of administration per 
day (Hauber, Johnson, Sauriol, & Lescrauwaet, 2005), than those not using insulin. 
Further, people with T2D who transfer from oral treatment to insulin therapy display 
significantly less negative insulin appraisals, as measured using the ITAS (Hermanns 
et al., 2010; Liebl et al., 2013) or study-specific items (Odawara et al., 2016), 
significantly greater self-efficacy in insulin therapy (Hayes et al., 2013) , and 
improved general treatment satisfaction (Wilson, Moore, & Lunt, 2004), after 
initiating insulin, suggesting that the use of insulin modifies attitudes.  
However, certain negative ITAS items are commonly endorsed by people with 
insulin-treated T2D. For example, the top areas of concern in the ITAS validation 
study, including a sample of people with insulin-treated T2D in the US, were side 
effects, inflexibility and pain of insulin use (Snoek et al., 2007). Chen et al. (2011) 
reported that Chinese people using insulin were more concerned about the meaning 
of insulin, endorsing items regarding diabetes severity and previous treatment failure. 
Both groups commonly agreed that using insulin was associated with friends and 
family becoming more concerned about them. Furthermore, the mean and standard 
deviations of observed ITAS scores in insulin-treated versus non-insulin-treated 
participants suggests that at least a minority of people with T2D using insulin display 
negative evaluations of insulin therapy equivalent to those not using insulin. 
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Among those already using insulin, research has focused on medication-taking 
behaviours (i.e. omission: purposively skipping an injection) and associated factors, 
rather than PIR explicitly (e.g. Karter et al., 2010; Peyrot, Barnett, Meneghini, & 
Schumm-Draeger, 2012b; Peyrot, Rubin, Kruger, & Travis, 2010). Rates of insulin 
omission vary widely across studies. A recent systematic review of 17 studies 
examining insulin-taking behaviours among those with type 1 diabetes or T2D 
concluded that self-reported insulin ‘adherence’ ranged from 43% to 86% (Davies et 
al., 2013). In the Global Attitudes of Patients and Physicians study, 35% of 
participants across eight countries reported omitting their insulin on at least one day 
within the last month (Peyrot, Barnett, Meneghini, & Schumm-Draeger, 2012a), 
while in the more recent US study, 46% of participants reported ‘non-adherence’ to 
their insulin regimen over the prior two weeks (Osborn & Gonzalez, 2016).  
Negative experiences or attitudes towards insulin therapy among those already 
using insulin may lead to insulin omission or delay of insulin injections. Quantitative 
research has examined reasons for, and implications of, insulin omission in T2D. For 
example, insulin omission among adults with type 1 diabetes and T2D may be 
related to stress or emotional problems, embarrassment of injecting in public, 
dissatisfaction with insulin treatment, the challenge of taking insulin every day at 
regular times as well as pain and side-effects caused by injections (Davies et al., 
2013; Farsaei, Radfar, Heydari, Abbasi, & Qorbani; Peyrot et al., 2012b; Peyrot, 
Rubin, Kruger, et al., 2010). Similarly, a recent study found that self-reported insulin 
omission was associated with negative impact of diabetes treatment on quality of life 
among Japanese participants with T2D (Mashitani et al., 2015). These data suggest 
that negative attitudes to, or experience of, insulin therapy may be commonplace for 
some people with T2D using insulin and may act as a barrier to optimal diabetes 
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management. Research is required to further explore change in insulin appraisals 
post insulin initiation, possible ongoing barriers to optimal insulin use, and factors 
associated with negative attitudes towards insulin therapy among those using insulin. 
In addition to insulin omission, negative attitudes to insulin therapy may also 
contribute to a person’s resistance or receptiveness to further treatment change, such 
as intensification. Survey data suggest that a third of adults with T2D using insulin 
are troubled by (Zambanini et al. 1999) or not motivated to consider (Martinez et al. 
2007) the possibility of additional daily insulin injections. However, research 
exploring PIR among adults with insulin-treated T2D rarely incorporates measures of 
receptiveness to intensify insulin therapy. In a recent study of PIR among adults 
attending primary care in Hong Kong, participants were asked an alternative to the 
hypothetical willingness item: “Will you agree to titrate insulin treatment, if 
advised…?” (K. P. Lee, 2015). Among those with insulin-treated T2D, 9% indicated 
that insulin titration would be “unacceptable”. Further, research is needed to identify 
rates of receptiveness/refusal to intensification of insulin therapy and understand 
attitudes, including barriers or concerns that may be distinct from those observed in 
relation to insulin initiation.  
2.4.5. Factors associated with psychological insulin resistance and 
receptiveness 
A growing body of research aims to identify healthcare system and clinical 
characteristics that add to the prediction of insulin uptake in large cohort studies of 
adults with T2D (Danne et al., 2015; K. Khunti et al., 2016; K. Khunti, Wolden, 
Thorsted, Andersen, & Davies, 2013; Shah, Hux, Laupacis, Zinman, & van 
Walraven, 2005). However, psychosocial factors are rarely measured in these 
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studies. Cross-sectional and some prospective research has examined demographic, 
clinical and/or psychosocial factors associated with attitudes towards insulin, 
willingness to begin insulin therapy and insulin omission. For example, the 
international Diabetes Attitudes Wishes and Needs (DAWN) study provided an 
initial insight into potential predictors of PIR in people with T2D from 13 countries 
(including Australia) using unvalidated single items about perceived efficacy of 
insulin, self-blame for needing insulin, and adherence to treatment (Peyrot et al., 
2005). Participants with a stronger belief in the efficacy of insulin were younger, had 
more diabetes-related complications, poorer relationships with HCPs, reported 
suboptimal diabetes outcomes, more diabetes-related distress and more frequent self-
monitoring of blood glucose. The DAWN study was the first to assess demographic, 
clinical, behavioural and psychosocial correlates of attitudes towards insulin, and is 
the only quantitative study of PIR in Australia to date. However, further research is 
needed to corroborate these findings and, ideally, would use validated measures of 
attitudes towards insulin (i.e. BIT, ITAS) and/or independent variables (e.g. diabetes-
related distress) rather than unvalidated single items. The section below describes the 
demographic, clinical, behavioural, and emotional characteristics associated with 
PIR or receptiveness among adults with non-insulin-treated and, where available, 
insulin-treated T2D. 
2.4.5.1. Demographic and clinical characteristics 
There are inconsistent findings regarding the association of PIR with age, 
gender, ethnicity and education. However, where an association has been found, 
those who report being unwilling to begin insulin or those with more negative insulin 
appraisals are consistently more likely to be women (e.g. Fu et al., 2016; Nam et al., 
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2010; Nur Azmiah et al., 2011; Polonsky et al., 2003; Polonsky, Fisher, Guzman, et 
al., 2005), older (Peyrot et al., 2005), of ‘non-white’ ethnic orientation (e.g. Makine 
et al., 2009; Nam et al., 2010; Polonsky, Fisher, Guzman, et al., 2005), and less 
educated (e.g. C. C. Chen et al., 2011; Wong et al., 2011). Among a sample of low-
income Latin and African-American adults with T2D, years living in the US was 
associated with PIR (Machinani et al., 2012). Those participants reporting living 
longer in the US were significantly more willing (hypothetically) to begin insulin and 
reported less endorsement across all negative insulin attitudes measured. In a recent 
study of insulin omission in Japan, Mashitani et al. (2015) reported that older adults 
with T2D were more likely to omit insulin than their younger counterparts. In 
contrast, a recent systematic review reported that women and those with higher 
education levels are more likely to report insulin omission, but that age was 
inconsistently associated with insulin omission (Davies et al., 2013).  
With regard to clinical characteristics, studies exploring predictors of insulin 
prescription and uptake within clinical samples report that those who initiate insulin 
have a higher HbA1c, longer diabetes duration, more diabetes-related complications 
and more prescribed OHAs (Danne et al., 2015; K. Khunti et al., 2013). This 
association with longer diabetes duration and worse glycaemic control may be in part 
due to the prescription of insulin being delayed by HCPs until absolutely necessary 
(Peyrot et al., 2005). Further to the delay of prescription, research suggests that 
people with T2D may be less receptive to insulin initiation, despite clinical need, if 
experiencing better diabetes outcomes and shorter disease progression. For example, 
Odawara et al. (2016) reported that those who initiated insulin had a longer diabetes 
duration (13 years and 11 years) and higher HbA1c (9.9% (84 mmol/mol) and 9.3% 
(78 mmol/mol), respectively), in addition to less negative insulin appraisals, 
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compared to those who remained on OHAs. Similarly, in a recent large-scale cross-
sectional study of PIR among adults with T2D in China, participants who reported 
refusing insulin had shorter diabetes duration, fewer complications and a lower 
HbA1c than those who accepted it (Xiong et al., 2014). Fu et al. (2016) reported a 
significant negative association between HbA1c and negative attitudes towards 
insulin among non-insulin treated Chinese with T2D, and in the DAWN study 
participants with stronger belief in the efficacy of insulin therapy reported more 
diabetes-related complications and worse perceived diabetes outcomes (i.e. glucose 
control) (Peyrot et al., 2005). Further, among those already using insulin, it has been 
reported that those with better glycaemic control (HbA1c), longer diabetes duration, 
and cardiovascular co-morbidities were less likely to omit insulin than their 
counterparts (Mashitani et al., 2015). Thus, people with T2D appear to be less likely 
to refuse, or omit, insulin when they perceive diabetes outcomes to be worse, perhaps 
due to a lack of awareness of worsening health and the necessity of insulin therapy. 
However, this delay of insulin, and associated prolonged hyperglycaemia, may 
increase the risk of diabetes-related complication development. The relationship 
between receptiveness and perceived diabetes outcomes has similarly been reported 
in qualitative research (Section 2.3.1.).  
2.4.5.2. Diabetes self-management and behavioural characteristics 
Current diabetes self-management needs and behaviours may be associated 
with receptiveness to treatment change. Consistent with the relationship between 
HbA1c and insulin receptiveness (or resistance) discussed above, a greater awareness 
of diabetes severity through SMBG and use of multiple daily OHAs may encourage 
increased receptiveness to insulin therapy. In the DAWN study, participants who 
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monitored their blood glucose more often reported stronger belief in the efficacy of 
insulin (Peyrot et al., 2005). In a cross-sectional study of Chinese adults with T2D, 
an increased number of prescribed OHAs was associated with endorsement of 
positive insulin self-efficacy beliefs, such as insulin-related knowledge, social 
support, insulin as a method to improve glucose, confidence in insulin 
administration, and management of diet in reference to insulin therapy (Fu et al., 
2016).  
Little further research has explored the relationship between self-management 
behaviours (i.e. taking medications and/or blood glucose monitoring as 
recommended) and attitudes toward insulin among adults with T2D not yet using 
insulin. However, studies have identified perceived suboptimal medication-taking 
behaviours, or ‘non-adherence’, as a reason for insulin prescription delay among 
HCPs. For example, Ratanawongsa et al. (2012) reported that 39% of HCPs would 
delay insulin initiation all or most of the time on the basis of their beliefs about a 
patient’s likelihood of adherence and 64% of HCPs perceive patient resistance as a 
reason not to recommend insulin. Similarly, people with T2D categorised as 
displaying suboptimal medication-taking behaviours were less likely to have 
medications intensified than those who displayed optimal medication-taking 
behaviours (Grant et al., 2007) and over 90% of physicians stated that lack of 
‘patient compliance’ was a barrier to insulin initiation (Nakar, Yitzhaki, Rosenberg, 
& Vinker, 2007). In contrast, in the DAWN study, HCPs who perceived their 
patients to be more ‘adherent’ to treatment recommendations and appointment times 
were more likely to delay insulin therapy (Peyrot et al., 2005). Further research 
should be conducted to identify any relationship between self-care behaviours, such 
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as SMBG and medication taking behaviours, and willingness to begin insulin therapy 
among those with non-insulin-treated T2D. 
With regard to those already using insulin therapy only one study has reported 
on the relationship between duration of insulin therapy use and negative insulin 
appraisals using a validated measure (C. C. Chen et al., 2011). Among Chinese 
adults with T2D using insulin therapy, duration of insulin therapy (<1 year compared 
to >1 year) was not associated with insulin appraisals (C. C. Chen et al., 2011). This 
suggests that, after insulin initiation, attitudes towards insulin, although more 
positive among those using insulin, do not necessarily change (become less negative) 
with greater insulin experience. Additional studies are needed to corroborate this 
finding. Further, Chen et al. (2011) also reported that mode of injections (syringe/pen 
injector) was not related to insulin appraisals. However, in research exploring 
predictors of insulin omission, switching from a vial/syringe to an insulin pen, or 
initiating insulin therapy using a pen injector device, was associated with less insulin 
omission (Davies et al., 2013). The relationship between insulin appraisals and 
prescribed number of injections per day is not known, to date, but studies report a 
positive association between injections per day and likelihood of insulin omission 
(Mashitani et al., 2015; Peyrot, Rubin, Polonsky, & Jennie, 2010). It may be that 
those using more injections per day perceived insulin to be more intrusive and hold 
more negative insulin appraisals. Future research should investigate the relationship 
between insulin use characteristics, such as duration, injections per day, and insulin 
omission, with negative insulin appraisals among those using insulin therapy.  
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2.4.5.3. Beliefs about medications  
Beliefs about insulin may relate to a person’s broader beliefs about health and 
medications, or their beliefs about current diabetes medications (i.e. OHAs). Horne 
et al. (1999) proposed that people hold beliefs about medicines in general (e.g. 
medicines are overprescribed), as well as beliefs about current medications specific 
to their diagnosed condition (e.g. insulin therapy is unnecessary for the management 
of T2D). The Beliefs about Medicines Questionnaire (BMQ) General was developed 
to assess cognitive representations of perceived ‘overuse’ and ‘harm’ of medications 
in general, while the BMQ Specific was developed to assess perceived ‘concerns’ 
about and ‘necessity’ of medications prescribed for personal use (such as OHAs) 
(Horne et al., 1999). Beliefs about medications, measured using the BMQ Specific 
and General, have been found to be associated with medication-taking behaviours 
across a range of chronic conditions, including T2D (Aikens & Piette, 2009; Horne 
& Weinman, 1999, 2002; Horne et al., 1999). In a cross-sectional study of 803 adults 
with T2D using various anti-hyperglycaemic medications, including insulin therapy 
(40%), underuse of treatment was associated with greater concern about current 
diabetes treatment (Aikens & Piette, 2009).  
Beliefs about current medications are likely related to beliefs about, and 
willingness to commence, medications not currently in use (e.g. insulin use). In the 
only T2D-specific study to explore the association between PIR and beliefs about 
current medications (Polonsky et al., 2011), participants with non-insulin-treated 
T2D who were hypothetically unwilling to commence insulin reported more negative 
beliefs about current oral medications than those who were receptive to insulin 
initiation (Polonsky et al., 2011). Thus, identifying and addressing negative beliefs 
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about current diabetes medications (OHAs) among those not yet insulin-treated may 
improve receptiveness to further diabetes medications, such as insulin therapy. 
However, the study conducted by Polonsky et al. (2011) is limited by the use of 
single items to measure beliefs about current oral medications and the fact that items 
did not specify whether the medications were for the management of diabetes 
(condition-specific beliefs) or other purposes (e.g. general medication beliefs). No 
further research has explored the role of beliefs about general or diabetes-specific 
medications on attitudes towards to insulin therapy. Further research using validated 
measures, such as the BMQ (Horne et al., 1999), is required to better understand the 
association between current medication beliefs and PIR or beliefs about future 
insulin therapy.  
2.4.5.4. Emotional wellbeing 
The relationship between PIR and emotional wellbeing, such as depression, 
anxiety, and diabetes-related distress has been a recent focus, perhaps in response to 
the availability of validated tools to assess PIR. Prevalence of depression and anxiety 
are reported to be higher amongst people with T2D compared to the general 
population (Ali, Stone, Peters, Davies, & Khunti, 2006; Grigsby, Anderson, 
Freedland, Clouse, & Lustman, 2002; Roy & Lloyd, 2012). Depressive symptoms 
have been found to be associated with impaired self-care behaviours (Gonzalez, 
Delahanty, Safren, Meigs, & Grant, 2008; Gonzalez et al., 2007), including insulin 
omission among adults with T2D (Mashitani et al., 2015). It has been suggested that, 
as depression is associated with reduced energy, perceived self-efficacy and 
motivation, depressive symptoms may also be associated with increased PIR and 
reduced likelihood to initiate insulin therapy (Gherman & Alionescu, 2015; Makine 
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et al., 2009; Nefs, Pop, Denollet, & Pouwer, 2013). Using the WHO-5 questionnaire 
to assess general emotional wellbeing (Bech, 2004), Snoek and colleagues (2007) 
found that those with a score above the cut-off indicative of depressive 
symptomatology displayed significantly higher ITAS scores than those with 
unimpaired wellbeing. Using various validated measures of depressive symptoms, 
others also report small-to-moderate significant associations between ITAS scores 
and depressive symptoms (Gherman & Alionescu, 2015; Larkin et al., 2008; Makine 
et al., 2009; Woudenberg et al., 2012) 
In regards to actual insulin uptake, a recent longitudinal study found that those 
with T2D experiencing greater severity of depressive symptoms required 
significantly more time and visits with HCPs training to self-inject, self-adjust and 
manage other aspects of insulin delivery (Dzida, Karnieli, Svendsen, Sølje, & 
Hermanns, 2015). However, no significant relationship between depressive 
symptoms and time to insulin initiation has been found (Iversen et al., 2015; Nefs et 
al., 2013). A recent cohort study of over 800 adults with T2D in Norway concluded 
that elevated depression was not associated with time until insulin initiation, but 
generalised anxiety was a predictor of delayed insulin initiation (Iversen et al., 2015). 
To date, the relationship between anxiety and attitudes towards insulin has not been 
explored among those not yet using insulin therapy. Further research is needed to 
examine the relationship between anxiety symptoms and insulin appraisals.  
 Diabetes-related distress is the emotional burden associated with living with 
diabetes (Polonsky et al., 1995). It is commonly measured using either Problem 
Areas In Diabetes (PAID) questionnaire (Polonsky et al., 1995) or the Diabetes 
Distress Scale (DDS) (Polonsky, Fisher, Earles, et al., 2005). Diabetes-related 
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distress is commonly reported among people with T2D. For example, in our cross-
sectional survey of Australian adults with diabetes, high or severe diabetes-related 
distress, measured using the DDS and PAID (Polonsky et al., 1995) respectively, was 
reported by 12% and 19% of those with T2D (Fenwick et al., 2016). Diabetes-related 
distress has been found to be moderately-to-strongly associated with depression and 
researchers in the area have noted that questionnaire measures of depressive 
symptoms may actually be capturing high levels of diabetes-related distress, rather 
than symptoms of major depression disorder (Fisher et al., 2007; Gonzalez, Fisher, & 
Polonsky, 2011). Snoek et al. (2015) proposed a need for better defined depression 
profiles, and, subsequently, measures, among people with diabetes accounting for the 
symptomatology of diabetes and diabetes-related distress, which may overlap with 
the measurement of depressive symptoms. Thus, the association between insulin 
appraisals and depression measures (noted above) may actually be accounted for, in 
part, by the contribution of diabetes-related distress. Indeed, Makine et al. (2009) 
reported that the significant association between depressive symptoms and ITAS 
scores was reduced after accounting for PAID scores in a cross-sectional study of 
adults with non-insulin-treated T2D. Elsewhere, a moderate positive relationship has 
been found between ITAS scores and PAID scores, where more negative attitudes 
are associated with increased diabetes-related distress (Snoek et al., 2007). Polonsky 
et al. (2011) reported that adults with T2D from eight countries who were ambivalent 
about or unwilling to initiate insulin were significantly more likely to endorse single 
diabetes-related distress items.   
Interestingly, the DAWN study found that increased belief in the efficacy of 
insulin was associated with increased diabetes-related distress (Peyrot et al., 2005), 
and participants who initiated insulin in a longitudinal study displayed slightly lower 
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ITAS scores but greater diabetes-related distress (higher PAID scores) at baseline 
than those who remained insulin naïve (Hermanns et al., 2010). In a large-scale UK 
prospective cohort study, Keij et al. (2016) reported that diabetes-related distress 
significantly added to the prediction of time until insulin uptake among newly 
diagnosed adults with T2D, whereby more distress was associated with a shorter 
time until insulin initiation. However, after accounting for insulin appraisals, 
measured using the BIT questionnaire, this independent contribution was no longer 
significant. These findings seem contradictory to the above positive relationship 
between PIR and diabetes-related distress, but it is possible that people with T2D 
who are willing to initiate insulin, and therefore have lower (less negative) ITAS 
scores, display greater diabetes-related distress due to concerns surrounding their 
current ineffective diabetes treatment. Indeed, diabetes-related distress may 
encompass feelings of distress relating to various aspects of living with the 
condition, including, but not limited to, self-management needs and behaviours (e.g. 
medication taking) (Polonsky et al., 1995; Polonsky, Fisher, Earles, et al., 2005). 
Understanding which, if any, aspects of diabetes-related distress (e.g. regimen-
related) are more highly associated with PIR, and actual insulin uptake, may be 
useful in the development of interventions or strategies to reduce PIR.  
Few studies have reported on the association between emotional wellbeing and 
PIR specifically among adults with T2D already using insulin. However, some 
studies offer a little insight into possible consequences, or correlates, of specific 
aspects of continued PIR among people with insulin-treated T2D. For example, 
Mollema et al. (2001) explored psychosocial outcomes in those with type 1 diabetes 
and insulin-treated T2D comparing those who displayed a fear of insulin injections 
and those who did not. Increased fear of self-injecting was associated with greater 
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diabetes-related distress and reduced general emotional wellbeing. In another study, 
those with greater injection-related anxiety reported greater concern about the 
possibility of additional injections (Zambanini et al. 1999). Of course, injections are 
just one of the potentially negative aspects of insulin use and, as such, further 
research is needed to investigate the emotional impact of ongoing PIR more 
comprehensively among those with T2D already using insulin.  
2.4.6. Summary of research quantifying psychological insulin resistance, 
receptiveness and associated factors   
While international and national real-world data is available on the delay of 
insulin initiation from a clinical perspective (e.g. time to and proportion of insulin 
use among those with T2D who clinically require insulin), little research has 
examined the proportion of delayed insulin initiation due to insulin refusal or delay 
specifically by the person with diabetes (i.e. due to PIR). The landmark UKPDS trial 
suggests an insulin refusal rate of 27% (U.K. Prospective Diabetes Study Group, 
1995), but smaller studies have reported refusal rates from 20% (Khan et al., 2008) 
to 43% (Odawara et al., 2016). More commonly, PIR and receptiveness have been 
assessed using self-report questionnaire tools that aim to quantify the proportion of 
people with T2D who are hypothetically (un)willing to initiate insulin therapy or the 
possible reasons for this (i.e. negative insulin appraisals).  
Willingness to begin insulin therapy among adults with T2D has not been 
examined within Australia. Elsewhere, depending on the population, study and 
measure used, the proportion of people with T2D ‘unwilling’ to commence insulin 
varies substantially from 6% (Polonsky et al., 2011) to 71% (Wong et al., 2011), and 
may not be reflective of a) willingness to initiate insulin among those for whom 
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insulin has been clinically indicated (e.g. prolonged hyperglycaemia on maximum 
OHAs) or b) actual insulin initiation or refusal. To examine whether this is predictive 
of actual insulin uptake, and gauge a valid representation of the size of the problem 
of PIR, additional prospective research is required involving people with T2D for 
whom insulin is clinically indicated. 
The ITAS is a widely used validated measure of insulin appraisals, which has 
the benefit of being suitable for completion by people with non-insulin-treated and 
insulin-treated T2D. However, the validation of the ITAS was conducted on a sample 
of adults with T2D with mixed treatment types (including insulin-treated and non-
insulin-treated individuals). Additional validation work should be conducted 
separately by treatment type to ensure the scale performs psychometrically well 
across, and is acceptable to, both insulin-treated and non-insulin treated populations. 
To date, no studies have used validated measures of PIR within Australia. Further, 
scale acceptability, reliability and validity should be assessed within Australia before 
proceeding with use and analyses of this questionnaire locally.  
Cross-sectional, and some prospective, research has examined demographic, 
clinical, self-management or psychosocial factors associated with attitudes towards 
insulin, willingness to begin insulin therapy, and insulin uptake. Among adults with 
non-insulin-treated T2D, identified demographic factors associated with PIR have 
included age, gender, ethnicity and education, whereby those who report being 
unwilling to begin insulin or those with more negative insulin appraisals are typically 
more likely to be women, older, of ‘non-white’ ethnic orientation, and less educated. 
With regard to clinical characteristics, higher HbA1c, longer diabetes duration and 
more diabetes-related complications are associated with insulin uptake, in 
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prospective research, and negative insulin appraisals, in cross-sectional studies. 
Positive insulin appraisals have been associated with more frequent SMBG and a 
greater number of prescribed OHAs among non-insulin-treated adults with T2D. 
However, comprehensive assessment of all of the above demographic, clinical and 
self-care characteristics in addition to psychosocial measures, preferably using 
validated tools, is uncommon.  
One study has highlighted the role of beliefs about current medications as 
predictive of receptiveness to future insulin uptake (Polonsky et al., 2011). However, 
this study employed unvalidated measures and did not distinguish between general 
medication beliefs and diabetes-specific medication beliefs. Additional research is 
needed to corroborate this finding, using validated measures of both general 
medication beliefs and specific current diabetes medication beliefs (i.e. OHAs), as 
well as accounting for other known correlates of PIR.  
Finally, the relationship between PIR and emotional wellbeing, specifically 
depressive symptoms and diabetes-related distress, has been a recent focus. After 
accounting for diabetes-related distress, the relationship between depressive 
symptoms and insulin appraisals is reduced. Furthermore, longitudinal research has 
shown no significant relationship between depressive symptoms and time to insulin 
initiation (Iversen et al., 2015; Nefs et al., 2013). In contrast the association between 
PIR and anxiety symptoms has received little attention, but a recent large (N=800) 
cohort study suggests generalised anxiety, but not depression, predicts delayed 
insulin initiation (Iversen et al., 2015). Further research is needed to examine the 
relationship between anxiety symptoms and insulin appraisals.  
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A moderate positive association is commonly reported between diabetes-
related distress and insulin appraisals, whereby more negative appraisals are 
associated with greater distress. However, in a longitudinal study, those who initiated 
insulin therapy displayed slightly lower ITAS scores but greater diabetes-related 
distress at baseline than those who remained insulin naïve (Hermanns et al., 2010) 
and a large prospective cohort study reported that diabetes-related distress was 
associated with a shorter time to insulin initiation (Keij et al., 2016). Additional 
research is needed to understand the direction and strength of the relationship 
between diabetes-related distress, PIR and insulin uptake and, further, to examine 
which, if any, aspects of diabetes-related distress are more highly associated with 
PIR. 
To date, research exploring PIR and associated factors has concentrated on 
gauging willingness to, or attitudes towards, insulin initiation among those who have 
not yet commenced insulin. However, some negative insulin appraisals are endorsed 
by people with insulin-treated T2D and, although rates vary considerably, insulin 
omission is a relatively common experience. Negative attitudes to, or experience of, 
insulin therapy may be commonplace for some people with T2D using insulin and 
may act as a barrier to optimal diabetes management. Research is required to further 
explore change in insulin appraisals post insulin initiation, possible ongoing barriers 
to optimal insulin use, and factors associated with negative attitudes towards insulin 
therapy among those using insulin.  
2.5. Conclusions and Direction of Research 
T2D is a progressive condition, which is likely to require eventual use of 
insulin in order to maintain optimal blood glucose and prevent/delay onset of 
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diabetes-related complications. Around 250,000 Australian adults with T2D 
currently use insulin (National Diabetes Services Scheme, 2016), but government 
reports indicate that many more have sub-optimal glycated haemoglobin indicative 
of complication risk, suggesting that treatment intensification may be needed 
(Swerissen, Duckett, & Wright, 2016). The delay of insulin initiation may, in part, be 
due to beliefs held by the person with diabetes, whereby negative perceptions of 
insulin use may lead to a reluctance to initiate insulin therapy. This is conceptualised 
as PIR, while the reverse, positive attitudes toward insulin therapy, is known as 
receptiveness. Beyond insulin initiation, PIR and receptiveness may also have 
explanatory value in predicting a reluctance to inject as often as recommended or to 
intensify treatment further.  
Qualitative studies have provided a rich description of attitudes towards 
insulin, and how they may develop, among people with T2D. However, less is 
known about attitudes post insulin initiation and going forward (e.g. intensification). 
Further, few qualitative studies have been conducted in the Australian healthcare 
context, and only one included people with T2D. Thus, little is known about whether 
these issues are relevant in Australian health context or the extent to which they 
differ from previous international findings.  
Typically, quantitative assessment of PIR has involved the measurement of 
either: 1) positive and/or negative insulin appraisals or 2) hypothetical ‘willingness’ 
to initiate insulin. Validated scales of insulin appraisals are freely available, 
including the ITAS (Snoek et al., 2007) and the BIT questionnaire (Petrak et al., 
2007). The widely used ITAS is advantageous in that it can be used among adults 
with T2D regardless of insulin treatment, allowing for prospective research 
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examining change in insulin appraisals. However, the ITAS has not been validated 
separately by treatment type and, therefore, it is not known whether the scale is 
acceptable and performs psychometrically well across treatment groups. 
Hypothetical (un)willingness to initiate insulin therapy has been assessed using a 
single item and is used as an indicator of likely insulin refusal. However, whether 
this single item reflects actual refusal rates is yet to be verified. Furthermore, the 
measurement of willingness to begin insulin in samples that include those who may 
be years from clinically requiring insulin therapy may limit the validity of this data. 
Existing research has highlighted factors associated with PIR among adults 
with T2D, including demographic and clinical characteristics, self-care behaviours, 
and general or diabetes-specific emotional wellbeing. However, this research has 
relied heavily on cross-sectional study design and has rarely comprehensively 
assessed the role of these factors using valid measures. A reduction in negative 
insulin appraisals has been demonstrated after insulin initiation and, thus, insulin 
uptake has been assumed to be synonymous with minimal PIR. However, research 
shows that certain negative appraisals are apparent among those already using 
insulin. Furthermore, insulin omission is common among adults with T2D. In-depth, 
prospective research is required to investigate how PIR changes over time in people 
with T2D (from non-insulin use to insulin initiation and intensification) and the 
potential implications of continued PIR in people with T2D using insulin. The aim of 
this research was to examine attitudes towards insulin among adults with T2D in 
Australia as well as correlates of, and the capacity for change in, appraisals of 
insulin. This program of doctoral research was designed to contribute to our 
understanding of: a) the measurement of insulin appraisals among Australians with 
T2D, b) the occurrence of, and factors associated with, PIR and intention to begin 
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insulin therapy among adults with non-insulin-treated T2D within national 
population level and clinical settings, c) the demographic, clinical and psychological 
predictors of actual insulin uptake, and d) attitudes toward insulin post-initiation, 
perceptions of benefits and consequences of insulin, and attitudes to further treatment 
intensification.  
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Chapter 3: Summary of Methods 
The research undertaken for this thesis uses mixed methods and includes 
analyses of data from three studies, resulting in six empirical papers (Chapter 4 to 9). 
Brief descriptions of the three studies are provided below along with the research 
questions that are addressed in Chapters 4 to 9. Research methods specific to each 
question are detailed in the relevant chapter. A detailed description of the methods of 
the three studies, as they relate to this thesis, is presented in Appendix C. 
3.1. Study 1: Diabetes MILES – Australia Study 
Diabetes MILES – Australia was a national cross-sectional survey of adults 
with type 1 diabetes or T2D. Detailed description of the study rationale, design, 
methods, and sample characteristics for the study have been published, co-authored 
by this PhD candidate (Speight, Browne, Holmes-Truscott, Hendrieckx, & Pouwer, 
2012). This thesis includes analyses of two sub-samples: adults with insulin-treated 
and non-insulin treated T2D who completed the ITAS and other questionnaires of 
relevance. Statistical analyses were driven by three research questions (below) and 
the findings are presented in three empirical papers (Chapters 4, 5 and 8).  
Research Questions: 
Study 1a.  Is the ITAS an acceptable and psychometrically sound 
measure of insulin appraisals for use with Australian adults with insulin-treated and 
non-insulin-treated T2D?  
Study 1b.  Among those with non-insulin-treated T2D, to what extent do 
general and diabetes-specific emotional wellbeing and beliefs about medicines 
contribute to current negative insulin therapy appraisals? 
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Study 1c. Do adults with insulin-treated T2D display negative insulin 
appraisals? Do clinical, self-care and psychosocial outcomes differ for those with 
more and less negative insulin appraisals? 
3.2. Study 2: Stepping Up Study 
Study 2 was a two-armed, 12-month cluster randomised controlled trial testing 
the effectiveness of the ‘Stepping Up’ model of care, compared to usual care, to 
facilitate timely and evidence-based initiation and up-titration of insulin in primary 
care for eligible adults with non-insulin-treated T2D. The Stepping Up protocol has 
been published elsewhere, co-authored by this PhD candidate (Furler et al., 2014). 
Demographic, clinical, self-management and psychosocial data, including insulin 
appraisals and willingness to begin insulin therapy, was collected at baseline at 12 
months among participant with T2D. Statistical analyses of the Stepping Up baseline 
(Chapter 6) and 12-month follow-up (Chapter 7) datasets were driven by two 
research questions. 
Research questions: 
Study 2a. What proportion of Stepping Up participants are 
hypothetically willing to initiate insulin therapy? What demographic, clinical, self-
management and psychosocial factors, including insulin appraisals, are associated 
with hypothetical willingness to begin insulin?  
Study 2b. Controlling for randomisation, to what extent do demographic 
and clinical factors, emotional wellbeing, attitudes towards insulin and hypothetical 
willingness to begin insulin at baseline predict actual insulin use among Stepping Up 
participants at 12 months? Do attitudes toward insulin change, from baseline to 12-
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month follow up, as a function insulin initiation and/or model of care (study arm 
allocation)? 
3.3. Study 3: Qualitative Study of Insulin Appraisals  
In study 3, exploratory interviews were conducted to elicit an in-depth 
narrative of the experience of diabetes and treatment progression among adults with 
T2D currently using insulin therapy. A subset of the collected data are reported in 
Chapter 9, with thematic analysis driven by the research question below. 
Research questions: 
Study 3. What is the impact of insulin use, including negative and 
positive consequences, for adults with T2D already using insulin? What attitudes do 
participants express about future insulin intensification (e.g. additional insulin 
injections)?  
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Abstract 
Background 
Negative attitudes towards insulin are commonly reported by people with type 
2 diabetes mellitus (T2DM) and can act as a barrier to timely insulin initiation. The 
Insulin Treatment Appraisal Scale (ITAS) is a widely used 20-item measure of 
attitudes towards insulin. While designed for completion by both insulin using and 
non-insulin using adults with T2DM, its psychometric properties have not been 
investigated separately for these groups. Furthermore, the total score is routinely 
reported in preference to the published two-factor structure (negative/positive 
appraisals). Further psychometric validation of the ITAS is required to examine its 
properties. 
Methods 
The ITAS was completed by a subgroup of 748 Diabetes MILES – Australia 
study participants with T2DM, who were either insulin using (n = 249; 45% women; 
mean age = 58 ± 9 years; mean diabetes duration = 13, SD = 8 years) or non-insulin 
using (n = 499; 47% women; mean age 57 ± 9 years; mean diabetes duration 7 ± 6 
years). We replicated the psychometric analyses reported in the ITAS development 
paper. In addition, we explored factor structure and investigated internal consistency 
separately for the insulin using and non-insulin using samples. 
Results 
Factor analyses supported a two-factor structure with good internal consistency 
(negative subscale α = .90; positive subscale α = .69). Scale performance differed 
slightly in the insulin using and non-insulin using samples, with some items loading 
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inconsistently between groups. A one-factor solution was not supported in either 
sample, with the positive items and some negative items failing to load adequately. 
Consistent with prior research, negative appraisals were significantly more common 
among non-insulin using participants compared to those using insulin (d = 1.04), 
while the positive subscale score did not discriminate between groups. 
Conclusions 
The data supported a two factor structure and the positive subscale did not 
discriminate between insulin using and non-insulin using participants. As such, we 
recommend use of the negative subscale score in preference to the ITAS total score, 
and suggest close attention is paid to the relevance of the positive items in the given 
population. 
Keywords 
Psychological insulin resistance, Type 2 diabetes, Questionnaire, Psychometric 
validation 
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Background 
Type 2 diabetes mellitus (T2DM) is a progressive condition and most people 
with this condition will eventually require exogenous insulin to maintain 
haemoglobin A1c within recommended targets [1,2]. However, a quarter of adults 
with T2DM report being unwilling to begin insulin therapy [3], commonly reporting 
concerns about the necessity of insulin, as well as the physical, social and symbolic 
adverse consequences of insulin use [4]. These negative attitudes, known as 
‘psychological insulin resistance’ (PIR), may lead to delays in insulin initiation or 
sub-optimal use once insulin is prescribed [3,5-8]. PIR is a complex construct that 
does not simply equate to “fear of the needle”, as people can base their reluctance to 
use insulin on many different aspects of the therapy. The construct has been 
operationalised through assessment of attitudes toward insulin (insulin appraisal) 
[3,9-13]. 
Two scales have been developed and validated specifically to measure attitudes 
towards insulin held by people with T2DM. The 14-item ‘Barriers to Insulin 
Treatment’ (BIT) self-report questionnaire measures attitudes towards insulin 
amongst people with non-insulin-treated T2DM [13]. BIT items commonly refer to 
the physical aspects of insulin use or technical concerns (e.g. side effects, pain) 
rather than the symbolic meaning of insulin initiation (e.g. feelings of failure/self-
blame or increased diabetes severity). The Insulin Treatment Appraisal Scale (ITAS) 
is a 20-item questionnaire, including 16 statements referring to barriers to insulin use 
and four referring to its benefits (12). Unlike the BIT, the more commonly used 
ITAS was developed and validated for use by people with T2DM regardless of 
current treatment type, with the advantage of enabling assessment both before and 
  
100 
 
after insulin initiation [12]. For non-insulin using respondents, the ITAS assesses 
expectations about future insulin use, while for those already using insulin, the 
measure is used to evaluate actual experience with insulin use. 
The clinical relevance of the ITAS has been demonstrated. In cross-sectional 
studies, a difference has been observed between insulin using and non-insulin 
participants in total ITAS scores of approximately one standard deviation [12,14]. 
Longitudinal research indicates that the ITAS is sensitive to treatment change from 
oral medication to insulin injections [15]. Furthermore, higher ITAS scores 
(indicating more negative appraisal of insulin) are associated with being 
hypothetically less ‘willing’ to begin insulin if recommended [10]. Previous research 
has identified associations between ITAS scores and general and diabetes-specific 
emotional wellbeing among people with T2DM [12,16]. 
Initial investigation of the structure of the ITAS revealed it to have a two-factor 
solution, identifying a positive subscale (benefits) and a negative subscale (barriers) 
[12]. Despite reporting low item commonalities in a one-factor structure, scale 
developers proposed the use of an ITAS total score (summation of all 20 items), to 
indicate a person’s overall insulin appraisal. Since the original US study [12], no 
further work has been published regarding the validation of the two-factor or one-
factor structure, and the ITAS total score has been used most commonly [9,10,16]. 
Despite reports that the ITAS is psychometrically sound for both insulin using and 
non-insulin using participants [12], psychometric analyses have not been reported 
separately for these groups. Given that these groups may have either quantitatively or 
qualitatively different attitudes towards insulin, based on expectations or actual 
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experience, an investigation is needed of how the scale performs psychometrically in 
each of these groups separately. 
Further psychometric analyses are required to assess the appropriateness of the 
scale in the two separate samples for which it was intended, as well as to further 
evaluate the validity of the ITAS total score. Thus, our aim was to further examine 
the psychometric properties of the ITAS separately among insulin using and non-
insulin using adults with T2DM in Australia. 
Methods 
This analysis utilises a subset of data from Diabetes MILES – Australia, a 
large-scale, national, cross-sectional survey of Australian adults (aged 18 to 70years) 
diagnosed with either type 1 diabetes or T2DM. The survey was conducted in July – 
August 2011. A detailed description of the methods, response rates and 
questionnaires has been published elsewhere [17]. Diabetes MILES – Australia 
received ethics approval from the Deakin University Human Research Ethics 
committee (reference number: 2011–046). 
Participants 
Diabetes MILES – Australia surveys were sent out to a random sample of 
15,000 National Diabetes Services Scheme (NDSS) registrants. The NDSS register 
includes >1.1 million registrants living with diabetes in Australia, of whom 87% 
have T2DM (http://www.ndss.com.au/en/Research/Data-Snapshots/). Survey 
booklets were matched to the recorded diabetes diagnosis and treatment (confirmed 
at registration by a health professional): T1DM, T2DM Insulin using or T2DM non-
insulin. 
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The survey was also made available online nationally, with respondents 
required to self-report their type of diabetes in order to receive the appropriate survey 
version. The database was cleaned to validate survey versions against self-report 
diabetes diagnosis, age at diagnosis, and treatment type to ensure the highest level of 
accuracy possible given the self-report nature of the survey. 
Overall, there were 3,338 eligible respondents, of whom 1,962 reported living 
with T2DM. Of these, 49% (n = 953) were women, the mean ± SD age was 59 ± 
9years and 37% (n = 724) were using insulin. The current analysis focuses on a 
subsample of participants with T2DM who were invited to complete the ITAS [12] 
and reported their diabetes treatment type as either insulin using, requiring oral anti-
hyperglycaemic tablets or following lifestyle recommendations. Participants 
reporting use of glucagon-like peptide-1 (GLP-1) agonist treatment were excluded 
from the current study. Like insulin, GLP-1 agonist is administered via injection, but 
differs from insulin use in a number of ways including, its efficacy; potential side 
effects (e.g. weight loss versus possible weight gain when using insulin) [18]; and 
the associated stigma of the treatment [19-22]. Therefore participants using GLP-1 
injections are not easily classified within either treatment group (insulin using and 
non-insulin using) relevant to this study. 
Measures 
The Diabetes MILES – Australia surveys included a set of core measures 
(completed by all respondents) and various additional measures (included in one or 
more of the six survey versions). Full details of the measures are published elsewhere 
[17]. Variables of interest to this study include: demographics (age, gender, 
relationship status, whether employed in paid work, education level, and body mass 
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index), diabetes health status (self-reported diabetes type, primary treatment and 
years living with diabetes), and the ITAS [12]. 
The ITAS asks respondents to indicate their level of agreement (‘strongly 
disagree’ = 1 to ‘strongly agree’ = 5) with 20 statements. Scores for 16 negatively-
worded items are summed to provide a ‘negative appraisal’ score (16–80); scores for 
four positively-worded items are summed to provide a ‘positive appraisal’ score (4–
20); all twenty items are summed (with positively-worded items reversed) to form a 
‘total’ score (20–100). Higher ‘total’ and ‘negative appraisal’ scores indicate more 
negative attitudes, while higher ‘positive appraisal’ scores indicate more positive 
attitudes towards insulin. Permission to use the ITAS was granted by the copyright 
holders. 
Statistical analysis 
Statistical analysis was undertaken using SPSS version 21 (Chicago, USA). 
Frequencies, means and standard deviation were obtained for ITAS and relevant 
demographics for insulin using and non-insulin using participants. Acceptability of 
the scale was assessed by examining completion rates and identifying ceiling effects 
for negative ITAS items and floor effects for positive ITAS items (i.e. >20% scoring 
minimum/maximum response) [23]. To replicate the methods described in the ITAS 
development paper [12], we conducted exploratory factor analysis (EFA) with 
oblimin rotation on the 20-item scale for the whole sample, as we expected the 
factors to be correlated. When inspecting the Eigenvalues, we used the Kaiser-
criterion (Eigenvalue >1) and reviewed the scree plot to determine the maximum 
number of factors. In accordance with the original development paper, item loadings 
were considered optimal if they were >0.40 on one factor and <0.30 on any other 
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factor [12]; a less conservative criterion of loading >0.30 (without concern for 
double loadings) was also adopted [24]. To replicate the hypothesised optimal scale 
structure, and to assess the suitability of the total score, forced two-factor and one-
factor solutions were conducted respectively. Internal consistency was estimated 
using Cronbach’s alpha and Guttmans λ2 [25], where ≥0.70 and <0.90 was 
considered reasonable. Item-total correlations were also calculated, with a score of 
<0.20 taken to indicate a poor relationship with the total scale score. These 
psychometric analyses were conducted for the insulin-using and non-insulin using 
samples separately and a forced one-factor solution was also investigated. 
Known-groups validity was explored by comparing mean ITAS total, negative 
and positive scores between treatment groups. Student t-tests or chi-squares were 
conducted to assess between-groups differences in ITAS scores. The association 
between demographics and total ITAS scores between groups was explored using 
Student t-tests and bivariate correlations. Statistical tests are two-sided with 
differences accepted at a significant level of p < 0.05. Effect sizes are reported using 
Cohen’s d. 
Results 
Overall, 887 participants with T2DM completed the Diabetes MILES – 
Australia survey versions in which the ITAS was included. Of these, 24 participants 
were excluded due to unreported treatment type or reported use of GLP-1 agonist 
injections. A further 115 (12.9%) participants were excluded due to non-completion 
of at least one ITAS item (see ‘Acceptability’ for further details). Of the 748 eligible 
respondents, one third were using insulin to manage their diabetes. Participant 
characteristics are shown in Table 1. Within the current sample, 193 participants 
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(26%) completed the online version of the survey, and 555 (74.2%) completed the 
hardcopy survey. 
 
Table 1 
Self-reported demographics and clinical characteristics of insulin using and non-
insulin using participants 
 Non-insulin users Insulin users 
N (%) 499 (67%) 249 (33%) 
Female sex 233 (47%) 112 (45%) 
Age - years 57 ± 9 (22 – 70) 58 ± 9 (21 – 70) 
Employment - in paid work 279 (56%) 104 (42%) 
Education   
Low 32 (7%) 36 (16%) 
Medium 314(66%) 157 (67%) 
High 132 (28%) 40 (17%) 
Having a partner 369 (75%) 178 (73%) 
Diabetes duration - years 7 ± 6 (<1 – 35) 13 ± 8 (<1 – 42) 
Primary Treatment   
Lifestyle modifications 130 (26%) - 
Blood glucose lowering tablets 369 (74%) - 
Insulin injections - 247 (99%) 
Insulin pump - 2 (1%) 
BMI 31 ± 7 (13 – 78) 34 ± 9 (15 – 92) 
NB. Valid percentage reported as n values vary due to missing data on individual variables. 
Data are mean ± standard deviation or N (%). 
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Acceptability 
Non-insulin using participants were slightly more likely to have missing data; 
83 (14%) non-insulin participants compared to 32 (11%) insulin-using participants 
missed at least one item. Of the non-insulin using participants with missing data, 
almost half (n = 39) skipped all 20 items. Thirty-three missed just one item and the 
remaining 11 missed between 2 and 19 items. The majority of insulin using 
participants with missing data skipped only 1 item (n = 26), and a further six skipped 
between 2 and 15 items: none skipped the entire scale. Excluding those who missed 
the whole scale, each of the 20 ITAS items was completed by ≥98.2% of non-insulin 
using participants and, similarly, by ≥98.2% of insulin using participants. 
Among the four positively-worded ITAS items, no floor effects were apparent 
amongst either insulin or non-insulin using participants (i.e. ≤20% of participants 
strongly disagreed with the benefits of insulin). Ceiling effects were apparent for 
four of the 16 negatively worded items among non-insulin using participants (>20% 
and <32% strongly agreed with items 1, 2, 5 and 6) but none were apparent among 
insulin using participants. 
Scale structure: whole sample 
EFA analyses conducted on the whole sample revealed a maximum of four 
factors with an Eigenvalue >1, explaining 57.1% of the total variance. The 
Eigenvalue for (and variance explained by) each factor respectively was 6.7 (33.4%), 
2.3 (11.7%), 1.3 (6.4%), and 1.1 (5.7%). Factors three and four were most easily 
interpretable: the four ‘benefits’ all loaded onto one factor suggesting a ‘positive 
appraisal’ subscale, and the two side-effect items (‘increases risk of hypoglycaemia’ 
‘weight gain’) loaded onto another factor. Eleven negative appraisal items loaded 
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onto the first factor with the remaining three loading onto the second factor, with no 
clear interpretation for either. 
Given the minimal additional variance explained by a 3- or 4-factor solution, 
and the aim to replicate the scale structure previously reported [12], a three-factor 
solution was not investigated. The two-factor solution explained 45% of the total 
variance with the first factor including all negatively-worded items except ‘weight 
gain’ and the second factor including the four positively-worded items. Only item 18 
(‘family and friends concerns’) loaded >0.3 on more than one factor. The correlation 
between factors was low (r = 0.06), suggesting a Varimax rotation would be more 
suitable, but the results of this rotation did not differ from the loading pattern 
obtained using the oblique rotation. A forced one-factor solution explained 33.4% of 
the variance, with all four positive items and the ‘weight gain’ item failing to load 
sufficiently. Overall, reliability was satisfactory for the 20-item scale (α = 0.87; λ2 = 
0.89), the 16-item negative subscale (α = 0.90; λ2 = 0.91), and for the positive 
subscale (α = 0.69; λ2 = 0.69). Table 2 displays both the forced one-factor and two-
factor solutions, with item loadings for the whole sample (described here) and by 
treatment type (described below). 
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Scale structure: by treatment type 
In the non-insulin using sample, inspection of the Eigenvalues after EFA 
revealed a maximum of four factors, explaining 57.2% of the total variance. The 
Eigenvalues for (and variance explained by) each factor respectively was 6.4 
(32.0%), 2.6 (12.9%), 1.4 (6.8%), and 1.1 (5.4%). Only factor four was interpretable, 
with all four ‘benefits’ loading >0.4, suggesting a ‘positive appraisal’ subscale. Item 
7 (‘increased risk of hypoglycaemia’) did not load >0.4 on any factor and six other 
items loaded ≥ 0.3 onto more than one factor. 
An EFA conducted for the insulin using participants revealed a maximum of 
five factors, explaining 57% of the total variance. The Eigenvalues for (and variance 
explained by) each factor respectively was 5.4 (27.0%), 2.2 (10.9%), 1.5 (7.7%), 1.2 
(6.1%), and 1.0 (5.2%). Once more, one factor included satisfactory loadings for all 
four positive items while the other factors were unclear. Ten items loaded ≥ 0.3 on 
two or more factors and two items did not load at all (‘weight gain’ and ‘concern 
from family and friends’). 
The two-factor solution within the non-insulin using group explained 44.9% 
total variance, with the first factor including 15 of the 16 negative items, and the 
second factor including all four positive items. Item 7 (‘increases risk of 
hypoglycaemia’) did not load on either factor, or four of the negative items double-
loaded (≥ 0.3) on both factors. Amongst the insulin using group, a two-factor 
solution explained 38% variance. Factor one included all 16 negative items and 
factor two included the four positive items. 
A forced one-factor solution explained 32% and 27% of the total variance in 
the non-insulin using and insulin using samples respectively. The positive items did 
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not load in either group. In the non-insulin using sample, all negative items except 
for item 7 (‘increases risk of hypoglycaemia’), loaded onto the factor and in the 
insulin using sample only item 9 (‘weight gain’) did not load. 
In the non-insulin using sample, Cronbach’s alpha was 0.85 for the 20-item 
scale, 0.89 for the 16-item negative subscale, and 0.69 for the positive subscale. 
Guttmans λ2 was 0.87, 0.90, and 0.71 respectively. Internal consistency was similar 
for insulin using participants: for the total scale α = 0.84 and λ2 = 0.85, for the 
negative subscale α = 0.85 and λ2 = 0.87, and for the positive subscale α = 0.68 and 
λ2 = 0.69. 
Within the total scale, all positive items displayed low item-total correlations; 
<0.1 for non-insulin participants and <0.32 for insulin using participants. All item-
total correlations for negatively worded items were >0.2 for both non-insulin and 
insulin using participants. When exploring the negative and positive subscales 
separately, all item-total correlations were above the >0.2 cut off for non-insulin 
using participants (negative subscale range = 0.31-0.69, positive subscale range = 
0.36-0.58) or for insulin using participants (negative subscale range = 0.35-0.63, 
positive subscale range = 0.38-0.58). 
Known-groups validity 
Table 3 displays, by treatment type, the mean and standard deviation for each 
of the ITAS items, total score, positive subscale and negative subscale, the t-test 
significance results and effect sizes showing between group differences, as well as 
the percentage who agreed or strongly agreed with each item. Non-insulin using 
participants reported significantly higher (more negative) scores compared to the 
insulin using participants on all negatively-worded items, except for ‘insulin causes 
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weight gain’, for which insulin using participants reported higher (more negative) 
scores. Moderate effect sizes were found between groups for 9 of the 16 negative 
items (d range = 0.54-0.76), and large effect sizes for 4 items (d range = 0.86-1.08). 
Item 6 (‘I’m afraid of injecting myself with a needle’) discriminated most highly 
between groups. 
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There were significant differences between treatment groups for the negative 
subscale (t (746) = 13.44, p < 0.001, d = 1.04) and total ITAS score (t (746) = 13.05, 
p < 0.001, d = 1.03). The percentage of participants who agreed with the benefits of 
insulin was high, regardless of treatment type, and the mean positive subscale score 
was not significantly different between groups (t (746) = 0.55, p = 0.582, d = 0.04). 
Associations between ITAS scores and demographics were comparable 
between groups. Total ITAS scores were weakly positively correlated with age for 
both insulin users (r = −0.29, p < 0.001) and non-insulin users (r = −0.18, p < 0.05). 
No significant relationship was apparent between ITAS scores and diabetes duration 
for either group (both p > 0.607). Between group ITAS scores did not differ by 
gender (p > 0.558 for both) or whether participants reported being in a relationship (p 
> 0.118 for both). Both insulin users (t (247) = −2.17, p = 0.03) and non-insulin users 
(t (494) = −3.65, p < 0.001) who participated in paid work reported significantly 
higher ITAS scores (more negative) than those not in paid work. 
Discussion 
In replication of the ITAS development paper [15], EFA and reliability tests 
were conducted on the whole sample and similar results were observed. However, 
contrary to the original recommendation to use a single ‘Total ITAS’ score, we 
believe the two-factor structure appears to be a better representation of the 20-item 
scale, with only ‘weight gain’ not loading on either scale. 
In exploring the two-factor solution for the insulin using and non-insulin using 
samples separately, we found variation in some item loadings. For non-insulin using 
participants, item 7 (‘increases risk of hypoglycaemia’) did not load onto either 
subscale. This might be due to a lack of knowledge among non-insulin using 
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participants regarding the potential risk of hypoglycaemia caused by insulin use, 
though almost half of this sample agreed or strongly agreed that this was a risk. In 
contrast to the whole sample, item 9 (‘weight gain’) loaded onto the negative 
subscale for non-insulin users and a number of other variables (items 2, 4, 5, 18) had 
multiple loadings, while all loading strongest on the negative subscale. Only item 18 
loaded > 0.4 on both the positive and negative subscale. This might be explained by 
non-insulin using participants feeling that insulin causing “family and friends to be 
more concerned about me” would in fact be a benefit of insulin use. Indeed, the item 
wording is not sufficiently negative for the direction to be clear. For insulin using 
participants, items 1 (‘insulin means my previous self-care has failed’), 2 (‘insulin 
means my diabetes is worse’) and 9 (‘weight gain’) were just shy of loading onto the 
negative subscale (if a stringent criterion of >0.4 was applied) but loaded well when 
a less conservative criterion (>0.3) was adopted. However these items were the three 
most highly endorsed among insulin using participants, which suggests they should 
not be removed from the scale. The forced two-factor solution was the best 
representation of the 20-item questionnaire for both samples. 
Reliability of negative and positive subscales was similar between groups, with 
the high negative subscale alpha suggesting the possibility for scale reduction. A 
small number of items performed inconsistently between treatment groups. They 
maybe candidates for removal or it may be that different items are important for 
different treatment groups. These items (1, 2, 7, and 9), which also had lower item-
total correlations and did not load consistently, were often more highly endorsed by 
participants than those which performed better statistically, suggesting they have 
strong face validity. It may be that these items are not performing statistically as well 
because they are conceptually quite independent of other negative aspects of insulin 
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use, while the items that load well and display high item-total correlations frequently 
refer to similar barriers to insulin (e.g. the burden of insulin injections in terms of its 
effect on lifestyle and responsibilities, as well the technical/physical aspects of 
having to inject). 
Given the high internal consistency reliability of the 20-item total scale, the 
ITAS total score has been recommended for use to quantify overall insulin appraisal 
[12]. However, in both the ITAS development paper and our current study, 
Cronbach’s alpha for the 20-item scale is lower than for the 16-item negative scale, 
and the positive items display very low item-total correlations. Unsurprisingly, a 
forced one-factor EFA reveals that the four positive items do not load on the factor 
for either treatment group. Given these results, we propose that the positive and 
negative subscales should not be combined to create a total score. 
Consistent with international findings adults with non-insulin-treated T2DM 
report significantly more negative attitudes towards insulin use than those using 
insulin, with total ITAS scores differing by approximately one standard deviation 
[12,14,15]. Non-insulin using participants reported higher (more negative) scores on 
15 of the 16 items, with ‘weight gain’ the only item for which insulin using 
participants reported more negative appraisals. This is also consistent with previous 
research [12,14]. With the exception of ‘weight gain’, the ranking of negative 
appraisals was similar between the two treatment groups; suggesting similar 
prioritisation of concerns about insulin between groups and differing only by 
intensity of endorsement. Ceiling effects were present for four ITAS items among 
non-insulin using participants, but not for the insulin using participants. However, as 
these ceiling effects are moderate (<33%), are in line with the expected scoring 
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direction of non-insulin using participants, and not displayed among insulin using 
participants, we suggest that they may not be cause for concern necessarily. 
While the ‘negative appraisal’ subscale showed strong discriminatory power, 
the positive subscale did not differ between treatment groups. Similar to previous 
studies, we found that participants not using insulin commonly endorsed positive 
statements about insulin [9,10,12,14,15]. This suggests that concerns about insulin 
initiation, or psychological insulin resistance, may exist independently of the belief 
that insulin may be beneficial. This may have implications for clinical care. For 
example, when counselling patients about their diabetes management options, it may 
be more beneficial to acknowledge, normalise and then minimise their perceived 
barriers to insulin use rather than emphasising only the actual benefits of insulin use. 
However, we recommend that the positive items are retained in the scale for further 
research purposes such as exploring the subscales association with other variables 
(e.g. self-care behaviours, optimal insulin taking behaviours). For example, previous 
research has reported optimal medication taking behaviours to be associated with 
belief in the benefit of the medication [26]. 
Strengths and limitations 
The strengths of this study include it being the first study to quantitatively 
explore PIR in an Australian sample using a validated measure. In addition, it is the 
only study to further evaluate the psychometric performance of the ITAS since its 
development. The large sample size and the inclusion of both insulin using and non-
insulin using participants to enable separate psychometric analyses are also 
advantages. 
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The limitations of Diabetes MILES – Australia are discussed in detail 
elsewhere [17]. Limitations of specific relevance to the current study are the self-
report nature of the diabetes diagnosis for 26% of the sample and the proportion of 
missing data. The ITAS was developed and validated for use among people with 
T2DM. Given the self-report nature of Diabetes MILES – Australia, it is impossible 
to tell whether all participants were accurately classified as having type 2 diabetes. 
However, it is expected that the following safeguards reduced the likelihood of 
participants being misclassified. The majority (74%) of respondents had received a 
pre-determined survey booklet type (specific to their diabetes type and treatment) 
based on their diabetes diagnosis as reported within in the NDSS [17]. These 
participants had the opportunity to complete the ITAS only if they were registered 
with the NDSS as having a diagnosis of T2DM; their data were removed from the 
current analysis if they subsequently reported a diagnosis of type 1 diabetes within 
the survey booklet. Online participants (26%) received the ITAS for completion only 
if they self-reported living with T2DM. Thus, any participant who received a type 1 
booklet or self-reported online that they had type 1 diabetes would not have had the 
opportunity to complete the ITAS. Prior literature concludes that self-reported 
diabetes diagnosis, not type specific, is reasonably accurate when compared to 
medical data [27,28]. However, to the author’s knowledge, no research has explored 
the validation of self-reported diabetes type comparing those with type 1 and those 
with T2DM. 
A further limitation of the current analysis was the missing data, which differed 
by treatment group, suggesting that the scale may be more acceptable or relevant to 
participants with T2DM using insulin than non-insulin using participants. It is 
probable that those non-insulin using participants who skipped the scale entirely 
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perceived it to be irrelevant for them, despite instructions asking non-insulin users 
“to answer each item based on their current knowledge and thoughts about what 
insulin therapy would be like”. Hence, we advise future ITAS users to consider 
including instructions that better emphasise that the questionnaire is to be completed 
by all participants, not just those already using insulin. After excluding participants 
who skipped the entire questionnaire, almost three quarters of those with missing 
data skipped just one item and no particular item displayed substantial non-
completion. This indicates acceptability of items among the majority of participants. 
Finally, the wording of some ITAS items assumes current or prior use of 
lifestyle modifications or blood glucose lowering tablets. However, it is possible that 
proportions of participants with insulin-treated T2DM have not actively managed 
their diabetes prior to beginning insulin, and therefore, may find some ITAS 
questions inappropriate. For example: “Taking insulin means I have failed to manage 
my diabetes with diet and tablets”. As the Diabetes MILES survey did not ask 
participants to report previous diabetes treatments, we are unable to clarify what 
proportion, if any, were prescribed insulin immediately after diagnosis of T2DM. 
This is a potential limitation of the questionnaire and we recommend that future 
users consider including assessment of prior diabetes management. 
Conclusions 
In the present study, the 20-item ITAS total score explained less variance and 
displays lower internal consistency reliability than the 16-item ‘negative appraisal’ 
score. We recommend that calculation of the 20-item ITAS total score be avoided in 
preference for the 16-item ‘negative appraisal’ score, with close attention paid to the 
relevance and usefulness of the ‘positive appraisal’ subscale in the given population. 
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Our findings support use of the ITAS in both treatment groups. As perceptions of 
insulin use appear to vary based on expectation versus actual experience, it is 
unsurprising that certain items performed inconsistently between groups. The ITAS 
is a relatively brief and easy to complete questionnaire which may be useful 
clinically to promote discussion with people with T2DM about their concerns 
regarding insulin use, or to evaluate interventions to reduce PIR. 
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Highlights 
 Cross-sectional study exploring factors associated with negative insulin 
therapy appraisals. 
 Insulin appraisals moderately associated with diabetes-specific emotional-
burden. 
 Insulin appraisals moderately associated with concerns about diabetes 
medications. 
 Weaker associations observed with general medication beliefs and wellbeing. 
 Interventions should look to improve diabetes-specific distress and medicine 
beliefs. 
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Abstract 
Aims 
To investigate the contribution of general and diabetes-specific emotional 
wellbeing and beliefs about medicines in the prediction of insulin therapy appraisals 
in adults with non-insulin-treated type 2 diabetes. 
Methods 
The sample included Diabetes MILES – Australia cross-sectional survey 
participants whose primary diabetes treatment was oral hypoglycaemic agents 
(N=313; 49% women; mean±SD age: 57±9 years; diabetes duration: 7±6 years). 
They completed validated measures of beliefs about the ‘harm’ and ‘overuse’ of 
medications in general (BMQ General); ‘concerns’ about and ‘necessity’ of current 
diabetes medications (BMQ Specific); negative insulin therapy appraisals (ITAS); 
depression (PHQ-9); anxiety (GAD-7), and diabetes distress (DDS-17). Factors 
associated with ITAS Negative scores were examined using hierarchical multiple 
regressions. 
Results 
Twenty-two percent of the variance in ITAS Negative scores (52±10), was 
explained by: number of complications (β=-0.15, p=0.005), DDS-17 subscale 
‘emotional burden’ (β=0.23, p<.001), and ‘concerns’ about current diabetes 
treatment (β=0.29, p<0.001). General beliefs about medications and general 
emotional wellbeing did not contribute significantly to the model.  
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Conclusions 
Psychological insulin resistance may reflect broader distress about diabetes and 
concerns about its treatment but not general beliefs about medicines, depression or 
anxiety. Reducing diabetes distress and current treatment concerns may improve 
attitudes towards insulin as a potential therapeutic option.  
Keywords 
Type 2 diabetes, Psychological insulin resistance, Beliefs about medications, 
Diabetes distress 
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Introduction  
Despite its proven efficacy among people with progressed type 2 diabetes 
mellitus (T2DM) [1,2], insulin therapy seems less popular than oral medication. 
Approximately one quarter of adults with non-insulin-treated T2DM refuse, or report 
being unwilling to begin, insulin [2, 3, 4]. In the UKPDS, for example, 27% of the 
participants who were prescribed insulin therapy initially refused this form of 
therapy, compared to 7-13% in the tablet-treated group [5]. In Australia, around 23% 
of adults with T2DM are currently using insulin to manage their diabetes [6], despite 
reports that the mean HbA1c of adults with T2DM overall is 8.0% (64 mmol/mol) 
[7]. Similar results have been found internationally [8-12]. Notwithstanding 
individual factors and individualised glycaemic targets that cannot be extricated in 
aggregated national datasets, these data suggest a failure to intensify treatment, e.g. 
timely insulin initiation, which may be due to the reluctance of the health 
professional (i.e. clinical inertia [10]) and/or the person with T2DM.  
People with T2DM may delay insulin initiation for many reasons, ranging from 
concerns about the perceived complexity of insulin therapy, to the belief that one has 
failed if insulin needs to be prescribed. The cluster of negative appraisals of insulin 
therapy is known as “psychological insulin resistance” [3, 13]. Understanding the 
factors associated with negative attitudes toward insulin therapy can inform 
strategies to improve attitudes towards, and uptake of, insulin among people with 
T2DM.  
Previous research has revealed an association between negative appraisals of 
insulin therapy and impaired emotional wellbeing, including depressive symptoms 
and diabetes distress [14-17]. In particular, diabetes distress has been shown to 
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account for a greater proportion of the variance in insulin therapy appraisals than 
depressive symptoms [15]. While other studies have also observed a moderate, 
positive relationship between insulin therapy appraisals and diabetes distress [13, 
17], it is unclear whether overall diabetes distress or specific components (e.g. 
regimen-related, physician-related, interpersonal distress) underlie negative insulin 
therapy appraisals.  
In a small longitudinal study, no change in anxiety scores from baseline to 
follow-up was observed for participants initiating insulin, nor was there any 
difference in baseline scores between those who initiated insulin and those who did 
not [14]. Other research has noted a relationship between increased injection-related 
anxiety (a component of psychological insulin resistance) and increased general 
anxiety and diabetes distress [18, 19]. However, the association between anxiety and 
negative insulin therapy appraisals has not been investigated explicitly.  
In an international study, participants with non-insulin treated T2DM who 
reported being hypothetically unwilling to begin insulin displayed increased diabetes 
distress and more negative beliefs about current oral medications than those who 
reported willingness to begin insulin if recommended [13]. However, in that 
particular study, the (unvalidated) single items used to measure beliefs about current 
oral medications did not specify whether the medications were for the management 
of diabetes or other purposes. Horne et al [20] suggest that people hold beliefs about 
medicines in general, as well as beliefs about medications specific to their condition 
(e.g. T2DM). Further, beliefs about medicines in general are likely to influence an 
individual’s initial orientation towards medicines (e.g. willingness to begin 
medication), but condition-specific beliefs about medications are more likely to 
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influence medication-taking behaviour (e.g. uptake and continuation of therapy as 
recommended) [21]. Thus, exploration of whether insulin therapy appraisals are 
associated with broader concerns about medicines in general and/or negative 
attitudes towards current diabetes-specific medications is required.   
Our aim was to investigate the contribution of impaired emotional wellbeing 
and beliefs about medications (both in general and diabetes-related) to negative 
appraisals of insulin therapy among adults with non-insulin-treated T2DM.  
Participants, Materials and Methods  
This study used data from Diabetes MILES – Australia 2011, a national cross-
sectional survey of adults with diabetes, focused on psychological and behavioural 
issues. A detailed description of the methods and questionnaires has been published 
elsewhere [22]. The study received ethics approval from the Deakin University 
Human Research Ethics committee (reference number: 2011-046).  
Participants 
Surveys were posted to a random sample of 15,000 National Diabetes Services 
Scheme registrants, and an online version was made available and advertised 
nationally. Overall, 3,338 eligible respondents took part (response rate=18% [22]), of 
whom 1,941 (58%) self-reported having T2DM (49% (n=953) women; aged 
58.5±8.7 years; 45% (n=876) using oral hypoglycaemic agents (OHAs)). The survey 
consisted of core questions completed by all respondents and, to reduce respondent 
burden, participants were allocated randomly to an ‘A’ or ‘B’ version. The current 
analysis was conducted using the 50% subsample of those with T2DM using OHAs 
who complete the ‘A’ version, which included the Insulin Treatment Appraisal Scale 
(ITAS).  
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Measures 
Demographic characteristics and self-reported clinical data included: age, 
gender, Socio-Economic Indexes for Areas (SEIFA) decile values for reported 
residential postcodes [23], body mass index (BMI), diabetes duration, and number of 
complications.  
Several psychological measures were included.  
Negative insulin therapy appraisals 
 Appraisals of insulin were assessed using the 20-item ITAS [17]. The measure 
includes 16 negative and four positive statements about insulin use, against which 
respondents indicate their level of agreement (strongly disagree=1, strongly 
agree=5). Scores are summed to provide an ITAS Negative score (range: 16-80) and 
ITAS Positive score (range: 5-20).The psychometric performance of the ITAS within 
the current sample has been reported elsewhere [24]. In the current study, the ITAS 
Negative subscale score is used to represent participants’ negative insulin therapy 
appraisals.  
Depression and anxiety 
 The presence and severity of depressive and anxiety symptoms were assessed 
using the 9-item Patient Health Questionnaire (PHQ-9) [25] and 7-item General 
Anxiety Disorder (GAD-7) questionnaire [26]. For each measure, respondents rate 
the frequency with which they have experienced symptoms over the past two weeks 
on a 4-point scale (not at all=0, nearly every day=3). Item scores are summed to form 
a total score (PHQ-9: 0-27; GAD-7: 0-21), where a cut-off score of ≥10 indicates 
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moderate-to-severe symptoms. Internal consistency in the current sample was 
satisfactory (PHQ-9: α=0.89; GAD-7: α=0.93).  
Diabetes-specific emotional distress 
Assessed using the 17-item Diabetes Distress Scale (DDS-17) [27]. 
Respondents indicate the degree to which each item has been a problem for them 
over the past month on a 6-point scale (not a problem=1, very serious problem=6). A 
composite score is derived by summing scores and dividing by 17 items, with a score 
of ≥2 indicative of moderate-to-high distress, and ≥3 indicative of high distress [28]. 
The DDS-17 also includes four subscales: emotional burden (5-items), physician-
related distress (4-items), regimen-related distress (5-items), and diabetes-related 
interpersonal distress (3-items).  Internal consistency in the current sample was 
satisfactory for the DDS-17 total score (α=0.93) and the four subscales (α= 0.89-
0.93). 
Beliefs about medications 
The Beliefs about Medications Questionnaire (BMQ) General (8-items) 
includes subscales addressing perceived ‘harm’ (5 items) and ‘overuse’ (3 items) of 
prescription medications in general [20]. The BMQ Specific (11-items) includes two 
subscales representing the perceived ‘necessity’ (5 items) of condition specific 
medications in maintaining health and ‘concerns’ (6 items) associated with having to 
take those medications in the long term, referring throughout to “your diabetes 
medicines”. Items are rated on a 5-point Likert scale (strongly disagree=1, strongly 
agree=5). Subscale scores are calculated by summing item scores and dividing by the 
number of items, with higher scores indicating stronger beliefs in the subscale 
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concepts. A necessity-concerns differential score is obtained by subtracting the 
‘concerns’ score from the ‘necessity’ score, enabling assessment of whether concerns 
outweigh belief in the necessity of taking the medications [29]. In this sample, the 
BMQ Specific and General subscales displayed good internal consistency (α=0.79-
0.80).  
Statistical analysis 
Statistical analysis was undertaken using SPSS version 21 (Chicago, USA). 
Missing were replaced according to developer’s recommendations for the DDS-17 (if 
≤2 missing items), ITAS, PHQ9 and GAD7 (all if ≤1 missing items). Individuals 
with missing demographic data required for the statistical analysis (age, diabetes 
duration, gender, and SEIFA decile) or the BMQ subscales were excluded from the 
analysis. Pearson’s correlation coefficients, Student’s t-tests, and Chi-square tests 
were calculated to explore the relationships between the ITAS Negative score and 
demographics, emotional wellbeing, and beliefs about medications. Where 
significant relationships existed, those variables were entered stepwise into a 
hierarchical multiple regression to determine associations with ITAS Negative score 
(dependent variable): (a) demographics, (b) depression (PHQ9) and anxiety (GAD7), 
(c) DDS-17 subscale and total scores, (d) BMQ General subscales (‘overuse’ and 
‘harm’), and (e) BMQ Specific subscales (‘necessity’ and ‘concern’). 
Multicollinearity problems were identified using the variance inflation factor (VIF) 
and tolerance, where values <4 and >0.20 respectively suggest no multicollinearity. 
Results are reported as mean±SD or %(n). All statistical tests were two-sided and 
differences were accepted as significant at p<0.05.  
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Results  
A total of 385 Diabetes MILES – Australia survey participants with self-
reported T2DM, reporting OHAs as their sole diabetes treatment, completed the 
relevant survey version. Of these, 62 were excluded due to missing data. The final 
sample (N=313) was 57±9 years old, with a diabetes duration of 7±6 years, and 49% 
(n=152) were women. Participants had a BMI of 32.2±7.0, which is classified as 
class 1 Obese. The mean SEIFA Decile was 6.4±2.7, where 1 is the lowest rating 
area for economic advantage and 10 is the highest rating area. The majority of the 
sample (n=195, 62%) reported no diabetes-related complications. Table 1 details 
participants’ mean±SD psychosocial outcomes and correlations between measures. 
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Negative insulin therapy appraisals 
Negative insulin appraisals were commonly endorsed by participants; mean 
ITAS Negative subscale score was 52.3±9.5 (range: 26-80). The top three negative 
beliefs about insulin endorsed (agreed or strongly agreed with) by participants were 
“taking insulin means my diabetes has become much worse” (82%, n=256), “taking 
insulin makes life less flexible” (63%, n=197), and “taking insulin means I have 
failed to manage my diabetes with diet and tablets” (62%, n=194). Despite the 
endorsement of negative aspects of insulin use, the majority of participants also 
endorsed insulin as assisting to “prevent complications of diabetes” (76%, n=238), 
“maintain good control of blood glucose” (72%, n=226), and “improve my health” 
(67%, n=208). Higher ITAS Negative scores were significantly associated with 
younger age (r=-0.20, p<0.001), and fewer diabetes complications (r=-0.14, 
p<0.014). No associations were apparent with duration of diabetes (r=-0.04, 
p=0.468), BMI (r=0.03, p=0.648) or SEIFA decile (r=-0.02, p=0.71), nor did ITAS 
Negative scores vary according to gender (t=(311)0.151, p=.88).   
Emotional wellbeing 
Moderate-to-severe depressive or anxiety symptoms were reported by 24% 
(n=74) and 16% (n=50) of participants, respectively. Higher ITAS Negative scores 
were associated with increased depressive symptoms (r= 0.25, p<0.001) and 
increased anxiety symptoms (r=0.21, p<0.001). 
A total of 29% (n=90) of participants reported moderate-to-high diabetes 
distress. ITAS Negative scores were moderately and positively related to diabetes 
distress. All DDS-17 subscales were positively related to ITAS Negative scores, with 
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the strongest relationships being with ‘emotional burden’ (r=0.41, p<0.001) and 
‘regimen distress’ (r=0.33, p<0.001).  
Beliefs about medications 
Average BMQ General subscale scores indicated disagreement with, or 
uncertainty about, the ‘overuse’ and ‘harm’ of medicines in general. A weak positive 
correlation was observed between ITAS Negative scores and ‘overuse’ (r=0.11, 
p=0.044) but not ‘harm’ (r=0.08, p=0.15) (Table 1).   
On average, participants indicated that their currently prescribed OHAs were a 
‘necessity’ and that they did not have ‘concerns’ about this medication. For 91% 
(285) of participants, perceived ‘necessity’ of current diabetes medicines outweighed 
‘concerns’ about them. ‘Concerns’ (r=0.35, p<0.001) but not ‘necessity’ (r=0.01, 
p>0.05) was significantly positively related with ITAS Negative scores.  
Model 
Table 2 displays the results of a hierarchal multiple regression analyses 
undertaken to assess the contribution of each of the five steps: 1) age and number of 
complications; 2) depressive and anxiety symptoms; 3) subscales of diabetes-related 
distress; 4) beliefs about medications in general; 5) beliefs about current diabetes 
medications, on the dependent variable (ITAS Negative score). Multicollinearity 
problems were not present according to VIF and Tolerance values. Depressive 
symptoms, but not anxiety, made a significant contribution to the prediction of ITAS 
score in step 2. Of the DDS-17 subscales introduced in step 3, only ‘emotional 
burden’ made a significant contribution and this rendered the contribution of 
depressive symptoms non-significant. Each step significantly improved the model 
except for step 4, in which BMQ General ‘overuse’ and ‘harm’ did not contribute to 
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the model. While BMQ Specific belief in ‘necessity’ did not contribute, ‘concerns’ 
made a significant independent contribution, increasing the variance accounted for 
between model 4 and model 5, and reducing the independent contribution of diabetes 
distress. The final model (step 5 in Table 2), included significant independent 
contributions from number of complications, DDS-17 ‘emotional burden’, and BMQ 
Specific ‘concerns’, and accounted for 22% of the variance in negative ITAS scores. 
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Discussion  
Our findings indicate that the majority of adults with T2DM using OHAs 
endorse negative beliefs about insulin therapy. Further, negative beliefs about insulin 
therapy are positively associated with number of diabetes-related complications, 
diabetes-related ‘emotional burden’ and ‘concerns’ about current diabetes treatment 
(i.e. OHAs). These results suggest that a focus on reducing distress about diabetes 
and alleviating concerns about its current treatment may act to improve attitudes 
towards insulin as a potential therapy. 
The mean ITAS Negative score, and highly endorsed barriers to insulin 
treatment, found in the current sample were similar to those reported elsewhere [14-
17, 30, 31]. In our sample, approximately one quarter reported a moderate-to-severe 
level of depressive symptoms or diabetes distress, and one in six reported moderate-
to-severe anxiety symptoms. While a weak association between negative insulin 
appraisals and anxiety was observed, anxiety did not add to the prediction of ITAS 
Negative scores. Consistent with previous research [15, 32], the contribution of 
depression scores in the prediction of insulin appraisals was reduced after including 
diabetes distress. Elsewhere, contradictory results have been reported regarding the 
prediction of self-care behaviours and HbA1c outcomes by depression and distress 
[33, 34]. It is likely that the correlation between depression and negative insulin 
therapy appraisals found here and elsewhere is, at least in part, strengthened by the 
measurement and symptom overlap between depression and diabetes distress [35]. 
Prospective research is needed to investigate the causal relationships between 
diabetes distress, negative insulin therapy appraisals, and insulin uptake.   
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BMQ Specific ‘concerns’ about OHAs, but not belief in treatment ‘necessity’ , 
was positively associated with negative insulin appraisals and added to the prediction 
of ITAS scores. Neither of the BMQ General subscales (‘harm’ or ‘overuse’) added 
to the prediction of ITAS Negative scores when entered (model 4). Horne et al [29] 
propose that while general beliefs about medicines may be a strong influence in 
initial orientation towards medicine use, specific beliefs about current medicines are 
more likely to influence ongoing medication-taking behaviours. The stronger 
association between negative insulin therapy appraisals and BMQ Specific 
‘concerns’ than between insulin appraisals and general beliefs in medicines suggests 
that people regard the future use of insulin as an extension of current diabetes 
treatment, rather than as a new medication (despite the difference in administration 
method, oral versus injection). Furthermore, to maximise treatment use, our findings 
indicate that current ‘concerns’ about OHAs need to be explored and resolved before 
any addition of insulin to the treatment regimen.    
Given the significant contribution of BMQ Specific ‘concerns’ about current 
diabetes treatment to the prediction of ITAS Negative scores, it is surprising that the 
DDS-17 subscale ‘regimen distress’ made no significant independent contribution. 
Furthermore, we observed only a weak-to-moderate relationship between ‘concerns’ 
about current treatment and ‘regimen distress’ (Table 1). However, the focus of the 
regimen-distress subscale is on the perception of the daily management of diabetes 
(e.g. “not feeling confident in my day-to-day ability to manage diabetes”) and it does 
not address concerns about, or refer explicitly to, diabetes medications.  
Despite endorsing negative aspects of insulin, the majority of participants were 
aware of the benefits of insulin use (e.g. improved health). Similarly, the ‘necessity’ 
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of current diabetes medications to maintain and improve health was endorsed by the 
vast majority of participants. This finding suggests that to improve attitudes towards 
future intensification of treatment, it is likely to be insufficient to focus solely on 
endorsing the benefits. Interventions are needed to identify, acknowledge and 
reframe negative attitudes toward current medications rather than focusing singularly 
on treatment benefits, of which many participants already report being aware.   
Diabetes-related ‘emotional burden’ and ‘concerns’ about current diabetes 
medications were more strongly associated with negative insulin appraisals than 
general emotional wellbeing (depression / anxiety) and beliefs about medicines in 
general. This suggests that while participants may have a general mistrust of 
medicines and or be experiencing impaired general emotional wellbeing (i.e. 
symptoms of depression or anxiety), this may not necessarily influence or be 
influenced by negative appraisals of insulin therapy specifically.   
Discussion of the general limitations of the Diabetes MILES – Australia study 
can be found elsewhere [22]. In particular, causality cannot be determined due to the 
cross-sectional nature of the data. Prospective research is required to understand 
exactly how the variables interact over time and influence treatment intensification. 
Further, studies have shown that more negative insulin appraisals (as assessed by 
ITAS scores) are positively associated with hypothetical unwillingness to initiate 
insulin if recommended [16, 31], but no prospective research has explicitly studied 
the influence of negative insulin therapy appraisals on actual insulin initiation. Thus, 
it is unclear whether or not the factors associated with negative insulin therapy 
appraisals identified here are in fact determinants of insulin uptake.  
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One consideration regarding the generalisability of the current study is that the 
sample includes participants with various diabetes durations, medication dosages, 
biomedical outcomes, and HbA1c is unknown. Therefore, we should not take the 
view that all would benefit from treatment intensification in the near future. The 
Diabetes MILES Study was not designed to include objective biomedical data (e.g. 
HbA1c). Understanding medication beliefs, emotional well-being and, in particular, 
insulin therapy appraisals in the context of current HbA1c levels would be of interest 
in future studies. Further, our results showed that those with more negative attitudes 
towards insulin also displayed more concerns about current diabetes medications, 
suggesting that they regard insulin as an extension of current diabetes treatment. 
Whether insulin is required, or not, these results suggest that participants would 
benefit from early discussion about the range of diabetes medications, and ways to 
improve their experience of these medications, with their health professional. Indeed, 
the recent ADA/EASD position statement on the management of hyperglycaemia in 
T2DM [36] now includes a ‘patient-centred approach’ and notes that patient attitudes 
to therapy are ‘potentially modifiable’.  
In conclusion, this is the first study, to our knowledge, to investigate (using 
validated measures) the associations between beliefs about current medicines and 
attitudes towards future insulin use. Diabetes-related distress and ‘concerns’ about 
currently prescribed diabetes medicines were more strongly associated with negative 
insulin therapy appraisals than general emotional wellbeing and beliefs about 
medicines in general. The findings of this study suggest that negative beliefs about 
future insulin use may reflect current diabetes distress and treatment concerns. Early 
intervention and education to improve current experiences of, and attitudes towards 
diabetes self-management, may improve receptiveness to future medication 
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intensification. Prospective research is needed to improve our understanding of the 
causal relationships between diabetes distress, and ‘concerns’ about current 
medications, and how these may influence negative insulin therapy appraisals and 
actual insulin uptake, as well as how to reduce barriers to medication intensification.  
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Highlights 
 Study explores ‘willingness’ to begin insulin among adults with T2DM in 
primary care. 
 Among those for whom insulin is clinically indicated, only 1 in 5 are ‘very 
willing’ to begin insulin. 
 Clinical factors and emotional wellbeing are not independently associated 
with ‘willingness’. 
 Socioeconomic status and insulin appraisals are independently associated 
with ‘willingness’. 
 Early acknowledgement and discussion of attitudinal barriers may improve 
insulin receptiveness. 
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Abstract 
Aims 
To determine ‘hypothetical willingness’ to initiate insulin, and identify 
associated factors, among adults with type 2 diabetes (T2DM) in primary care for 
whom insulin is clinically indicated. 
Methods 
Eligible participants were adults with T2DM with an HbA1c ≥7.5% (58 
mmol/mol) and prescribed maximum oral hypoglycaemic agents. A total of 261 
participants were recruited from 74 Victorian general practices: mean age 62 ± 10 
years; 39% (n = 103) women; diabetes duration 10 ± 6 years; HbA1c 9.0 ± 1.3% (75 
± 14 mmol/mol). Data collected by the Stepping Up Study: demographic and clinical 
characteristics, ‘willingness’ to initiate insulin, insulin appraisals, depressive 
symptoms, and diabetes-related distress. A multinomial regression investigated 
predictors of ‘willingness’. 
Results 
Nineteen percent (n = 50) were ‘very willing’ to initiate insulin, if 
recommended. The final regression model (R2 = .44, χ2(12) 145.91, p < .001) 
demonstrated higher socioeconomic status and less negative attitudes to insulin were 
associated with increased willingness to initiate insulin. 
Conclusions 
Among adults with T2DM for whom insulin is clinically indicated, only one in 
five are ‘very willing’ to begin insulin therapy. Independent of demographics, 
clinical factors and emotional wellbeing, insulin appraisals were associated with 
‘willingness’. This study highlights the importance of addressing attitudinal barriers 
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to insulin therapy among adults with T2DM in primary care to improve insulin 
receptiveness. 
Keywords 
Type 2 diabetes, Primary care, Insulin therapy 
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1. Introduction 
Due to the depletion of beta cell function over time [1], type 2 diabetes mellitus 
(T2DM) requires timely intensification of treatment throughout disease progression 
[2]. Insulin therapy is the most effective glucose lowering treatment option available 
[3] and [4] but is often delayed [5]. This may be due to a reluctance by health 
professionals, known as clinical inertia [6], or reluctance among people with T2DM, 
known as ‘psychological insulin resistance’ [7], [8] and [9]. 
In the UK Prospective Diabetes Study, 27% of the participants for whom 
insulin was prescribed initially refused this form of therapy, while just 7–13% 
refused intensification of tablet treatment [10]. In a qualitative study in a UK 
Bangladeshi population, one in five participants refused insulin, even after attending 
counselling about treatment intensification [11]. There has since been little research 
on the refusal of insulin among people with T2DM, and refusal rates are largely 
unknown. 
Several studies have explored the behavioural concept of ‘hypothetical 
willingness’ to begin insulin therapy if recommended, where being hypothetically 
unwilling is regarded as a proxy of insulin refusal [12], [13], [14], [15], [16], [17], 
[18] and [19]. Approximately 17% of adults with non-insulin-treated T2DM report 
being hypothetically unwilling to begin insulin, although rates vary across countries 
[18] and cultural groups [13]. Exploring, and intervening at the level of, insulin 
appraisals (or attitudes) may be critical in understanding and improving 
receptiveness toward insulin therapy uptake. Attitudes have been investigated widely 
using both quantitative [20] and qualitative methods [21]. 
     161 
Despite attitudes being strong predictors of intention [22], little research has 
investigated the relationship between attitudes towards insulin and hypothetical 
willingness appropriately. In two previous studies using a validated measure of 
insulin appraisals, the regression model included attitudes towards insulin as the 
dependent variable, with hypothetical willingness and other psychosocial variables as 
predictors [14] and [19]. This is in contrast to the more logical and theoretically-
grounded expectation that attitudes (insulin appraisals) would be predictive of 
intention (willingness) and behaviour (insulin uptake) [22]. Thus, a more suitable 
approach is to explore the role of attitudes, and associated factors, in the prediction 
of hypothetical willingness. In other studies, unvalidated or single item assessments 
of insulin appraisals have been used [13], [16] and [18]. Further research using 
validated measures to corroborate these findings. 
In research exploring attitudes or willingness to initiate insulin, few studies 
have explored the role of other psychosocial variables (e.g. emotional wellbeing) 
and/or behavioural factors (e.g. current medication-taking behaviours), in addition to 
clinical factors (e.g. glycaemic levels). Diabetes-related distress has been shown to 
be an important underlying predictor of insulin appraisals [23] and [24]. However, 
willingness to initiate insulin was not explored in these studies and objective clinical 
data were limited. Where the relationship between emotional wellbeing and 
willingness to initiate insulin has been explored, depressive symptomatology, rather 
than diabetes-related distress, has been measured [14] and [19], or unvalidated 
measures have been used [16]. In summary, a comprehensive analysis is needed of 
the clinical and psychosocial factors (using validated measures) associated with 
willingness to begin insulin to guide clinical practice. 
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Our aims were to: (1) to determine hypothetical willingness to initiate insulin 
therapy among adults with T2DM for whom insulin is clinically indicated, who 
receive their diabetes healthcare in general practice, and (2) to identify demographic, 
clinical and psychosocial factors, including attitudes toward insulin therapy, 
associated with hypothetical willingness to begin insulin. 
2. Participants, materials and methods 
Baseline data were collected from adults with T2DM participating in the 
Stepping Up Study, a cluster randomised trial conducted in 74 general practices 
across the state of Victoria, Australia. A detailed description of the trial protocol has 
been published elsewhere [25]. A cross sectional analysis of baseline data collected 
between October 2012 and June 2014 was undertaken. 
Ethical approval was received from the University of Melbourne Health 
Sciences Human Research Ethics Sub-committee (ID 123740) and Deakin University 
Human Research Ethics Committee (2012-108). The trial is registered with the 
Australian New Zealand Clinical Trial Registry (ACTRN12612001028897). 
2.1. Participants 
Eligible practices were recruited through Medicare Locals (local networks of 
general practices) and the University of Melbourne Department of General Practice 
database of teaching and research active practices. Of the 74 participating practices, 
77.0% (n = 57) were privately owned; the median (IQR) number of registered 
patients with a recorded diagnosis of T2DM was 233 (131, 349), and 37.8% (n = 28) 
were located outside the metropolitan area. Eligible patients were adults with non-
insulin-using T2DM, an HbA1c ≥7.5% (58 mmol/mol) in the past 6 months and for 
whom maximal oral therapy (≥2 oral hypoglycaemic agents (OHAs) at maximum 
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tolerated doses) had been prescribed or for whom the GP considered insulin initiation 
appropriate. Patients were ineligible if they were >80 years of age, unable to give 
consent, had unstable cardiovascular disease, and/or an existing debilitating medical 
condition. 
Potentially eligible patients (N = 521) were identified by the practice and sent a 
letter stating that study participants may benefit from assessment and more intensive 
diabetes management (which may include insulin therapy) and inviting the person to 
attend the practice to learn more about the study. 422 participants responded to this 
invitation. Upon consent, participants completed the baseline questionnaire and 
undertook an HbA1c test. Those with HbA1c <7.5% (58 mmol/mol), were excluded. 
Following screening, the eligible participating Stepping Up sample included 51% (n 
= 266) of the potential population. 
2.2. Measures 
Full details of the Stepping Up outcome measures are described elsewhere 
[25]. Measures relevant to the current analysis are detailed below. 
Hypothetical willingness to initiate insulin was assessed using a single item 
that asks individuals to indicate how willing they would be to take insulin if 
recommended by their doctor (‘very’, ‘moderately’, ‘not very’, ‘not at all’) [16]. In 
prior studies, responses have been recoded as a binary or trichotomised using various 
cut points [16] and [18]. Given previous scoring inconsistencies, we used all four 
categories. 
Attitudes towards insulin: Two measures of attitudes toward insulin were 
included to enable greater comparability of insulin appraisals of the current sample to 
participants across national [23] and international data [14], [18], [19] and [26]. 
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(i) The Insulin Treatment Appraisal Scale (ITAS) is a validated 20-item scale 
that explores participant beliefs and expectations about future insulin use [26]. 
Respondents indicate their level of agreement with 20 statements on a five-point 
scale (1 = ‘strongly disagree’ to 5 = ‘strongly agree’). The ITAS was conceptualised 
as two-dimensional, including a negative insulin therapy appraisal score (the sum 
score of 16 items, where higher scores indicate more negative appraisals) and a 
positive insulin therapy appraisal score (the sum of four positive appraisals, where 
higher scores indicate more positive appraisals). In addition, the scale developers 
suggested the use of a total ITAS score (sum of all 20 items) [26]. However, in more 
recent analysis, the total score has not been recommended [27]. As such, the current 
analysis employs the positive and negative ITAS subscales only. 
(ii) A single question tool developed by Polonsky et al. [18], hereafter referred 
to as the ‘single attitudinal item’, asks participants to identify two out of six 
statements that best match how they feel about the possibility of starting insulin [18]. 
Half of these statements are positively worded (e.g. ‘helps you feel better’); and half 
are negatively worded (e.g. ‘connected to disease worsening’). The number of 
positive and negative endorsements for each participant is summed to provide a 3-
point scale, where 0 = positive attitudes, 1 = mixed attitudes, 2 = negative attitudes. 
If only one response is selected then scoring is based on whether the response is 
positive or negative (0 or 2). 
Depressive symptoms were assessed using the 9-item Patient Health 
Questionnaire (PHQ-9) [28]. Respondents rate symptom frequency over the past two 
weeks on a four-point scale (0 = ‘not at all’ to 3 = ‘nearly every day’). Item scores 
are summed to form a total score from 0 to 27, where higher scores indicate greater 
depressive symptoms and scores of ≥10 indicate moderate-to-severe symptoms [28]. 
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Diabetes-related distress was measured using the 20-item Problem Areas In 
Diabetes (PAID) scale [29]. Respondents rate the extent to which each item is a 
problem for them on a 5-point scale (0 = ‘not a problem’ to 4 = ‘serious problem’). 
Item scores are summed and standardised to form a total score from 0 to 100, where 
scores ≥40 indicate severe diabetes distress [30]. 
Medication-taking behaviour was assessed using the 6-item Medication 
Adherence Rating Scale (MARS) [31]. For each item, a parameter relating to 
suboptimal medication-taking behaviour, participants indicate the frequency with 
which they behaved accordingly on a 5-point scale (1 = ‘always’ to 5 = ’never’). The 
scale was adapted, with the developer's permission, to refer to diabetes-specific 
medications. A total score (from 6 to 30) is calculated by summing each item score, 
where higher scores indicate more optimal medication-taking behaviours. 
In addition, the following data were retrieved from participants’ medical 
records: demographics (including: age; gender; country of birth; English as primary 
language; residential postcode, which was used to determine the Socio-Economic 
Indexes For Areas Index of Relative Socio-economic Advantage and Disadvantage 
(SEIFA IRSAD) [32] and clinical data (body mass index (BMI: weight (kg)/Height 
(m)2); diabetes duration; number of co-morbid conditions [33]; current medications 
prescribed). Frequency of self-monitoring of blood glucose was self-reported, and 
baseline HbA1c data were extracted from the study database. 
2.3. Statistical analysis 
Statistical analysis was undertaken using SPSS version 22 (Chicago, USA). 
Missing data were rare across psychosocial scales. As imputation procedures for the 
scales vary across studies (for example: [19] and [24]), a conservative ≤10% rule was 
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used to replace missing data with the series mean for the PAID and ITAS (i.e. if ≤2 
missing items), and PHQ-9 (i.e. if ≤1 missing item). Five participants were excluded 
due to non-completion of any survey questions or missing data on the dependent 
variable (‘hypothetical willingness’). One-way ANOVAs and Chi-square tests were 
calculated to explore the relationships between hypothetical willingness and 
demographic, clinical, and psychosocial data. Pearson's correlation coefficients were 
calculated to explore the relationships between independent variables. To explore the 
prediction of hypothetical willingness, a multinomial logistic regression was 
conducted, entering in the model all independent variables that differed significantly 
by hypothetical willingness. A multinomial regression was conducted, as the 
assumption of proportional odds was not met. 
Results are reported as mean ± standard deviation, n(%) or median 
(interquartile range: IQR). All statistical tests were two-sided and differences were 
accepted as significant at p < .05. 
3. Results 
Of the 266 baseline Stepping Up Study participants, data on psychosocial 
questionnaires and hypothetical willingness item were available for 261 participants. 
Table 1 details the demographic, clinical and psychosocial characteristics of the 
overall sample, and by hypothetical willingness to initiate insulin. On average, 
participants were 62 years old, diagnosed with T2DM 10 years; 39.5% (n = 103) 
were women. 
  
   
 
16
7 
Ta
bl
e 
1 
 
D
em
og
ra
ph
ic
, c
lin
ic
al
 a
nd
 p
sy
ch
os
oc
ia
l c
ha
ra
ct
er
ist
ic
s b
y 
wi
lli
ng
ne
ss
 to
 in
iti
at
e 
in
su
lin
 th
er
ap
y 
 
To
ta
l s
am
pl
e 
 
N=
26
1 
N
ot
 a
t a
ll 
w
ill
in
g 
n=
59
 (2
2.
6%
)  
N
ot
 v
er
y 
w
ill
in
g 
n=
76
 (2
9.
1%
) 
M
od
er
at
el
y 
w
ill
in
g 
n=
76
 (2
9.
1%
) 
V
er
y 
w
ill
in
g 
n=
50
 (1
9.
2%
) 
Si
g 
D
em
og
ra
ph
ic
s 
G
en
de
r: 
W
om
en
 
10
3 
(3
9.
5%
) 
23
 (3
9%
) 
34
 (4
4.
7%
) 
31
 (4
0.
8%
) 
15
 (3
0.
0%
) 
N
s 
A
ge
 (y
ea
rs
) 
62
±1
0 
62
±1
0 
61
±1
0 
62
±1
1 
63
±9
 
N
s 
In
 re
la
tio
ns
hi
p 
18
2 
(6
9.
7%
) 
40
 (2
2.
0%
) 
55
 (7
2.
4%
) 
51
 (2
8.
0%
) 
36
 (1
9.
8%
) 
N
s 
A
us
tra
lia
 b
or
n 
16
1 
(6
1.
7%
) 
29
 (4
9.
2%
) 
49
 (6
4.
5%
) 
49
(6
4.
5%
) 
34
 (6
8.
0%
) 
N
s 
En
gl
is
h 
as
 p
rim
ar
y 
la
ng
ua
ge
 
24
5 
(9
3.
9%
) 
52
 (8
8.
1%
) 
73
 (9
6.
1%
) 
73
 (9
6.
1%
) 
47
 (9
4%
) 
N
s 
SE
IF
A
 d
ec
ile
 
5.
8±
2.
6 
4.
9±
2.
9c
 
5.
6±
2.
6 
6.
5±
2.
5a
 
5.
8±
1.
9 
.0
03
 
Cl
in
ic
al
 C
ha
ra
ct
er
ist
ic
s &
 D
ia
be
te
s M
an
ag
em
en
t 
D
ia
be
te
s d
ur
at
io
n 
(y
ea
rs
) 
9.
8±
6.
4 
10
.5
 ±
7.
1 
9.
4±
5.
13
 
10
.7
±7
.6
 
8.
2±
5.
2 
N
s 
B
od
y 
M
as
s I
nd
ex
 (k
g/
m
2 )
 
32
.7
 ±
6.
5 
33
.6
±6
.5
 
32
.6
±6
.0
 
32
.6
±7
.3
 
31
.7
±5
.9
 
N
s 
№
 c
o-
m
or
bi
d 
co
nd
iti
on
s 
2.
6±
1.
9 
2.
4±
1.
8 
2.
5±
1.
9 
2.
6±
2.
0 
3.
1±
2.
2 
N
s 
H
bA
1c
 (%
)  
   
   
   
   
(m
m
ol
/m
ol
) 
9.
0 
±1
.3
  
75
 ±
14
 
9.
2±
1.
3 
 
78
±1
5 
8.
8±
1.
2 
 
73
±1
3 
8.
9±
1.
3 
 
74
±1
4 
8.
9±
1.
3 
74
±1
4 
N
s 
SM
B
G
: a
t l
ea
st
 o
nc
e 
da
ily
  
13
3 
(5
1.
0%
) 
25
 (4
2.
4%
) 
28
 (5
0.
0%
) 
42
 (5
5.
3%
) 
28
 (5
6.
0%
) 
N
s 
D
ia
be
te
s 
m
ed
ic
at
io
ns
: n
um
be
r p
re
sc
rib
ed
 
fo
r d
ia
be
te
s  
7.
5±
3.
8 
7.
1±
3.
3 
7.
6±
3.
9 
7.
8±
4.
0 
7.
7±
3.
7 
N
s 
   
 
16
8 
 
To
ta
l s
am
pl
e 
 
N=
26
1 
N
ot
 a
t a
ll 
w
ill
in
g 
n=
59
 (2
2.
6%
)  
N
ot
 v
er
y 
w
ill
in
g 
n=
76
 (2
9.
1%
) 
M
od
er
at
el
y 
w
ill
in
g 
n=
76
 (2
9.
1%
) 
V
er
y 
w
ill
in
g 
n=
50
 (1
9.
2%
) 
Si
g 
M
A
R
S 
to
ta
l (
6-
30
) 
27
.3
±3
.7
 
27
.1
±3
.8
 
27
.1
±3
.6
 
27
.1
±3
.7
 
27
.9
±3
.5
 
N
s 
Ps
yc
ho
so
ci
al
 
PH
Q
-9
 to
ta
l (
0-
27
) 
 
m
od
er
at
e-
to
-s
ev
er
e 
(P
H
Q
-9
 to
ta
l 
≥1
0)
 
4.
5±
4.
9 
39
 (1
5.
0%
) 
5.
2±
4.
8 
10
 (1
7.
2%
) 
5.
3±
5.
7d
 
15
 (1
9.
7%
) 
4.
3±
4.
7 
10
 (1
3.
2%
) 
2.
8±
3.
3b
 
4 
(8
.0
%
) 
.0
16
 
PA
ID
   
to
ta
l (
0-
10
0)
 
se
ve
re
 d
ist
re
ss
 (P
A
ID
 to
ta
l: 
≥4
0)
 
19
.7
±1
8.
2 
39
 (1
5.
0%
) 
24
.0
±2
1.
2d
 
15
 (2
5.
4%
) 
20
.0
±1
7.
0 
11
 (1
4.
5%
) 
20
.0
±1
8.
7 
10
 (1
3.
2%
) 
13
.4
±1
3.
4a
 
3 
(6
.0
%
) 
.0
21
 
Si
ng
le
 a
tti
tu
di
na
l i
te
m
 (0
-2
) 
0.
9±
0.
8 
1.
5±
0.
7c
d  
1.
3±
0.
8c
d  
0.
6±
0.
7a
bd
 
0.
2±
0.
5a
bc
 
<.
00
1 
IT
A
S 
Po
sit
iv
e 
(5
-2
0)
 
14
.3
±2
.0
 
13
.3
±1
.9
cd
 
14
.1
±1
.9
c  
15
.0
±1
.8
ab
 
14
.9
±2
.1
a  
<.
00
1 
IT
A
S 
N
eg
at
iv
e 
(1
6-
80
) 
46
.9
±8
.5
 
50
.7
±9
.1
cd
 
49
.1
±7
.8
d  
46
.1
±7
.3
ad
 
40
.2
±6
.5
ab
c  
<.
00
1 
D
at
a 
ar
e 
M
ea
n±
SD
 o
r n
(%
). 
V
al
id
 p
er
ce
nt
ag
es
 re
po
rte
d 
du
e 
to
 m
is
si
ng
 v
ar
ie
d 
N
’s
 fo
r e
ac
h 
qu
es
tio
nn
ai
re
. S
in
gl
e 
at
tit
ud
in
al
 it
em
: h
ig
he
r 
sc
or
es
 in
di
ca
te
 g
re
at
er
 e
nd
or
se
m
en
t o
f n
eg
at
iv
e 
in
su
lin
 a
pp
ra
is
al
s;
 IT
A
S 
= 
In
su
lin
 T
re
at
m
en
t A
pp
ra
isa
l S
ca
le
 [2
6]
, h
ig
he
r s
co
re
s 
in
di
ca
te
 g
re
at
er
 e
nd
or
se
m
en
t o
f n
eg
at
iv
e 
in
su
lin
 a
pp
ra
isa
ls 
(I
TA
S 
N
eg
at
iv
e)
 o
r p
os
iti
ve
 in
su
lin
 a
pp
ra
isa
ls 
(I
TA
S 
Po
sit
iv
e)
; M
A
RS
 =
 
M
ed
ic
at
io
n 
A
dh
er
en
ce
 R
at
in
g 
Sc
al
e 
[3
1]
, h
ig
he
r s
co
re
s i
nd
ic
at
e 
m
or
e 
op
tim
al
 m
ed
ic
at
io
n-
ta
ki
ng
 b
eh
av
io
ur
s;
 P
A
ID
 =
 P
ro
bl
em
 A
re
as
 In
 
D
ia
be
te
s [
29
], 
hi
gh
er
 sc
or
es
 in
di
ca
te
 g
re
at
er
 d
ia
be
te
s-
re
la
te
d 
di
st
re
ss
; P
H
Q
-9
 =
 P
at
ie
nt
 H
ea
lth
 Q
ue
st
io
nn
ai
re
 [2
8]
, h
ig
he
r s
co
re
s i
nd
ic
at
e 
m
or
e 
de
pr
es
si
ve
 s
ym
pt
om
s;
 S
EI
FA
 =
 S
oc
io
Ec
on
om
ic
 In
de
x 
Fo
r A
re
as
 [3
2]
, h
ig
he
r s
co
re
s 
in
di
ca
te
 g
re
at
er
 re
la
tiv
e 
so
ci
oe
co
no
m
ic
 
ad
va
nt
ag
e 
an
d 
lo
w
er
 d
isa
dv
an
ta
ge
; S
M
B
G
 =
 se
lf-
m
on
ito
rin
g 
of
 b
lo
od
 g
lu
co
se
. S
ig
ni
fic
an
tly
 d
iff
er
en
t f
ro
m
  
a 
“n
ot
 a
t a
ll 
w
ill
in
g”
, b
 “n
ot
 v
er
y 
w
ill
in
g”
, c
 “m
od
er
at
el
y 
w
ill
in
g”
, d
 “v
er
y 
w
ill
in
g”
.  
 
169 
 
Some level of hypothetical willingness to initiate insulin was observed in 
nearly half of the sample, with 19.2% reporting being ‘very willing’ and 29.1% 
responding as ‘moderately willing’ to begin insulin therapy if recommended by their 
doctor. A further 29.1% were ‘not very willing’, with the remaining 22.6% being 
‘not at all willing’. 
3.1. Participant demographic characteristics 
Demographic characteristics did not differ significantly by willingness to 
initiate insulin, with the exception of SEIFA IRSAD deciles (Brown–Forsythe F(3, 
234.6) = 4.6, p = .003), where those reporting being ‘not at all willing’ resided in 
more socio-economically disadvantaged areas than those who were ‘moderately 
willing’ (Mean diff = −1.61,p = .002). 
3.2. Clinical and diabetes management variables 
Clinical characteristics did not differ significantly by hypothetical willingness 
to initiate insulin therapy. Half (n = 133) of the participants reported checking their 
blood glucose at least daily. Clinical records show a mean current HbA1c of 
9.0 ± 1.3% (75 ± 14 mmol/mol) (median = 8.6% (70 mmol/mol), IQR = 8.0, 9.7% 
(64, 83 mmol/mol)). Ninety per cent of participants had at least one diagnosed co-
morbid condition, and a median of two (IQR = 1–4) diagnosed co-morbid conditions. 
The median number of medications prescribed per person on record was seven 
(IQR = 5, 10). A minority (n = 14, 5.4%) were currently using a non-insulin 
injectable treatment (e.g. exenatide) to manage their diabetes. MARS scores reveal 
that, on average, participants report taking their diabetes medications as 
recommended, and this did not differ by hypothetical willingness. 
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3.3. Emotional wellbeing 
Moderate-to-severe depressive symptoms were reported by 15.0% (n = 39) and 
severe diabetes-related distress was also reported by 14.9% (n = 39). Seven per cent 
(n = 19) reported both moderate-to-severe depressive symptoms and severe diabetes-
related distress. Depressive symptoms and diabetes-related distress both differed by 
hypothetical willingness to use insulin (PHQ-9: Brown–Forsythe F(3, 242.5) = 3.5, 
p = .016; PAID: Brown–Forsythe F(3, 229.4) = 3.3, p = .021). Post-hoc comparisons 
reveal that participants who report being ‘very willing’ to begin insulin reported 
significantly less diabetes-related distress than those who reported being ‘not at all 
willing’ (Mean diff = 10.65, p = .013), and significantly less depressive symptoms 
than those who reported being ‘not very willing’ to begin insulin (Mean 
diff = 2.54, p = .025). 
The PAID total score displayed a weak-to-moderate positive correlation with 
the single attitudinal item score (r = .251, p < .001) and the ITAS negative score 
(r = .403, p < .001). Similarly, the PHQ-9 showed a weak positive relationship with 
the single attitudinal item (r = .268, p < .001) and ITAS negative (r = .281, p < .001). 
There was no significant relationship between the ITAS positive scale and the PAID 
total or PHQ-9 total scores. 
3.4. Attitudes towards Insulin 
ITAS negative (Brown–Forsythe F(3, 229.12) = 19.61, p < .001) and ITAS 
positive scores (Brown-Forsythe F(3, 225.04) = 9.8, p < .001) differed significantly 
by hypothetical willingness. Post-hoc comparisons revealed that those who were 
‘very willing’ to begin insulin reported significantly less negative insulin appraisals 
than all other groups (Mean diff range = −5.9 to −10.5, all p < .001) and significantly 
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higher positive ITAS positive scores than those who were ‘not at all willing’ (Mean 
diff = 1.5, p < .001). Table 2 shows mean and standard deviations for ITAS items as 
well as the percentage of participants who endorsed (‘strongly agreed’ or ‘agreed’ 
with) each item. The most commonly endorsed ITAS negative items were ‘taking 
insulin means my diabetes has become much worse’ (item 2; n = 174; 66.9%) and 
‘taking insulin means I have failed to manage my diabetes…’ (item 1; n = 133, 
51.2%). For all 20 ITAS items, mean scores differed significantly by hypothetical 
willingness (p < .05 to p < .001), whereby greater willingness was associated with 
less negative attitudes, with four exceptions: items 2 (‘insulin means my diabetes has 
become much worse’), 7 (‘insulin increases the risk of low blood glucose’), 9 
(‘insulin causes weight gain’), and 20 (‘insulin makes me more dependent on my 
doctor’). 
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Table 2 
Insulin appraisals: mean and standard deviation ITAS item scores and percentage 
endorsing (agree/strongly agree) 
Items Mean ± 
SD 
Agree 
or 
Strongly 
agree % 
1 Taking insulin means I have failed to manage my 
diabetes with diet and tablets 
3.3 ± 1.2 51.2% 
2 Taking insulin means my diabetes has become much 
worse 
3.7 ± 0.9 66.9% 
3^ Taking insulin helps to prevent complications of 
diabetes 
3.7 ± 0.8 66.2% 
4 Taking insulin means other people see me as a sicker 
person 
2.9 ± 1.2 33.8% 
5 Taking insulin makes life less flexible 3.0 ± 1.1 32.3% 
6 I'm afraid of injecting myself with a needle 2.8 ± 1.3 34.2% 
7 Taking insulin increases the risk of low blood glucose 
levels (hypoglycaemia) 
3.3 ± 0.8 36.3% 
8^ Taking insulin helps to improve my health 3.7 ± 0.6 65.3% 
9 Insulin causes weight gain 3.1 ± 0.6 15.4% 
10 Managing insulin injections takes a lot of time and 
energy 
2.9 ± 0.9 22.9% 
11 Taking insulin means I have to give up activities I 
enjoy 
2.4 ± 0.8  7.7% 
12 Taking insulin means my health will deteriorate 2.4 ± 0.8 7.3% 
13 Taking insulin is embarrassing 2.5 ± 0.9 15.8% 
14 Injecting insulin is painful 2.8 ± 0.9 18.2% 
15 It is difficult to inject the right amount of insulin 
correctly at the right time every day 
2.9 ± 0.9 22.4% 
16 Taking insulin makes it more difficult to fulfill my 
responsibilities (at work, at home) 
2.6 ± 0.9 17.8% 
17^ Taking insulin helps to maintain good control of my 
blood glucose 
3.7 ± 0.7 67.2% 
18 Being on insulin causes family and friends to be more 
concerned about me 
3.3 ± 1.0 49.8% 
19^ Taking insulin helps to improve my energy levels 3.3 ± 0.6 31.3% 
20 Taking insulin makes me more dependent on my doctor 3.2 ± 0.9 39.4% 
SD: standard deviation; ^ positive ITAS items. Scoring: 1 (strongly disagree) to 5 
(strongly disagree). 
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The distribution of the single attitudinal item total scores indicated an 
approximately equal sample split between those with positive (n = 98, 38.3%), mixed 
(n = 79, 30.9%), or negative (n = 79, 30.9%) attitudes toward insulin. Scores differed 
significantly by hypothetical willingness to initiate insulin (Brown–Forsythe F(3, 
239.99) = 43.4, p < .001), where mean scores were significantly less negative for 
those reporting being ‘very willing’ compared to all other groups (Mean diff range = 
−.4 to −1.3, all p < .05). The most commonly endorsed single attitudinal item 
response option was ‘feeling that the disease is getting worse’ if I need to begin 
insulin (n = 107; 41.2%), closely followed by insulin means the ‘opportunity to have 
better control of my diabetes’ (n = 103; 39.6%). 
The ITAS negative and single attitudinal item scores were moderately 
correlated (r = .521, p < .001). The ITAS positive and single attitudinal item scores 
displayed a weak, but significant negative relationship (r = −.198, p = .001). There 
was no significant relationship between the ITAS positive scale and the ITAS 
negative. 
3.5. Modelling ‘willingness’ 
The following variables (which had differed significantly by ‘willingness’) 
were included in a multinomial logistic regression: SEIFA, PHQ-9, PAID, and ITAS 
negative, ITAS positive and single attitudinal item scores. Total PHQ-9 and PAID 
scores did not contribute to the model. The final model included SEIFA, ITAS 
negative, ITAS positive and single attitudinal item scores. Significant main effects 
were observed for SEIFA (p = .002), ITAS positive and negative (p < .001 and p = 
.001, respectively), and single attitudinal item scores (p < .001). Table 3 displays the 
results of the final significant model (χ2(12) 145.91, p < .001), which correctly 
predicted 52.5% of hypothetical willingness responses. While socio-economic status 
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significantly added to the model overall, no significant independent contribution was 
observed. Increases in ITAS negative and single attitudinal item scores, and a 
decrease in ITAS positive scores, were significantly associated with being ‘not at all 
willing’ compared to ‘very willing’ to begin insulin, and ‘not very willing’ compared 
to ‘very willing’. However, ITAS positive scores did not add to the prediction of 
‘moderately willing’ versus ‘very willing’ responses. 
 
Table 3  
Multinomial logistic regression analyses predicting hypothetical willingness to begin 
insulin 
 B SE Lower 
95% CI 
Odds 
Ratio 
Upper 
95% CI  
Not at all willing vs. very willing 
Intercept -0.27 2.25    
SEIFA -0.14 0.10 0.72 0.87 1.06 
ITAS Negative Score**  0.12 0.04 1.05 1.13 1.21 
ITAS Positive Score** -0.43 0.12 0.51 0.65 0.83 
Single Attitudinal Item Score***  2.28 0.43 4.27 9.82 22.57 
Not very willing vs. very willing 
Intercept -2.30 2.09    
SEIFA -0.01 0.09 0.83 0.99 1.18 
ITAS Negative Score**  0.11 0.03 1.05 1.12 1.19 
ITAS Positive Score* -0.22 0.11 0.65 0.80 0.99 
Single Attitudinal Item Score***  1.83 0.38 2.94 6.22 13.17 
Moderately willing vs. very willing 
Intercept** -5.97 2.11    
SEIFA  0.16   .09 1.00 1.17 1.39 
ITAS Negative Score**  0.10   .03 1.04 1.11 1.18 
ITAS Positive Score  0.04   .10 0.86 1.05 1.27 
Single Attitudinal Item Score*  0.80   .38 1.06 2.21 4.63 
R2=.44 (Cox & Snell), .47 (Nagalkerke). Model χ2 (12) 145.91, p<.001.  
*p<.05, **p<.01, ***p<.001 
ITAS = Insulin Treatment Appraisal Scale [26]; SEIFA = Socio-Economic Index For 
Areas [32].  
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4. Discussion 
This study demonstrates that one in four adults with non-insulin-treated T2DM, 
for whom insulin is clinically indicated, are ‘not at all willing’ to begin insulin 
therapy, and only one in five are ‘very willing’. The strongest predictors of 
hypothetical willingness are attitudes towards insulin therapy, and this relationship is 
independent of demographics, clinical factors and emotional wellbeing. These 
findings emphasise the importance of identifying, and addressing attitudes towards 
insulin to enhance psychological receptiveness to this effective therapy. 
Our finding that 22% were hypothetically ‘unwilling’ to initiate insulin is 
consistent with recent international data [18]. The most commonly endorsed negative 
insulin appraisal, across both measures, concerns the initiation of insulin being 
regarded as a sign of a worsening health, as similarly observed nationally and 
overseas [18], [26] and [27]. This appraisal may draw on the factual explanation of 
insulin initiation being necessitated, in most cases, by beta cell destruction, and has 
the potential to motivate treatment intensification. In contrast, this belief may be 
maladaptive if the individual delays uptake of insulin because they are not ready to 
accept this symbol of worsening of health or if they believe that initiating insulin will 
mean their health will deteriorate further. The second most commonly endorsed 
negative attitude concerns insulin initiation symbolising for the person a personal 
failure to manage their condition well enough to avoid the need for insulin. 
The mean positive ITAS scores observed within this primary care setting are 
consistent with results from a national, population-based Australian dataset [27], 
whereby the majority of participants endorse the positive aspects of insulin therapy. 
However, mean ITAS negative scores are significantly less negative in this primary 
care setting. This may be a function of diabetes duration and progression. Compared 
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with the national population-based study, this clinical study included only those 
whose HbA1c was above target (≥7.5%; 58 mmol/mol) and who were using 
maximum OHAs. It may be that participants in the current study had previously 
discussed treatment intensification (i.e. insulin initiation) with their health 
professionals, acknowledging that more effective management of elevated glycaemic 
levels was needed, and thereby potentially reducing negative insulin appraisals. 
Similarly, a recent qualitative study of people with T2DM participating in an RCT 
concluded that they may be more receptive to insulin initiation and intensification 
than traditionally acknowledged [34] and [35]. Indeed, almost half of the current 
sample were at least ‘moderately willing’ to begin insulin, suggesting that insulin 
initiation in primary care, among those who would benefit most, would be acceptable 
for many adults with T2DM requiring treatment intensification. 
In the current sample, diabetes-related distress and depressive symptoms were 
also less common in comparison to national Australian data [36]. It is also possible 
that the participants (who were recruited to a trial in which treatment intensification 
would be discussed) have comparatively better emotional well-being and less 
negative attitudes to insulin than those in the broader primary care setting. This 
would suggest that our findings potentially underestimate the scope of the problem. 
Prior research has found women to be significantly less willing to initiate 
insulin than men [12], [15], [16] and [17] but, in the current study, the SEIFA 
IRSAD score was the only demographic characteristic that differentiated 
hypothetical willingness. Univariate statistics indicated a general trend of increasing 
willingness to initiate insulin among those living in more socio-economically 
advantaged areas. However, those ‘moderately willing’ lived in more advantaged 
areas than those who were ‘very willing’ suggesting a complexity to the relationship. 
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Further research is needed to clarify the role of socio-economic status in shaping 
attitudes to insulin initiation. 
Interestingly, clinical factors such as HbA1c, co-morbidities and number of 
prescribed medications also did not differ significantly by willingness. While 
depressive symptoms and diabetes distress were associated significantly with both 
insulin appraisals and willingness, consistent with previous research [14], [16], [19], 
[23], [24], [26] and [37], neither general nor diabetes-specific emotional wellbeing 
added to the prediction of willingness. Assuming hypothetical willingness is an 
indicator of eventual insulin uptake, this is in keeping with previous longitudinal 
primary care research, which concluded that the presence of baseline depressive 
symptoms, but not anxiety, was not associated with insulin uptake or time to insulin 
initiation [38]. 
The relationship between insulin appraisals and willingness has been explored 
previously [14] and [19] but the proposed direction of the relationship, and 
subsequent analysis, was contradictory to well-established theories that attitudes 
predict behavioural intention and intention predicts behaviour [22]. Our findings 
indicate that the strongest known predictors of hypothetical willingness to initiate 
insulin are positive and negative attitudes towards insulin. Interestingly, the ITAS 
positive score added to the prediction of willingness over and above the ITAS 
negative subscale and the single attitudinal item. Previously, we have recommended 
limited use of the positive subscale [27] given its inability to discriminate between 
treatment groups (insulin vs. non-insulin) [26] and [27] or between those with more 
and less negative attitudes [37]. Our findings suggest that endorsement of positive 
insulin therapy appraisals are independent of negative attitudes, not merely the lack 
of negative attitudes, and may have utility in predicting future insulin uptake. 
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However, longitudinal research is needed to explore the role of attitudes towards 
insulin (positive and negative) in actual uptake of insulin. 
Both the ITAS subscales and the single attitudinal item contributed 
independently to the prediction of hypothetical willingness, suggesting that they are 
not measuring precisely the same concepts. A chief advantage of the single item is its 
brevity and, perhaps, its narrow focus on commonly endorsed appraisals. However, 
its development has not been fully documented and it has not been psychometrically 
validated [18]. Our findings indicate that it has a weak relationship with the ITAS 
positive score and is only moderately correlated with the ITAS negative score, 
suggesting sub-optimal convergent validity with the longer ITAS. This may indicate 
that the single item does not provide comprehensive assessment of participant 
attitudes towards insulin or it may indicate some redundancy in the 20-item ITAS. 
Indeed, 8 of the 16 negative ITAS items were endorsed by ≤25% of the current 
sample suggesting that these items may not be relevant to many people. For example, 
the ITAS includes items about expected weight gain and hypoglycaemia which 
health professionals commonly perceive to be patient concerns, as shown in several 
qualitative studies [39], [40], [41] and [42]. However in the current sample, and in 
our national, cross-sectional data [23] and [27], we found that the majority of 
participants either disagreed (13%) or neither agreed nor disagreed (50.6%) that 
hypoglycaemia was a concern, and 76% of participants were unsure whether insulin 
causes weight gain. Further, responses to these items were not associated with 
hypothetical willingness. These data suggest that health professionals may 
overestimate the concerns of people with T2DM or perhaps misattribute their own 
concerns as those of their patients. 
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4.1. Strengths and limitations 
The strengths of the current study include it being the first to explore and 
report factors associated with rates of hypothetical willingness to initiate insulin 
among Australians with non-insulin-treated T2DM; it is also among the first to 
explore these variables among people with T2DM for whom insulin therapy is 
clinically indicated: i.e. with sub-optimal HbA1c and already prescribed maximum 
doses of OHAs within a primary care setting. An additional strength of the current 
study is that it includes validated clinical data (e.g. HbA1c, co-morbid conditions and 
number of prescribed medications) as well as psychometrically robust psychosocial 
measures (e.g. ITAS, PHQ-9, PAID). 
A limitation of the current study is that the sample may not be representative of 
the wider primary care population. The current sample reported lower rates of 
diabetes-related distress and depressive symptoms than found in a non-clinical 
national sample [36], and includes only English-speaking participants who self-
selected to participate in a trial that may involve treatment intensification. 
4.2. Clinical implications and future directions 
The current data suggest a mismatch between receptiveness to initiate insulin 
among people with T2DM and actual insulin uptake in Australia. Approximately half 
of participants were, at least, moderately receptive to initiating insulin yet insulin 
initiation is frequently delayed in primary care [43]. Indeed, there are multiple causes 
of delays in treatment intensification, including not only psychological insulin 
resistance among people with diabetes but also physician reluctance (i.e. clinical 
inertia) and systemic barriers [44]. Interventions to increase the timely initiation of 
insulin within primary care are needed at both the practice/systems level (e.g. the 
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Stepping Up model of care [25]) and the patient level. Further, multifactorial 
research is needed to explore the interaction between patient, health professional and 
practice level barriers in the prediction of insulin uptake among adults with T2DM. 
Our study shows the potential of modifying patient barriers to insulin initiation. 
For example, two thirds of participants believe that initiating insulin therapy means 
their diabetes has become worse while half interpret insulin use as a personal failure 
to manage their diabetes effectively. Both of these highly endorsed negative 
perceptions regarding insulin therapy might be prevented/minimised by health 
professionals educating people with T2DM that progressive beta cell destruction will 
necessitate regular review and intensification of management strategies aimed at 
maximising the patient's well-being in longer-term. For example, “Targets, Insulin, 
Management and Encouragement” is a practical guidance tool for use by health 
professionals that highlights readying the person with diabetes for insulin throughout 
the progression of their condition as well as monitoring emotional wellbeing and 
attitudes towards insulin [45]. Other recommendations highlight the importance of 
using sensitive, non-judgmental language when discussing treatment options and 
HbA1c targets to positively frame insulin therapy and foster receptiveness among 
people with T2DM [8], [46], [47], [48] and [49]. Despite a wealth of literature 
offering practical suggestions and recommendations for increasing receptiveness 
among people with T2DM for insulin initiation, few patient-level interventions have 
been evaluated. While additional research is needed to explore the predictive role of 
insulin therapy appraisals in relation to actual, real-world, insulin uptake, the 
relationship between insulin appraisals and hypothetical willingness observed in the 
current study suggests that interventions aimed at altering attitudes towards insulin 
among people with T2DM are also warranted. 
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5. Conclusion 
The current study demonstrates that one quarter of Australians with non-
insulin-treated T2DM and suboptimal HbA1c (despite maximal oral therapy) are ‘not 
at all willing’ to begin insulin therapy, if recommended by their GP, and only one in 
five are ‘very willing’. Demographics, clinical factors and emotional wellbeing have 
little explanatory value while attitudes to insulin therapy contribute significantly to 
hypothetical willingness to initiate insulin. Importantly, despite the majority 
endorsing positive appraisals of insulin, two thirds believe that insulin means their 
diabetes has become worse and half interpret insulin use as a personal failure to 
manage their diabetes effectively. These results emphasise the importance of GPs 
intervening early to counsel people with T2DM effectively to encourage 
psychological receptiveness towards insulin. 
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Highlights 
 Comprehensive prospective study of predictors of insulin use for type 2 diabetes.  
 Insulin uptake is predicted by baseline HbA1c and hypothetical willingness. 
 The predictive model was independent of the model of care received.  
 Negative, but not positive, insulin appraisals improved following insulin uptake. 
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Structured Abstract 
Aims 
We aimed to investigate predictors of insulin uptake, and change in insulin 
appraisals, among adults with type 2 diabetes mellitus (T2DM) who participated in 
the Stepping Up trial.  
Methods  
The Stepping Up model of care, supporting timely insulin initiation in primary 
care, was evaluated in a two-armed cluster-randomised controlled trial. Participants 
were 266 adults (mean±SD age 62±10 years; 39% women) with T2DM (median 
(IQR) duration 8.5 (5, 13) years) from 74 primary care practices (Stepping Up 
intervention: 57%, control 43%). At 12 months, 47% (n=126) had commenced 
insulin. Controlling for randomisation, logistic regression was used to explore 
baseline predictors of insulin uptake, including: demographic and clinical 
characteristics, emotional wellbeing (depressive symptoms and diabetes-related 
distress), insulin treatment appraisals, and, ‘willingness’ to initiate insulin. Two-way 
analysis of variance examined effects of, and interaction between, randomisation and 
insulin uptake on 12-month change in insulin appraisals.  
Results 
Participants using insulin at 12 months were more likely (all p<0.05) than 
those using tablets alone to report: lower socioeconomic status, higher baseline 
HbA1c (median Diff: 0.3%; 3mmol/mol), greater willingness to commence insulin 
(very willing: 27% vs 12%), and less negative and more positive insulin appraisals. 
All contributed significantly to the final model (2(8)=92.1, p<0.001) except insulin 
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appraisals. Regardless of trial allocation, those initiating insulin reported 
significantly greater reductions in negative insulin appraisals.  
Conclusions 
Controlling for randomisation, 12-month insulin use was predicted by higher 
baseline HbA1c and ‘willingness’ to use insulin if recommended. Negative insulin 
appraisals reduced following insulin initiation. 
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1. Introduction 
Insulin therapy is recommended for people with type 2 diabetes mellitus 
(T2DM) with suboptimal glycated haemoglobin (HbA1c), typically greater than 
5.7% (59 mmol/mol) using maximum oral hypoglycaemic agents (OHAs) [1,2]. 
Insulin is effective for lowering HbA1c [3,4], and preventing development or 
progression of diabetes-related complications [5]. However, insulin initiation is 
frequently delayed [6,7]. Reasons for delaying insulin initiation are multifaceted, 
including systemic healthcare, clinician, and patient barriers [6,8].  
People with non-insulin-treated T2DM commonly report negative attitudes 
(appraisals) to insulin therapy [8-10], known as ‘psychological insulin resistance’. 
Such negative appraisals include, but are not limited to: concerns about daily 
injections, side effects, insulin symbolising their ‘failure’ to manage diabetes [8,11]. 
Negative insulin appraisals have shown to improve after insulin initiation [12,13]. 
Insulin appraisals can be measured using multi-item scales covering both negative 
and positive expectations about insulin use (for example: Insulin Treatment 
Appraisal Scale (ITAS) [14]). Insulin appraisals are predictive of hypothetical 
‘willingness’ (intention) to begin insulin. For example, one in four Australians with 
T2DM requiring treatment intensification report being ‘not at all willing’ to begin 
insulin if recommended, and have more negative attitudes towards insulin than those 
who are ‘very willing’ [10], consistent with international findings [9]. Hypothetical 
(un)willingness has been used as a proxy measure of the proportion of people with 
T2DM who might delay insulin therapy [9], but, to our knowledge, it has not been 
established whether it predicts actual insulin uptake.  
Research into predictors of actual insulin uptake have focused largely on the 
clinical characteristics (e.g. previous treatment, HbA1c) [7,15]. With regard to 
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psychological factors, studies have found no association between time to insulin 
uptake and depressive symptoms [16] or, after accounting for insulin appraisals, 
diabetes-specific distress [17]. A multi-clinic study in Japan concluded that those 
who commenced insulin therapy had a higher HbA1c and reported less negative, and 
more positive, insulin appraisals, at baseline, compared with those who remained on 
OHAs alone [12]. However, these findings have not been corroborated in a 
comprehensive, prospective investigation of demographic, clinical and psychological 
predictors of actual insulin uptake in adults with T2DM.  
The Stepping Up model of care [18] was developed to reduce clinical inertia 
and systemic barriers [6] to timely insulin initiation in Australian primary care. The 
model involves training the in-practice team (i.e. General Practitioner (GP) and 
Practice Nurse (PN)) to enable insulin prescription, initiation and intensification 
within primary care, with support from diabetes specialists as necessary. A cluster-
randomised controlled trial demonstrated that this model of care was successful in 
increasing insulin initiation (69.5% insulin uptake vs 21.7% in usual care) among 
adults with T2DM for whom insulin was clinically indicated [19]. 
The primary aim of the current study, using data collected in the Stepping Up 
study, was to investigate the role of the participants’ demographic profile, clinical 
characteristics, emotional well-being (diabetes-specific distress and depressive 
symptoms), insulin appraisals (positive and negative) and hypothetical willingness to 
initiate insulin in the prediction of actual insulin uptake, controlling for study 
randomisation. Our secondary aims were to investigate change in positive and 
negative insulin appraisals from baseline to 12-month follow-up, and examine the 
effects of, and interaction between, study arm (control vs intervention) and insulin 
uptake on 12-month change in insulin appraisals.  
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2. Participants, Materials and Methods 
2.1. Study design  
The current study used baseline data to predict insulin therapy use at 12 months 
in a  two-armed, cluster-randomised controlled trial (RCT), which tested the 
‘Stepping Up’ model versus usual care in general practices across the state of 
Victoria, Australia. The trial protocol, and primary outcome findings have been 
published elsewhere [18,19]. Participant data were collected between October 2012 
and April 2015. 
Ethical approval was received from the University of Melbourne Health 
Sciences Human Research Ethics Sub-committee (ID 123740) and Deakin 
University Human Research Ethics Committee (2012-108). The trial was registered 
with the Australian New Zealand Clinical Trial Registry (ACTRN12612001028897). 
2.2. Participants 
Primary care practices were eligible if they employed at least one consenting 
GP and PN and provided care to at least one eligible patient. 74 practices participated 
and their characteristics are described elsewhere [10,19]. 
Patients were eligible for inclusion in the study if they: were adults with 
T2DM, had HbA1c ≥ 7.5% (58 mmol/mol), had a prescription ≥2 OHAs at 
maximum tolerated doses or insulin initiation was considered clinically appropriate 
by the GP, had no previous insulin use. Patients were ineligible if they: were >80 
years of age, unable to give consent, had unstable cardiovascular, or an existing 
debilitating medical, condition. Potential participants were identified by the practice 
(N=521) and sent a letter stating that they may benefit from clinical assessment and 
treatment intensification, which may include insulin therapy. A response was 
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received from 81% (n=422) of those invited. Consenting participants completed the 
baseline questionnaire and gave a blood sample for HbA1c analysis. If HbA1c was 
<7.5% (58 mmol/mol), they were excluded. The final sample included 266 
participants. 
2.3. Stepping Up Model 
The Stepping Up model of care has been published elsewhere [18]. In brief, the 
model of care intervened at the practice level, providing GPs and PNs with training 
to enable timely insulin prescription, with support from the study Diabetes Nurse 
Educator (DNE) as required. The 1-2 hours group training focused on: evidence for 
timely insulin initiation; familiarisation with insulin delivery systems and titration 
tools; common patient barriers to insulin initiation and techniques to deal with them, 
including motivational interviewing training and goal setting strategies. Practices 
were supported by face-to-face, telephone and email contact from the study DNE 
during the 12-month follow-up period. The GP’s primary role was to discuss and 
prescribe insulin initiation, while the PN led insulin education, initiation and 
adjustment. If participants did not commence insulin at first, they continued to visit 
the PN and GP, as often as clinically appropriate.  
Control practices were provided with a copy of the Royal Australian College of 
General Practitioners (RACGP) guidelines for the management of T2DM [2] and 
required to undertake a clinical review of, and consultation with, participants.  
2.4. Measures 
Participants’ medical records were accessed to extract demographic 
characteristics (age; gender; country of birth; primary language, and; postcode, used 
to determine the Index of Relative Socio-economic Advantage and Disadvantage 
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(IRSAD) decile [20]) and clinical characteristics (HbA1c; body mass index (BMI)); 
diabetes duration; number of co-morbid conditions [21], 12-month insulin uptake 
status). Psychological outcomes were collected at baseline and 12-months, with 
surveys completed in clinic or at home (and returned via post).  
Depressive symptoms over the previous 2 weeks were assessed using the 9-
item Patient Health Questionnaire (PHQ-9) [22]. Total scores range from 0 to 27, 
with higher scores indicating greater depressive symptoms, and scores ≥10 suggest at 
least moderate depressive symptoms [22]. Diabetes-specific distress was measured 
using the 20-item Problem Areas In Diabetes (PAID) scale [23]. Higher total scores 
(range: 0 to 100) indicate greater distress  [23]. Scores ≥40 suggest severe diabetes-
specific distress [24]. 
Attitudes to insulin were assessed using the 20-item ITAS [14], which includes 
16 negative items (ITAS Negative, score range:16 to 80) and four positive items 
(ITAS Positive, score range: 4 to 20). Higher scores indicate more negative/positive 
insulin appraisals. Hypothetical ‘willingness’ to initiate insulin was assessed using a 
single item asking individuals to indicate how willing they would be to take insulin if 
recommended by their doctor (responses: ‘very’, ‘moderately’, ‘not very’, ‘not at 
all’) [25]. 
2.5. Statistical analysis 
Analysis was undertaken using SPSS version 22 (Chicago, USA). For the 
psychological measures, minimal (~10%) missing datapoints were replaced with the 
series mean. Where scale data were >10% missing, participant data were excluded 
from specific analyses as required. No independent variables of interest differed 
significantly by study randomisation at baseline (p>0.05). Students t-tests, Chi-
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square, and Mann Whitney tests were used to investigate the relationships between 
insulin uptake (yes/no) at 12-months and baseline demographic, clinical, and 
psychological data. To identify predictors of insulin uptake, a hierarchical logistic 
regression was conducted including variables found to be significant in univariate 
analyses, controlling for randomisation. To check for cluster effects, this analysis 
was repeated using mixed-effects logistic regression in Stata 13 (StataCorp, TX, 
USA), with Practice entered as the random effect. The random effect was non-
significant (data not reported).   
Repeated measures t-tests were conducted to explore change in ITAS subscales 
from baseline to follow-up, overall. Two-way factorial Analysis of Variance 
(ANOVA) was conducted to investigate the main effects of insulin uptake (yes/no) 
and randomisation (control/intervention), and any interaction effect, on ITAS change 
scores. Results are reported as mean ± standard deviation, median (IQR), or % (n). 
All statistical tests were two-sided and differences were accepted as significant at 
p<0.05 
3. Results 
Demographic, clinical and psychological characteristics of the sample 
(N=266), and by insulin uptake at 12 months, are shown in Table 1. Participants were 
men (61%, n=163), 62±10 years old and diagnosed with T2DM for 8.5 (5,13) years. 
Overall, 14% (n=37) reported moderate-to-severe depressive symptoms and 15% 
(n=39) reported severe diabetes-specific distress.  
3.1. Factors associated with insulin uptake 
Overall, 126 (47%) participants were using insulin therapy at 12-month follow-
up. Those using insulin (compared to those not using insulin) were more likely to 
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have been randomised to the intervention arm implementing the Stepping Up model 
of care (81% vs 35%, 2 (1)=57.1, p<0.001), reside in significantly less advantaged 
areas (U=7489.0, p=0.032), and have higher baseline HbA1c (U=10757.5, p=0.002). 
Insulin use at 12 months did not differ by other demographic or clinical 
characteristics. Baseline depressive symptomology and diabetes-specific distress did 
not differ between those who were and were not using insulin at 12 months (Table 
1).  
Among those using insulin at 12 months (compared to those not using insulin), 
baseline ITAS Negative scores were significantly lower (t(258)=2.5, p=0.015), and 
ITAS Positive scores were significantly higher (t(259)=-2.8 p=0.006) (Table 1). 
Similarly, insulin uptake also differed significantly by baseline hypothetical 
willingness (2(3)14.9, p=0.002). Of those using insulin at 12 months, the majority 
(59%, n=72) reported at baseline being ‘moderately’ or ‘very willing’ to begin 
insulin, in contrast with 39% (n=54) of those not using insulin.
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3.2. Predicting insulin uptake 
In the hierarchical logistic regression socioeconomic status (step 1) did not 
significantly improve the base model, which accounted only for study arm 
(randomisation). At step 2, HbA1c added significantly to the model (β=0.32, 
SE=0.12, p=0.008). At step 3, both ITAS Negative (β=-0.04, SE=0.02, p=0.016) and 
Positive (β=0.19, SE=0.08, p=0.014) scores added significantly to the prediction of 
insulin use. However, at step 4, the independent contribution of ITAS scores was 
negated by intention (willingness) to begin insulin therapy. After accounting for 
randomisation status, the final model (2(8)=92.1, p<0.001) included independent 
contributions from socioeconomic status (IRSAD), HbA1c and hypothetical 
willingness (Table 2). Specifically, participants using insulin at 12 months were 9.5 
times more likely to have been allocated to the intervention and, 5.6 times more 
likely to report being ‘very willing’ to begin insulin, compared to those using tablets 
alone. Every unit increase in HbA1c was associated with 1.4 times increase in the 
likelihood of 12-month insulin use. Confidences intervals suggest no meaningful 
association between IRSAD decile and insulin uptake, as such the independent 
contribution of socioeconomic status is not interpreted further. 
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Table 2 
Final model of hierarchical logistic regression predicting insulin uptake at 12 
months 
 
b SE Exp(B) 
Lower, upper  
95% CI 
p value 
Intercept -5.9 1.9 0.003  0.002 
Control variable: Randomisation 
(ref=control) 
2.2 0.33 9.5     5.0, 18.1 <0.001 
Step 1: Demographics      
IRSAD decile -0.1 0.1 0.9 0.8, 1.0 0.048 
Step 2: Clinical characteristics      
    HbA1c 0.4 0.1 1.4 1.1, 1.8 0.004 
Step 3: Insulin appraisals      
    ITAS Negative score -0.0 0.0 1.0 0.9, 1.0 0.289 
    ITAS Positive score 0.1 0.1 1.2 1.0, 1.4 0.072 
Step 4: Intention to begin insulin       
    Willingness (ref=not at all)      
Not very willing 0.6 0.4 1.8 0.7, 4.2 0.189 
Moderately willing 0.6  0.5 1.9 0.7, 4.6 0.176 
Very willing 1.7  0.5 5.6 1.9, 16.3 0.001 
      
Log likelihood 
Model (df) Chi2, p value  
Pseudo R2: Cox and Snell; Nagelkerke 
-265.5 
(8) 92.1, p <0.001 
0.2998; 0.400 
CI= Confidence Interval, SE= Standard Error, ITAS= Insulin Treatment Appraisal 
Scale [14], IRSAD= Index of Relative Socio-economic Advantage and Disadvantage 
[20]. 
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3.3. Change in insulin appraisals 
Overall, there was a significant reduction in ITAS Negative scores from 
baseline to 12-month follow-up (-4.3±10.1; t(214)=6.3, p<0.001). Two-way 
ANOVA revealed significant main effects of both randomisation (F(1,212)=7.7, 
p=0.006) and insulin uptake (F(2,212)=16.6, p<0.001) on change in ITAS Negative 
scores, where intervention participants reported greater mean reductions in scores 
compared to control arm participants (-7.3±10.5 vs -0.4±1.0, respectively), and 
initiating insulin resulted in a greater reduction in scores compared to those who 
were using tablets alone at 12 months (-8.3±9.6 vs -0.4±0.9, respectively). No 
significant interaction between randomisation and insulin uptake was observed, 
indicating that the reduction in ITAS Negative scores associated with insulin uptake 
was the same regardless of study arm allocation and vice versa.  
Overall, ITAS Positive scores remained stable over time, with no significant 
difference from baseline to 12-month follow-up (0.1±2.69; t(215)=-0.4, p=0.724). 
Further, change in ITAS Positive scores, from baseline to 12-month follow-up, did 
not differ by randomisation (F(1,214)=0.8,p=0.363) or insulin uptake 
(F(2,214)=1.5,p=0.219).  
4. Discussion 
After accounting for the intervention (allocation to the Stepping Up model of 
care), our findings demonstrate that adults with T2DM, for whom insulin is clinically 
indicated, who have higher HbA1c and report being ‘very willing’ to begin insulin 
are more likely to agree to insulin initiation.  Further, insulin uptake is associated 
with a significant reduction in negative insulin appraisals, regardless of the model of 
care 
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Consistent with prior research [12], higher baseline HbA1c was associated with 
greater likelihood of insulin uptake. Possible explanations for this relationship 
include people with T2DM perceiving their higher HbA1c, or hyperglycaemic 
symptoms, as indicating a greater need for insulin therapy [26]. Similarly, when a 
higher HbA1c is recorded, clinicians may be more convinced by the need for insulin, 
and the inefficacy of OHAs alone. This is consistent with evidence that clinicians 
prefer to delay insulin initiation until perceived to be absolutely necessary [27].  
Consistent with previous research [16,17], both depressive symptoms and 
distress were unrelated to insulin uptake. As expected, baseline insulin appraisals 
were associated with 12-month insulin use. However, their predictive effect was 
negated in the regression model after the inclusion of hypothetical ‘willingness’. This 
suggests that asking adults with T2DM whether they are willing to consider insulin 
therapy is a useful first step in gauging readiness for and receptiveness to insulin. 
However, one in four are ‘not at all willing’, and understanding this position requires 
healthcare professionals to enquire about individuals’ attitudes to, understanding or 
expectations of insulin therapy. Our previous work has shown that attitudes towards 
insulin predict willingness [10]. Further, these findings should not be interpreted as 
meaning that those who report being ‘not at all willing’ will inevitably refuse insulin. 
Indeed, 41% (n=50) of those using insulin at 12 months had indicated being ‘not 
very’ or ‘not at all’ willing to begin insulin therapy at baseline. Of this group, the 
majority (data not shown above: 82%, n=41) were allocated to the intervention, 
highlighting the effectiveness of the Stepping Up model of care as an intervention to 
overcome psychological insulin resistance. 
In the current study, those who initiated insulin reported significant reductions 
in negative insulin appraisals at 12 months compared with baseline, consistent with 
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previous longitudinal research [12,13], but no change in positive insulin appraisals. 
The ITAS Positive items focus on perceptions of the effectiveness of insulin for 
maintaining optimal blood glucose concentrations, improving energy, improving 
health in general, and preventing future complications. Thus, the relative lack of 
improvement in positive appraisals may relate to the ‘invisibility’ of improvements 
in health or prevention of complications in the short-term. Indeed, target HbA1c in 
the intervention arm was achieved by just 36% of participants [19]. Alternatively, the 
lack of change in positive appraisals may be due to questionnaire ceiling effects, 
caused by high endorsement of positive insulin appraisals at baseline.  
Given the enhanced role of the PN in the Stepping Up model of care (i.e. 
insulin education, initiation and adjustment) compared with usual care, an interaction 
effect was expected between insulin uptake and randomisation on change in insulin 
appraisals, whereby those who initiated insulin and participated in the intervention 
would report the greatest change. While the Stepping Up model of care was effective 
at increasing insulin uptake [19], it offered no relative advantage over actual insulin 
uptake for reducing negative insulin appraisals. This may be because, while insulin 
was more likely to be initiated in the intervention arm, in the instances where insulin 
was initiated in the control arm, there was a similar level of clinician contact and 
counselling. Further, the main focus of the Stepping Up training was to reduce the 
primary care team’s clinical inertia. Thus, ongoing concerns about insulin post-
initiation may not have been evaluated or tackled differently in the two arms. This 
suggests there is opportunity for further refinement of the Stepping Up model of care 
to engage more specifically, and perhaps directly with the person with T2DM, to 
improve insulin appraisals over time. 
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4.1. Strengths and limitations 
This is the first study to undertake comprehensive investigation of the role of 
demographic, clinical and psychological factors associated with insulin uptake in a 
large, prospective primary care sample of adults with T2DM among whom insulin is 
clinically indicated. Further, this study includes validated clinical data (e.g. HbA1c, 
co-morbid conditions and number of prescribed medications) and psychometrically 
robust psychological measures (e.g. PHQ-9, PAID). To our knowledge, this is the 
first study to assess the predictive validity of the single-item measure of hypothetical 
‘willingness’ to begin insulin.   
As this study was conducted in a trial setting with clinical eligibility 
parameters and self-selection bias, the sample may not be representative of the wider 
Australian T2DM population. Specifically, we observed lower rates of diabetes-
specific distress and depressive symptoms than found elsewhere [28], and included 
only those who were English speaking and self-selected to participate in a trial in 
which they would, potentially, undertake treatment intensification.  
We investigated baseline predictors of insulin use at 12 months. However, it is 
possible that participants initiated and stopped using insulin between these time-
points. Further, we were unable to assess willingness or attitudes immediately prior 
to insulin initiation. Thus, change in attitudes may have occurred before insulin use 
(influencing uptake) or after initiation (with experience influencing attitudes.)    
5. Conclusion 
This study demonstrates that willingness to begin insulin therapy is an 
independent predictor of actual insulin uptake, in addition to HbA1c, independent of 
the model of primary care. This highlights the need within primary care to assess 
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receptiveness to insulin, and understand reasons for lack of willingness, to encourage 
appropriate insulin uptake among people with T2DM for whom it is clinically 
indicated.  
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Novelty Statement  
 This is the first study to explicitly explore appraisals of insulin therapy 
among adults with Type 2 diabetes currently using insulin using validated 
measures. 
 Despite insulin use, some people with Type 2 diabetes report negative 
appraisals of insulin therapy including physical and psychological barriers.  
 Diabetes duration, years using insulin, injections and blood glucose checks 
per day do not differ between those with more and those with less negative 
appraisals of insulin therapy.  
 Participants reporting more negative insulin appraisals also report poorer 
general and diabetes-specific emotional well-being, reduced diabetes-specific 
self-efficacy and satisfaction with blood glucose levels compared with those 
with more positive appraisals.  
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Abstract 
Aims 
To identify insulin therapy appraisals among adults with Type 2 diabetes using 
insulin and how negative appraisals relate to clinical, self-care and psychosocial 
outcomes.   
Methods 
Diabetes MILES – Australia 2011 was a national survey of adults with 
diabetes, focused on behavioural and psychosocial issues. Subgroup analyses were 
conducted on the responses of 273 adults with Type 2 diabetes using insulin (46% 
women; mean ± SD age: 59 ± 9 years; diabetes duration: 12 ± 7 years; years using 
insulin: 4 ± 4). They completed validated measures of insulin therapy appraisals 
(ITAS), depression (PHQ-9), anxiety (GAD-7), diabetes distress (PAID) and 
diabetes-specific self-efficacy (DES-SF). 
Results 
Insulin was perceived to be very important, and its benefits (e.g. improves 
health) were endorsed by most (82%). Fifty-one percent believed that taking insulin 
means their diabetes has become worse; 51% that insulin causes weight gain; 39% 
that they have ‘failed to manage’ their diabetes. Those with the greatest and least 
‘ITAS Negative’ scores did not differ by diabetes duration or years using insulin, or 
by average number of insulin injections or blood glucose checks per day. Those with 
more negative insulin appraisals were significantly younger (Mean Diff. = 5 years, P 
<0.001), less satisfied with recent blood glucose levels (P <0.001, d = 0.63), had 
reduced diabetes-specific self-efficacy (P <0.001, d = 0.7), and were more likely to 
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report depressive symptoms, anxiety, or diabetes distress (all P  <0.001, d range = 
0.65–1.1). 
Conclusions 
Negative insulin therapy appraisals are common among adults with Type 2 
diabetes using insulin, and are associated with lower general and diabetes-specific 
emotional well-being, reduced diabetes-specific self-efficacy and satisfaction with 
blood glucose. 
 
 
This article includes data presented at a scientific meeting: Holmes-Truscott E, 
Skinner TC, Pouwer F, Speight J. Psychological Insulin Resistance In Australians 
With Type 2 Diabetes Already Using Insulin: Results From Diabetes MILES – 
Australia. Australian Diabetes Society – Australian Diabetes Educators Association 
(ADS-ADEA) 2012, Gold Coast, Australia, 28-31 August 2012. 
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Introduction 
Beta-cell failure generally occurs within 10 years for individuals with Type 2 
diabetes mellitus [1]. Timely intensification of insulin therapy, and achieving and 
maintaining optimalHbA1c, significantly reduce the risk of developing or worsening 
of microvascular complications [2]. ‘Psychological insulin resistance’ describes the 
negative appraisal of insulin therapy, which may act as barrier to insulin initiation or 
use [3–5]. 
People with Type 2 diabetes using insulin report less negative insulin therapy 
appraisals compared with those not yet using insulin [6–9], leading some to suggest 
that the experience of insulin mitigates previously perceived barriers to insulin 
therapy [10]. However, research into insulin omission, or suboptimal insulin taking, 
suggest that psychological barriers continue to be of relevance for people with Type 
2diabetes using insulin [11,12]. For example, 20% of Americans with Type 2 
diabetes skip their insulin injections ‘often’ or ‘sometimes’, and 46% change their 
daily activities to avoid additional injections [13]. Insulin omission is significantly 
associated with treatment dissatisfaction, pain and embarrassment, being younger 
and requiring a greater number of injections per day [12]. An international study 
reported common reasons for insulin omission, including stress or emotional 
problems, embarrassment of injecting in public and the challenge of taking insulin at 
regular times [11]. The above studies suggest that, for some, negative appraisals and 
barriers to insulin use persist beyond insulin initiation.  
The Insulin Treatment Appraisal Scale (ITAS) [9] measures insulin therapy 
perceptions among those with Type 2 diabetes. For those already using insulin, it 
measures the lived experience of insulin therapy. Previous research with this measure 
has primarily focused on the insulin appraisals of those not yet using insulin [14,15]; 
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and on the differences in scores between those using insulin and those not using 
insulin, with the former generally displaying significantly lower mean ITAS scores, 
indicating less negative appraisals [6–9,16]. However, the variance in ITAS scores 
commonly reported amongst adults with Type 2 diabetes using insulin suggests that a 
proportion have negative evaluations of insulin therapy equivalent to those of not 
using insulin.  
Few studies have investigated the associations between insulin therapy 
appraisals and socio-demographic, clinical and psychosocial characteristics in adults 
with insulin-treated Type 2 diabetes. To our knowledge, only one study reports on 
the relationship between mode and duration of insulin injections and negative insulin 
appraisals using a validated measure [6], and although the association between 
emotional well-being and perceptions of insulin therapy has been more widely 
explored among those not using insulin, or where treatment is unspecified 
[9,14,15,17], no study has reported on these associations specifically among adults 
with Type 2diabetes using insulin.  
The aim of the current study is therefore to determine the extent to which 
adults with insulin-treated Type 2 diabetes experience positive and/or negative 
aspects of insulin therapy and to investigate whether those who report above average 
ITAS scores differ from those with lower scores in terms of other psychosocial 
factors, self-reported clinical factors and self-care behaviours.  
Methods 
The Diabetes MILES Study is an international collaborative exploring the 
psychosocial aspects of living with diabetes [18,19]. This study used a selection of 
data from the Diabetes MILES – Australia 2011 survey, a national cross-sectional 
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survey of adults with Type 1 diabetes or Type 2 diabetes. A detailed description of 
the methods and overall sample characteristics have been published elsewhere [18]. 
Diabetes MILES – Australia received ethics approval from the Deakin University 
Human Research Ethics committee (reference number: 2011-046).  
Participants  
Survey booklets were posted to a random sample of 15 000 National Diabetes 
Services Scheme registrants and the survey was also made available nationally 
online. In total, 3338 eligible respondents took part, including 1962 adults with Type 
2 diabetes, of whom 724 (37%) were using insulin (49%, n = 953 female; age 59±9 
years; diabetes duration13±8 years). The survey included core measures, asked of all 
participants, and non-core questions asked in survey subsets to reduce respondent 
burden. This analysis includes participants who reported managing their Type 2 
diabetes with insulin injections and completed questionnaires of interest (n = 279) 
(see below).  
Measures  
Self-reported demographic and clinical characteristics were collected from all 
participants: age, gender, relationship status, employment status, education level, 
BMI, diabetes duration, years using insulin and the presence of diabetes-related 
complications (yes/no).  
Insulin therapy appraisals were measured with the 20-itemITAS [9]. The ITAS 
includes 16 negative and 4 positive statements against which respondents indicate 
their level of agreement (1 = strongly disagree to 5 = strongly agree). Scores are 
summed to provide an ITAS Negative score (16–80), an ITAS Positive score (5–20) 
and a total ITAS score (20–100). Our psychometric validation of the ITAS indicated 
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that the negative subscale score is the most robust [16] and, hence, the ‘ITAS 
Negative’ score is used here instead of the ITAS total score.  
Depressed mood and anxiety were assessed using the nine-item Patient Health 
Questionnaire (PHQ–9) [20] and seven-item Generalized Anxiety Disorder (GAD–7) 
questionnaire [21]. For each measure, respondents rate symptom frequency over the 
past 2 weeks on a 4-point scale (0 = not at all to 3 = nearly every day). Item scores 
are summed to form a total score (0–27 for PHQ–9; 0–21 for GAD–7). For both, 
scores of ≥ 10 indicate moderate-to-severe symptoms.  
Diabetes distress was measured using the 20-item Problem Areas in Diabetes 
Scale (PAID) [22]. Respondents rate the extent to which each issue is a problem for 
them on a 5-pointscale (0 = not a problem to 4 = serious problem). Item scores are 
summed and standardized to a score out of 100, where scores ≥ 40 indicate severe 
diabetes distress.  
Diabetes-specific self-efficacy was measured using the eight-item Diabetes 
Empowerment Scale – short form (DES–SF) [23]. Respondents indicate the extent to 
which each item is true for them on a 5-point scale (1 = strongly disagree to 5 = 
strongly agree). A composite score (range 1–5) is calculated by summing item scores 
and dividing by eight.  
Self-care behaviours and beliefs were assessed using single items from the 
Diabetes Self-Care Inventory-Revised (DSCI–R) [24]. Participants were asked to 
indicate the number of injections they require per day, whether they take the required 
number of injections (1 = never to 5 = always), their perceived importance (1 = not at 
all to 4 = very) and the burden associated with these injections (1 = not at all to4 = a 
great burden). Because there was little variance in responses, these three categorical 
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variables were dummy coded to represent optimal versus suboptimal responses, with 
the former equating to ‘always’ taking insulin as recommended, considering it ‘very’ 
important, or ‘not at all’ a burden. Participants also recorded the average number of 
blood glucose checks performed per day, and satisfaction with their blood glucose 
levels (0 = very dissatisfied to 6 = very satisfied), over the past 2 weeks. 
Statistical analysis 
Participants with more than one missing value on the ITAS (n = 6) were 
excluded. According to scale guidance, missing data points were replaced with 
participants’ summed mean scores (for the PAID, if two or more items were missing, 
and for the ITAS, PHQ–9 and GAD–7, when only one item was missing). Missing 
data were not replaced for other variables. Valid percentage is used throughout. 
Statistical analysis was undertaken using SPSS version 21(Chicago, IL, USA). 
Univariate differences between groups were assessed by Student’s t–tests (for 
continuous variables) and chi-squared tests (for categorical variables). Participants 
who reported negative ITAS scores within the first or fourth quartile were compared 
on demographic, clinical, self-care and psychosocial variables. Results are reported 
as mean ± sd or % (n). All statistical tests were two-sided and differences were 
accepted as significant at P < 0.05. 
Results 
A sample of 273 adults with Type 2 diabetes using insulin injections completed 
the ITAS. Table 1 displays demographic, clinical and psychological characteristics of 
the sample.
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The mean ITAS Positive score was high overall (14.9 ± 2.6), with three of the 
four positive items being endorsed (‘agree’ or ‘strongly agree’) by ≥ 75% of the 
sample. The mean ITAS Negative score was 41.4 ± 9.7. The mean number of 
negatively worded ITAS items endorsed by participants was 4 ± 3, with 27 (9.9%) 
participants endorsing no barriers and one individual endorsing all 16. The most 
commonly endorsed negative aspects of insulin use concerned weight gain and 
condition progression (n = 140, 51.3% for both).  
To characterize how participants reporting most and least negative insulin 
appraisals differed, the upper quartile (UQ; ≥ 48) and lower quartile (LQ; ≤ 36) of 
ITAS Negative were examined. The mean ITAS Positive score did not significantly 
differ between groups.  
Table 2 displays the total sample and percentage of participants in the UQ and 
LQ who agreed or strongly agreed with each ITAS item, ranked in descending order 
according to the UQ group. Table 2 also displays the percentage difference in item 
endorsement between groups, i.e. item discrimination. Each of the 16 negative items 
was more highly endorsed by the UQ group and each of the four positive items was 
more highly endorsed by the LQ group. Although the degree of endorsement is 
different between groups, similar trends in item rankings were apparent. For 
example, five of the top six most endorsed ITAS Negative items for each group were 
the same. ‘Insulin means my diabetes has become much worse’ was the most 
commonly endorsed ITAS Negative item among those in the UQ, while ‘Insulin 
causes weight gain’ was the most commonly endorsed ITAS Negative item among 
LQ respondents. The item that discriminates best between UQ and LQ is ‘insulin 
makes life less flexible’, with a 61% difference in endorsement between groups. 
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As seen in Table 1, UQ and LQ groups did not differ substantially on any 
demographic variables except age (t (148) = 3.5, P = 0.001, d = 0.57) and 
employment (2(1) = 6.2, P = 0.013, d = 0.46), where participants reporting more 
negative insulin appraisals were younger and more likely to be in paid employment.  
Regardless of ITAS scores, participants injected insulin approximately twice 
per day and the majority felt that it was ‘very important’ to take all of their 
recommended daily injections. However, participants reporting greatest negative 
insulin appraisals (UQ) were significantly more likely to report taking their required 
daily insulin injections (2 (1) = 5.17,P = 0.023, d = 0.39) and that taking these 
injections were at least somewhat of a burden (2 (1) = 46.99, P < 0.001, d = 1.4) 
compared with the LQ group. Although there was no significant difference in 
duration of insulin use (years) between groups, more participants in the UQ group 
had been using insulin for ≤ 1 year compared with the LQ group (39.6% vs.16.4%; 
2(1) = 7.40, P = 0.007, d = 0.54). Participants reported a similar frequency of self-
monitoring of blood glucose (SMBG) per day over the past 2 weeks, but the UQ 
group were significantly less satisfied with their blood glucose levels than the LQ 
group (t(148) = 3.9, P < 0.001, d = 0.63). 
Participants reporting greatest ITAS Negative appraisals displayed significantly 
lower diabetes-specific self-efficacy than those in the LQ (t(144) = 4.2, P < 0.001, d 
= 0.73). The UQ reported significantly lower mean item scores, compared with those 
in the LQ (P = 0.012 to < 0.001;d = 0.42–0.91), except for item 1: ‘I know what parts 
of taking care of my diabetes I am dissatisfied with’ (Mean Diff. = - 0.116, t (144.41) 
= - 0.597, P = 0.551), and item8: ‘I know enough about myself as a person to make 
diabetes care choices that are right for me’ (Mean Diff. = 0.2, t(148) = 1.9, P = 
0.056). 
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Participants reporting more negative insulin appraisals (UQ) reported 
significantly more depressive symptoms (t(144) = - 4.5, P < 0.001, d = 0.74) and 
anxiety symptoms (t(143) = - 4.0, P < 0.001, d = 0.66) than those with the least 
negative appraisals (LQ). Half (n = 40, 54.4%) of UQ participants reported 
moderate-to-severe depressive and/or anxiety symptoms compared with 28.6% (n = 
22) in the LQ group. Participants in the UQ also reported significantly greater 
diabetes distress than those in the LQ(t(112.5) = - 6.4, P < 0.001, d = 1.07). Of those 
participants in the UQ, 42.4% (n = 28) reported severe diabetes distress compared 
with 8.9% (n = 7) of those in the LQ. 
Discussion 
Our findings demonstrate that negative appraisals of insulin therapy are evident 
among adults with insulin-treated Type 2diabetes. Furthermore, those who report 
more negative experiences of insulin therapy are also more likely to report poorer 
general emotional well-being, greater diabetes dis-tress, lower diabetes-specific self-
efficacy and less satisfaction with blood glucose levels. Consistent with other studies 
[6,7,9], our findings suggest that negative insulin therapy appraisals may persist 
beyond insulin initiation, and may need to be evaluated as part of ongoing holistic 
diabetes care, particularly where concerns exist regarding other diabetes outcomes. 
Although, on average, people with Type 2 diabetes currently using insulin hold 
significantly less negative insulin appraisals than those not using insulin [6,7,9,16], 
only 10% of the current sample did not experience any barrier regarding insulin 
therapy. The most highly endorsed negative appraisals are similar between groups, 
with two exceptions. ‘Insulin causes weight gain’ (item 9) was the most endorsed 
negative aspect of insulin use among the LQ group. For the UQ group, four other 
aspects to insulin use were perceived to be more problematic than weight gain. 
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‘Insulin makes lifeless flexible’ (item 5), ranked second for the UQ group but eighth 
for the LQ group, making it the item that discriminated most strongly between the 
two groups. Given that UQ participants were younger and more likely to be in paid 
employment, it is unsurprising that insulin is perceived to be a greater inconvenience 
to these participants.  
Previous studies have reported inconsistent results regarding the association of 
demographic characteristics and insulin appraisals among people with Type 2 
diabetes. Where a significant association has been reported, those with greater 
negative appraisals were consistently more likely to be women [25–28] and less 
educated [6,29]. However, participants with greatest and least negative appraisals in 
the current study did not differ significantly by gender or education. Nor did the two 
groups differ according to clinical characteristics: BMI, diagnosis of diabetes-related 
complications, diabetes duration.  
With regard to diabetes self-care, no significant between-group differences 
were apparent in the average number of years using insulin, number of insulin 
injections per day or frequency of SMBG per day over the past 2 weeks. When years 
using insulin therapy was categorized as ≤ 1 year or >1 year there was a significant 
difference between groups, with a greater number of UQ participants having started 
insulin therapy within the past year. This contrasts with the findings of a Chinese 
outpatient study [6]. Further, the majority of participants (regardless of ITAS 
quartile) had been using insulin for more than 1 year. This supports the idea that, for 
some, insulin therapy appraisals may not change radically after initiation of insulin 
therapy or may even increase with greater experience of using insulin.  
Psychological barriers to insulin therapy have been reported as associated with, 
or a reason for, insulin omission [11,12], while optimal medication-taking 
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behaviours are reportedly associated with belief in the benefit of the medication [30]. 
By contrast, participants reporting the greatest negative appraisals of insulin therapy 
in the current study were actually more likely to report ‘always’ taking their 
injections as recommended, compared with those with less negative ITAS scores; 
and the vast majority of the sample reported that taking their insulin as recommend 
was very important and endorsed the benefits of insulin use. This suggests that 
negative insulin appraisals may be, at least in part, independent of beliefs in the 
benefits of insulin use [16]. Further, negative insulin appraisals alone do not appear 
to influence actual insulin-taking behaviour and investigation into the behavioural 
consequences of negative insulin appraisals is warranted. 
Participants reporting the greatest negative appraisals of insulin (UQ) were 
significantly less satisfied with their blood glucose levels over the past 2 weeks. 
Furthermore, UQ participants reported lower diabetes-specific self-efficacy than 
those in the LQ but reported a similarly high belief that they knew which parts of 
their diabetes they were dissatisfied with (DES–SF item 1). It may be that 
participants with the greatest negative appraisals are less satisfied as a result of not 
seeing expected improvements in blood glucose levels following insulin initiation, 
and feel unrewarded for their efforts in undertaking a more demanding treatment 
regimen. The assessment of insulin appraisals may provide an indicator of whether 
the insulin type or dosage needs to be reconsidered to improve not only blood 
glucose levels but also treatment satisfaction. However, it is beyond the scope of the 
current study to assess the longitudinal relationship between insulin therapy 
appraisals and satisfaction with diabetes management, and we do not have 
HbA1cdata with which to further examine this relationship.  
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Participants with greatest negative insulin appraisals (UQ) were also more 
likely to report depressive symptoms, anxiety symptoms and diabetes distress than 
participants in the LQ. One possible explanation for this is that those who generally 
have a more negative demeanour or mood may be more susceptible to negative 
beliefs, whether it be about insulin, blood glucose levels or life in general. Given the 
cross sectional nature of this study we are unable to make a determination and it is 
unclear whether poor emotional well-being (general or diabetes-related) preceded 
insulin use or may be more directly connected to the negative experience of insulin 
use. However, one third of participants with the greatest negative appraisals (UQ) did 
not report elevated levels of depressive symptoms, anxiety symptoms or diabetes 
distress. It is more likely that a combination of the above (i.e. the presence of 
emotional distress and dissatisfaction with blood glucose outcomes) is intertwined 
with this group’s lack of physical adjustment (to the side effects and inconvenience) 
and psychological adjustment (‘I’m sicker now’) to insulin use. Assessment of 
insulin appraisals and intervention may improve treatment satisfaction and indirectly 
improve diabetes-specific and general emotional well-being. Unlike depression, 
which may require referral to a mental health specialist, insulin therapy appraisals 
may be suitably assessed and addressed within the diabetes care setting by health 
care professionals. 
The Diabetes MILES – Australia study has several limitations, which are 
detailed elsewhere [18]. Of particular relevance to the current analysis is the lack of 
HbA1cdata, which would have been useful for investigating the impact of negative 
appraisals of insulin on an indicator of complication risk (i.e. diabetes outcome). 
Furthermore, the cross sectional nature of the study means that causality cannot be 
determined. In addition, the self-care data collected (e.g. insulin-taking behaviours) 
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were all uncorroborated self-report using single items from a new self-care measure 
(in development). Finally, to undertake a comparative analysis of those with greatest 
and least negative insulin appraisals, continuous ITAS Negative scores were 
categorized and only the extreme upper and lower quartiles were included, with half 
the sample(n = 123) discarded from analysis. This does not, however, appear to have 
diminished the power of our study nor artificially inflated relationships. 
Supplementary analysis (data not reported), using the whole sample, confirmed 
significant associations between ITAS Negative scores (as a continuous variable) and 
the demographic, clinical and psychosocial variables shown to be significant in Table 
1. 
Conclusion 
Negative appraisals of insulin therapy are evident among adults with Type 2 
diabetes currently using insulin. Previous research has focused on negative appraisals 
among people with non-insulin-treated Type 2 diabetes with an (unwritten) 
implication that insulin initiation represents overcoming those barriers. Our data 
suggest that this view is flawed. More negative appraisals of insulin are associated 
with poorer emotional well-being (general and diabetes-specific) and lower diabetes 
self-efficacy. Although greater negative appraisals do not appear to be related to sub-
optimal insulin-taking behaviours, they are associated with reduced satisfaction with 
blood glucose levels, and this marker of disappointment with the efforts required by 
a more intensive diabetes treatment regimen needs to be further explored. 
Prospective studies are needed to examine the associations between negative 
appraisals of insulin before and after insulin initiation and the extent to which these 
may affect insulin-taking behaviours, HbA1cand emotional distress.  
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Abstract  
Background 
As type 2 diabetes (T2DM) is a progressive chronic condition, regular clinical 
review and treatment intensification are critical for prevention of long-term 
complications. Our aim was to explore the personal impact of insulin therapy, both 
positive and negative consequences, and attitudes towards future insulin 
intensification. 
Methods 
Twenty face-to-face interviews were conducted, and transcripts were analysed 
using thematic inductive analysis. Eligible participants were adults with T2DM, 
using insulin injections for <4 years. Participants were mostly men (n=13, 65%), 
(median (range)) aged 65 (43-76) years, living with T2DM for 11.5 (2-27) years. 
Results 
Five themes emerged regarding the consequences (positive and negative) of 
insulin therapy, including: physical impact, personal control, emotional well-being, 
freedom / flexibility, (concerns about) others’ reactions. Increased inconvenience and 
the perceived seriousness of using fast-acting insulin were both reported as barriers 
to future insulin intensification, despite most participants being receptive to the idea 
of administering additional injections. 
Conclusions 
Positive and negative experiences of insulin therapy were reported by adults 
with T2DM and most were receptive to insulin intensification despite reported 
barriers. These findings may inform clinical interactions with people with T2DM and 
interventions to promote receptiveness to insulin initiation and intensification.  
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1. Introduction 
Type 2 diabetes mellitus (T2DM) is a progressive metabolic condition, which 
requires ongoing clinical review and responsive treatment intensification to avoid 
chronic hyperglycaemia, and the associated development of diabetes-related 
complications (Holman, Paul, Bethel, Matthews, & Neil, 2008; UKPDS, 1998). 
Early initiation and ongoing intensification of insulin therapy is recommended across 
international guidelines (Inzucchi et al., 2012; Nathan et al., 2009). However, among 
adults with T2DM, negative appraisals of insulin treatment, known as ‘psychological 
insulin resistance’, may lead to the delay of insulin initiation (Polonsky & Jackson, 
2004). In addition, research exploring predictors of insulin omission suggests that 
psychological barriers may continue to be prevalent among people with T2DM post-
insulin initiation (Peyrot, Rubin, Kruger, & Travis, 2010; Peyrot, Barnett, 
Meneghini, & Schumm-Draeger, 2012). However, little research has explored the 
lived experience of insulin use among adults with T2DM. 
Most commonly, investigation of psychological insulin resistance post insulin 
initiation has been in quantitative, questionnaire-based research exploring differences 
in insulin appraisals amongst adults with non-insulin-treated T2DM versus those 
using insulin (Chen et al., 2011; Hermanns, Mahr, Kulzer, Skovlund, & Haak, 2010; 
Snoek, Skovlund, & Pouwer, 2007). Those using insulin generally report fewer 
negative attitudes to insulin overall compared with those who are not yet using 
insulin therapy (Chen et al., 2011; Hermanns et al., 2010; Holmes-Truscott, Pouwer, 
& Speight, 2014; Snoek et al., 2007), but they commonly endorse negative 
experiences in the form of side effects (e.g. hypoglycaemia and weight gain) 
(Holmes-Truscott et al., 2014; Snoek et al., 2007). For some, barriers to insulin use 
may persist beyond insulin initiation and are associated with greater impairment of 
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emotional wellbeing (Holmes-Truscott, Skinner, Pouwer, & Speight, 2015). 
However, quantitative assessments of insulin appraisals post-initiation have been 
conducted using questionnaires designed for those not using insulin, which may be 
inappropriate in content or emphasis, and may not fully capture the experience of 
those already using insulin (Polinski et al., 2012). 
Qualitative research has explored attitudes towards insulin therapy among 
those not yet using insulin (Ho & James, 2006; Morris, Povey, & Street, 2005), as 
well as experiences, and retrospectively reported facilitators, of initiating insulin 
among those already using insulin (Abu Hassan et al., 2013; Jenkins, Hallowell, 
Farmer, Holman, & Lawton, 2010). However, there is a dearth of research exploring 
the experience of using insulin post-initiation. In one small-scale interview study (n 
= 8), participants reported that their experience of insulin therapy was less negative 
than anticipated, and resulted in increased self-reported diabetes knowledge and 
improved health (Phillips, 2007a). However, participants also reported increased 
anxiety about the possibility of experiencing hypoglycaemia and experiencing 
discrimination (within the workplace, and in regard to driving licensing and travel 
insurance) (Phillips, 2007a). Additional qualitative research is needed to corroborate 
this single study. 
Insulin therapy may also need to be intensified over time, in response to 
diabetes progression, through increased dose, the addition of more injections per day 
and/or changes in insulin types (e.g. a single or twice-daily basal or mixed injection 
to a basal bolus regimen). However, international research suggests that there is a 
gap between the number of people with T2DM who would benefit from insulin 
intensification, and what actually occurs in clinical practice (Grant, Buse, & Meigs, 
2005; Guler, Vaz, & Ligthelm, 2008). A few studies have offered limited insights 
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into attitudes to future insulin intensification: it has been reported that one third of 
participants with T2DM using insulin are troubled by (Zambanini, Newson, Maisey, 
& Feher, 1999), or not ‘motivated’ to consider (Martinez et al., 2007), the possibility 
of additional daily insulin injections, but reasons for this have not been identified. To 
our knowledge, only one qualitative study has explored attitudes towards insulin 
intensification (Jenkins, Hallowell, Farmer, Holman, & Lawton, 2011). Participants 
who had intensified their insulin therapy within a three-year insulin trial reported 
being generally receptive to insulin intensification. However, they reported concerns 
relating to the need to juggle their daily routine to make time for additional injections 
and wishing to avoid injecting in public. Further qualitative research is needed 
outside the trial setting to explore drivers of willingness to intensify insulin in the 
real world. 
An understanding of the experience of insulin use post-initiation, and attitudes 
towards intensification, will assist researchers and clinicians in developing 
interventions and clinical strategies to optimise diabetes care and improve 
receptiveness to treatment intensification over time. In this paper, we report on the 
findings of a qualitative study exploring the lived experience of adults with T2DM 
already using insulin, including their perceptions of the consequences of insulin use, 
and of future insulin intensification. 
2. Methods 
We conducted semi-structured, face-to-face interviews with adults with T2DM 
currently using insulin therapy. Ethical approval was obtained from Deakin 
University Human Research Ethics Committee (2013-048). 
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2.1. Participants and recruitment  
Participants were eligible if they were: English-speaking adults (aged 18+ 
years) with T2DM, using insulin therapy for less than four years, and able to attend 
an interview in Melbourne or Geelong (in the state of Victoria, Australia). 
Participants were recruited through advertisements placed on the Diabetes Victoria 
and The Australian Centre for Behavioural Research in Diabetes (ACBRD) websites, 
social media (Twitter, Facebook) and e-newsletters from June 2013 to February 
2014. Purposive sampling was used with the aim of achieving gender balance and a 
broad age range. We aimed to interview approximately 20 participants, with the 
possibility of conducting further interviews, if necessary, to achieve data saturation.  
Potential participants were invited to contact the research team by telephone or 
email to obtain study information and undergo eligibility screening. Overall, 52 
enquiries were received: 20 were ineligible, 12 declined or made no further contact 
after receiving study information, and 20 proceeded to interview.   
2.2. Interview schedule and procedure 
Informed by existing literature (Gherman et al., 2011; Snoek et al., 2007; 
Wang & Yeh, 2012), a semi-structured schedule was designed to elicit a narrative 
from participants about their lived experience of diabetes, insulin initiation and use 
(including perceived advantages and disadvantages) and attitudes to insulin 
intensification.  
Prior to conducting face-to-face interviews, participants provided written 
informed consent. All interviews were conducted by EHT and audio-recorded in a 
private meeting room in a non-clinical setting. The mean interview duration was 42 
minutes (range: 20-69 minutes). Post-interview, participants completed a short 
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demographic questionnaire. Participants were given a $AUD20 department store gift 
voucher as a token of appreciation.  
2.3. Transcription and analysis  
Audio recordings were transcribed verbatim, checked and uploaded to QSR 
NVivo Version 10.  Inductive (data-driven) thematic analysis was conducted using a 
non-linear iterative process informed by Braun and Clarke’s (2006) six-phase 
process for undertaking thematic analysis. An initial coding framework was 
formulated, reviewed iteratively and revised by all authors. A sample of the 
transcripts was double-coded using the revised framework with a high level of 
coding consistency (mean inter-coder agreement rating = 99.5%). Themes relevant to 
the current study were identified. All authors reviewed the final themes to ensure 
they represented the data adequately and reflected the study aims.  
3. Results 
3.1. Sample characteristics 
The sample included 20 participants, aged 43 to 76 years (median = 65, IQR = 
58-69 years) with a median diabetes duration of 12 years (IQR = 7-16 years), 65% (n 
= 13) men. Median time since insulin initiation was two years (IQR = 9-36 months), 
with most participants (n = 17) taking ≤2 (range = 1-4) injections per day. Most 
participants (70%, n = 14) were born in Australia with six participants born 
elsewhere: five in the UK and one in Germany. The majority of participants (70%, n 
= 14) were retired/not working and 55% (n = 11) had a university degree.  
3.2. Data saturation 
Data saturation was achieved at participant #7, after which point no new 
themes emerged. However, purposive sampling continued until a reasonable 
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demographic spread was achieved. Due to an over-representative early response 
from male participants, women only were invited to participate from September 2013 
onwards.   
3.3. Impact of insulin therapy use 
Five main themes emerged from participant discussion surrounding the 
perceived impacts or consequences of insulin therapy: physical impact, personal 
control, emotional well-being, freedom and flexibilities, and (concerns about) others 
reactions.  
3.3.1. Physical impact  
The negative physical impact of insulin therapy concerned changes to diabetes 
symptoms or medical outcomes since insulin initiation, e.g. bruising/bleeding/pain at 
injection site, weight gain, and hypoglycaemia.  
Injection pain was described as infrequent and surprising when it occurred. It 
was related sometimes to injecting cooled (refrigerated), rather than room 
temperature, insulin. Participants described occasional bruising and bleeding but 
these were not considered major problems.  
“It still hurts sometimes. And that's a bit of a surprise when it hurts so 
much…the bruises are massive.” (#18, woman, age 54) “Sometimes it 
might bleed and bruise… but it's fine.” (#15, woman, age 65) 
Some noted that their doctor had discussed the possibility of weight gain prior 
to them commencing insulin. Others were unsure of the direct relationship between 
insulin and weight gain but suspected insulin had caused or contributed to their 
weight gain. 
     248 
“It piles weight on and I said to [my doctor] ‘there's something bizarre 
about this’.” (#03, man, age 67) 
Participants discussed hypoglycaemia as a sign that they needed to reduce their 
insulin dose or increase their food intake at particular times of day. Some discussed 
the need to carefully consider their insulin dose, food intake, and blood glucose 
levels before exercising and some emphasised a preference to keep their blood 
glucose levels higher to avoid hypoglycaemia.  
“I do have hypos and that was one of the things that alerted me to the 
fact that…I might've gone just a bit too far [with insulin dose].” (#03, 
man, age 67) “I'm not that happy to let it go below five. Because I just 
have an innate feeling it's probably not actually safe or proper… to let it 
drop too low because accidents happen.” (#08, man, age 68) 
Physical benefits of insulin use were also reported: the most salient was a 
glycaemic improvement following insulin initiation, with 19/20 participants stating 
that their blood glucose levels, HbA1c, or “control” had improved or stabilised.  
“I was taking my blood sugar several times a day to monitor it, quite 
excited about how I was controlling it, bringing it down very quickly.” 
(#01, man, age 57) “The greatest benefit would be it obviously controls 
my blood sugar levels.” (#10, man, age 69) 
The physical benefits extended to perceived improvement in general health. 
For example, some participants reported “feeling healthier” (#20, woman, age 73) 
and “much more energetic” (#03, man, age 67). They also reported a belief that 
lowering their blood glucose would have positive effects on their future health, or 
help to prevent diabetes-related complications.  
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“Insulin is helping me control my diabetes. That is negating the harmful 
effects of having high sugar on my kidneys, on my eyes, on everything.” 
(#05, man, age 45) 
However, a minority offered vague comments suggesting they were uncertain 
or ambivalent about the broader beneficial health impacts. 
“I don't think it improves your health… I suppose, if you didn't take it, 
you wouldn't last that long.” (#09, man, age 75) “I haven't seen any 
benefits personally.”(#05, man, age 45)  
3.3.2. Personal control 
Feeling “in control” psychologically was an important theme for participants. 
For some, initiating insulin was associated with a sense of loss of personal control 
over their diabetes management, and disappointment in their prior efforts to manage 
their diabetes. This disappointment extended to clinician titration of insulin doses, 
which was perceived to be an indicator of the condition worsening and their “failure” 
to manage diabetes appropriately. In some instances, participants reported that this 
feeling waned over time. 
“You sort of felt, well, I guess, a sense of failure. That you couldn't 
control your blood sugars. That you needed that outside intervention.” 
(#14, man, age 64) "Then it [insulin dose] went up to 40 [units] and with 
each increase I was defiant, saying ‘well, this is dreadful’.  This is 
supposed to control my diabetes and at, at this rate, I'm going to be using 
a whole bloody pen just to kind of keep it under control… I thought 
rather naïvely that, you know, I'd get at least 10, 15 years on the tablets 
and I haven't.” (#05, man, age 45)  
     250 
While insulin represented a loss of personal control for some, others reported 
an enhanced sense of control. They reported increased ownership over, or confidence 
in, their diabetes management as a result of being able to adjust their insulin dose to 
account for physical activity or hypoglycaemia – a benefit not afforded to them while 
taking oral medication alone. 
"If I know for a week I'm not going to exercise, well, I just increase the 
insulin level to compensate.  So I've got a lot of control over it." (#01, 
man, age 57) 
This sense of greater personal control over diabetes led participants to self-
regulate other daily diabetes self-management behaviours. For example, they 
reported more frequent blood glucose checking and paying more attention to food 
intake.  
“I'm a lot more rigorous about my testing since I've been on insulin and, 
as a consequence of that, I tend to be a lot more rigorous about when 
and how much I eat.” (#01, man, age 57) 
3.3.3. Emotional wellbeing 
Participants reported that increased personal control over their diabetes 
management and/or improvements in their blood glucose levels left them feeling 
better emotionally, or more positive about life with diabetes. 
"Mentally I've accepted the need for it. I realise the benefits and I can see 
the benefits so that's made me happier with the outcome." (#04, man, age 
76) “I'm more satisfied that I'm doing everything I can to control the 
diabetes.” (#12, man, age 63) 
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The emotional impact of injections varied across participants. Participants 
recalled their initial fear of injections at insulin initiation and, for some, a sense of 
relief, followed when they experienced injections as surprisingly painless while 
others reported ongoing distress.  
“I realised that it [injecting] wasn't the traumatic experience that I 
expected it to be. I was quite pleasantly surprised actually." (#04, man, 
age 76) "You think, ‘I don't want to do this. I don't want to. Let's go. Suck 
it up. Let's do it. Get it over and done with. If it hurts it hurts but nothing 
you can do about it’." (#16, man, age 68) 
3.3.4. Flexibility and freedom  
Participants reported feeling that insulin made life less flexible or was 
inconvenient, which had broader negative impacts on their activities. Injections were 
perceived as burdensome, interfering with their ability to be spontaneous (e.g. go out 
for dinner, go to bed early) and required an increased level of daily structure and 
routine (e.g. scheduled mealtimes).  
“Injecting at the correct time is very difficult because the demands on 
your lifestyle are not regimented…[they’re] dictated by circumstances, 
which change every day.” (#08, man, age 68) 
Participants felt that having to carry insulin and supplies when going out for 
the day was burdensome. 
“You pack all your stuff together and, even just going out for dinner, it 
doesn't have to be overnight stay or anything…you've got to think ahead. 
It's like packing for an extra person.” (#18, woman, age 54) 
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Insulin was perceived as restricting opportunities, especially those involving 
travel. This included difficulty transporting insulin/supplies; needing refrigeration; 
carrying enough insulin to last a trip; obtaining travel insurance; obtaining letters 
from doctors to provide to airports or travel insurance; driving licensing; and 
travelling to places where healthcare and medications are accessible in case of 
emergency.  
"That's probably the hardest part, going away, telling the tour directors 
of two different tours that I needed a fridge in every room …making sure 
you've got letters on the plane… Travelling, yes, you wish you didn't have 
it then." (#15, woman, age 65) 
In contrast to insulin use limiting participants’ freedoms, the increased sense of 
control over diabetes management (i.e. ability to adjust insulin) enabled, for some, a 
greater level of freedom. For example, being able to alter insulin dosage according to 
food intake. 
“If ever I go out for lunch, I'm not going to say, ‘I'm not going to have 
that dessert’. In fact, actually, I will have that dessert because I know 
that I can have an extra few notches of insulin.” (#05, man, age 45) 
3.3.5. (Concerns about) others’ reactions 
Participants reported concern about other people’s negative reactions to their 
insulin use, which generally constituted family members expressing concern that 
insulin symbolised a worsening condition. Participants recognised that insulin 
therapy made their diabetes more visible to those around them compared with their 
previous tablet-only regimen. They believed that negative reactions were borne out 
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of well-intentioned concern for their health and wellbeing but, nonetheless, they 
experienced the reactions as unnecessary and frustrating.   
"‘Oh, he's on insulin.  Oh, isn't that terrible!’  And, you know, ‘Oh God, 
you know, when’s he going to die?’ sort of thing... actually, it really 
annoys me. Yeah, I mean I suppose their heart's in the right place." (#08, 
man, age 68) 
Participants also reflected on the general public’s attitudes towards insulin. 
Some reported feeling that others may think of them differently because of their 
insulin use, and a minority discussed unwanted advice or interference. 
"I was asked to disclose whether there were any illnesses that the 
company should be aware of and …you would've thought that, you know, 
I said I'm a two-headed monster from Mars…because, all of a sudden, 
I'm appointed a buddy!" (#03, man, age 67) “You get a lot of good 
meaning, well-intentioned advice from other people that wouldn't know 
what an insulin pen looked like.” (#16, man, age 68) 
Participants also expressed concern about having to inject insulin in public. 
Some participants felt embarrassed or self-conscious, and were uneasy that it may 
result in negative reactions / judgments, or upset others. Others simply wished to 
avoid undertaking what they perceived as a “private” activity in public. For some, 
this meant avoiding injecting outside the home except when absolutely necessary, 
seeking out private locations (e.g. bathrooms) and attempting to be discreet. Some 
reported becoming more comfortable with injecting in public over time.   
“If people didn’t understand what a diabetic was, why a diabetic has a 
pen, that sort of thing, [they might think] oh you know ‘oh, she’s shooting 
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up.’  (#19, woman, age 69) “I sneak in… ‘I hope nobody comes, I'm not 
going into the toilet, I'm going to do it here. Hope nobody's coming, hope 
nobody's coming’ and I'm looking around and I quickly do it and get 
out.” (#17, woman, age 63) “I used to go to the ladies and then I 
thought, ‘hang on, it's silly’, I'll just do it like that and put it back in my 
bag.” (#15, woman, age 65) 
3.4. Attitudes to future insulin intensification 
Participants differed with regard to how they felt about the possibility of 
intensifying their insulin treatment in the future. Just over half (n=12) reported that 
the prospect of administering additional injections each day was not a major concern 
to them.  
“It's just like anything, when I find out anything new, I get ‘the sads’ for 
a couple of days and then I just get over it and do it.” (#06, woman, age 
43) “What I know now, and the fact there's no pain, [means] there's no 
barrier to additional treatments if I had to.”(#04, man, age 76) 
Others expressed a desire to avoid additional injections, indicating they would 
be more willing to increase the dose of existing injection(s) to avoid additional 
injections. 
“That would p*** me off. Yeah, that would be concerning”(#13, man, 
age 56) “If it needed to be increased I'd increase it on the one dose, so I 
might go up to 40 [mmol/L] or something like that” (#07, man, age 59) 
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Two key barriers to insulin intensification were identified. First, participants 
felt that additional injections each day would be annoying, difficult to implement in 
their daily routine, and were concerned that they might forget to take them.  
"It would be a nuisance because I think, I can forget, you know, I get into 
a routine…if I had to take more than one it would be the nuisance factor, 
the inconvenience rather than the actual injections." (#11, man, age 68) 
"I would tend to resist that because…I'd have to organise to do it in the 
middle of the day and that would most likely be inconvenient most days." 
(#12, man, age 63) 
Second, participants were concerned specifically about fast-acting insulin. 
They considered it to be particularly inconvenient and more serious, due to the need 
for pre-prandial injections and counting carbohydrates, and felt anxious about the 
associated increased risk of hypoglycaemia.  
“The alternative was to change my insulin from a slow-acting insulin to 
a fast-acting insulin. Again, I was incredibly reluctant to do that because, 
with a slow-acting insulin, I feel I have more control. I know that I'm not 
necessarily going to go into a hypo.” (#05, man, age 45) “[It] was a 
scary prospect of like, carb counting, like the Type 1s do and that was 
scary.” (#18, woman, age 54) 
Finally, a minority of participants considered insulin intensification as a 
reflection on their diabetes self-management efforts. 
“I’d probably feel disappointed… because I’d feel that maybe I hadn’t 
paid enough attention to my diet. Or maybe I needed to exercise more.” 
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(#20, woman, age 73) “I just want to stay on the two [injections]...so I’d 
better work a bit harder” (#15, woman, age 65) 
4. Discussion 
To our knowledge, this is the first in-depth qualitative investigation of the lived 
experience of insulin use among adult Australians with T2DM, and the first to 
qualitatively explore attitudes toward insulin intensification outside a trial setting. 
Our findings demonstrate that negative appraisals of insulin therapy persist after 
insulin initiation. Consistent with previous research (Guimarães et al., 2010; Hayes, 
Bowman, Monahan, Marrero, & McHorney, 2006; Tan et al., 2011), participants 
commonly reported negative physical side effects of insulin therapy, including: 
hypoglycaemia, weight gain and pain caused by or associated with insulin injections. 
In addition to these well-known physical impacts, the negative emotional impact of 
insulin therapy was also highlighted in our study. Similar to previous research (Abu 
Hassan et al., 2013; Furler, Spitzer, Young, & Best, 2011; Hayes et al., 2006; Jenkins 
et al., 2010; Morris et al., 2005; Noakes, 2010; Phillips, 2007a, b), some participants 
reported a sense of relief following their initial insulin injection. Others reported 
ongoing concern caused by daily injections and a wish to avoid adding extra 
injections to their regimen in the future. In addition, some participants reported that 
insulin use, and potential insulin intensification / dosage increases, signified for them 
a “failure” of their prior diabetes self-management and a further loss of “control” 
over their health. This “self-blame”, or the belief that personal failure to manage 
one’s health is an antecedent of treatment intensification has been reported elsewhere 
(Bogatean & Hâncu, 2004, Morris et al., 2005).  
     257 
Participants reported a loss of freedom following insulin initiation, feeling that 
insulin therapy was an inflexible treatment option that impacted negatively on their 
ability to be spontaneous. The need to carry and administer insulin impacted on 
participants’ decisions to eat out and go on day trips. In particular, participants were 
concerned with the perceived difficulty of travelling (e.g. overseas holiday) as 
someone requiring insulin therapy. These findings reflect previous quantitative 
research, which has highlighted “insulin makes life less flexible” as a key 
discriminating item between those with most and least negative insulin appraisals 
(Holmes-Truscott et al., 2015), and the negative impact of insulin-treated diabetes on 
aspects of quality of life such as travel (Bradley & Speight, 2002).  
The perceived inconvenience or inflexibility of insulin injections may be 
heightened for those who wish to avoid injecting in public. Attitudes towards public 
injections varied, with some participants wishing to avoid them entirely while others 
reported attempting to be discreet and seeking out some level of privacy. Participants 
reported feeling embarrassed about injecting in public and concern that others may 
think of them differently because of their insulin use. While not raised in the current 
study, fears about injecting in public may have consequences for optimal diabetes 
self-management. Previous research has reported people missing or delaying insulin 
doses due to social embarrassment (Brod, Kongsø, Lessard, & Christensen, 2009; 
Browne, Ventura, Mosely, & Speight, 2014; Jenkins et al., 2011; Shiu, Kwan, & 
Wong, 2003).  
In addition to negative consequences of insulin therapy, participants raised a 
number of benefits, none more salient than direct improvements in blood glucose 
levels. For some, such improvement extended to indirect improvements in energy 
and health in general, and a belief that these improvements would reduce their risk of 
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developing long-term complications. This is consistent with our recent cross-
sectional survey of Australians with insulin-treated T2DM where the majority of 
participants endorsed positive aspects of insulin therapy (Holmes-Truscott et al., 
2015).  
A certain satisfaction with insulin therapy was implied as participants reported 
that insulin therapy provided them with a greater a sense of personal “control”, and 
flexibility, over their diabetes management and this led them to feel more positive 
emotionally about their diabetes and blood glucose outcomes. For example, 
participants reported improved recognition of blood glucose patterns, self-regulating 
other diabetes self-management behaviours (e.g. food intake) and liking the ability to 
adjust insulin doses according to glucose patterns, food intake or physical activity. 
Similarly, other studies have shown that adults with insulin-treated T2DM report an 
increased understanding of their diabetes and its treatment following insulin 
initiation, improved diabetes self-management, and a greater sense of perceived 
control over their body and health (Morris et al., 2005; Phillips, 2007a; Vinter-
Repalust, Petriček, & Katić, 2004). 
A gap has been identified between the proportion of people with insulin-treated 
T2DM who would benefit from insulin intensification and actual clinical practice 
(Grant et al., 2005, Guler et al., 2008). Polonski et al. (2012) conducted a systematic 
review of studies exploring attitudes towards insulin intensification in people with 
T2DM concluding, from limited published research, that prior insulin experience was 
associated with increased acceptability of insulin intensification. Consistent with 
this, most participants in the current study reported being receptive to insulin 
intensification. Where barriers to additional injections were reported, participants 
discussed the ‘nuisance factor’. However, participants did not discuss inconvenience 
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in reference to injecting in public, as was a key finding elsewhere (Jenkins et al., 
2011), but, rather, as an interruption to their routine and an increased likelihood of 
forgetting to inject. Changes in insulin type appeared to concern participants, who 
raised the increased risk of hypoglycaemic episodes and the need to carefully 
monitor blood glucose and carbohydrate intake as barriers to the use of fast-acting 
insulin.  
4.1. Clinical implications and future directions 
It is critical to the wellbeing and optimal self-management of people with 
T2DM that barriers to insulin initiation, maintenance, and intensification, are 
identified, acknowledged and used to guide patient education, counselling and/or 
regimen optimisation. Previously published recommendations suggest early 
education about the progressive nature of T2DM and the potential need for insulin 
initiation (Meneghini et al., 2010). The attitudes towards insulin intensification 
reported here, in particular with regard to concerns around fast-acting insulin, 
suggest that education and counselling about insulin therapy should not end at insulin 
prescription and initiation. Clinicians need to engage in ongoing discussions with 
people with T2DM about treatment intensification, including early discussion of the 
types of insulin available and the potential benefits and side effects of each type of 
insulin. Further, insulin regimen options need to be explored in the context of a 
person’s daily routine to support them to manage their diabetes optimally (e.g. 
through developing strategies for remembering to inject).  
Attitudes towards insulin are not static. Indeed, a reduction in negative 
attitudes towards insulin has previously been observed after initiation (Hermanns et 
al., 2010) and, in the current study, some participants commented on their change in 
attitudes with greater insulin experience over time (e.g. becoming more comfortable 
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with injecting in public with experience). Similarly, it could be expected that 
participants’ attitudes towards intensified insulin regimens would change with 
experience. However, in this single timepoint study, it is not possible to observe 
actual change in attitudes towards insulin use, which might occur as a function of 
experience with, understanding and education about, and change in insulin regimen. 
To further understand how attitudes towards insulin change over time, and the 
mechanisms by which this occurs, longitudinal qualitative research is needed to 
investigate attitudes towards insulin pre- and post-initiation of insulin, and/or 
structured education or counselling about insulin therapy, and/or insulin 
intensification.   
Despite reporting various negative consequences of insulin therapy, 
participants in our study also reported experiencing benefits. Namely, improvements 
in blood glucose outcomes leading to increased perceptions of personal control over 
the condition, flexibility and freedoms, suggesting at least some experienced greater 
satisfaction with treatment following insulin initiation. The perceived positive and 
negative impacts of insulin therapy, as reported here and elsewhere (Wang & Yeh, 
2012) could be used to inform the development of evidence-based interventions and 
messaging to increase psychological receptiveness towards insulin initiation.  
4.2. Strengths and limitations  
The current study is one of the first in-depth explorations of the lived 
experience of people with T2DM using insulin, focusing on both the positive and 
negative aspects of insulin use, and on attitudes to insulin intensification in the real 
world. Purposive sampling was used to maximise variability in participants’ age and 
gender. Consistent with the average age of Australians with T2DM (National 
Diabetes Services Scheme, 2015), this study mainly included older, retired adults 
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who had been living with diabetes for over a decade. As such, the findings of this 
study may not be representative of the experiences of younger adults with T2DM, an 
emerging group (Browne, Scibilia, & Speight, 2013). Further, this English-speaking 
participant group was predominately born in Australia or the UK and generally well 
educated. As such, the experiences of this group may not be representative of 
Australians with culturally and linguistically diverse backgrounds, and the current 
study was unable to explore insulin therapy experiences, which may be specific to 
different cultural groups within Australia. Further, participant recruitment was 
challenging, with just 50 people expressing an interest over an 8-month period, and 
over half of those being ineligible or not participating. This may suggest that those 
who did take part were more engaged in their diabetes self-care and diabetes issues 
than the general T2DM population.  
5. Conclusions 
This study demonstrates that people with T2DM experience several ongoing barriers 
to insulin use and have concerns regarding future insulin intensification. While 
certain concerns and negative experiences (e.g. injection anxiety, avoidance of public 
injections) lessened over time and with experience for some, other negative 
consequences are more persistent (e.g. impact on freedom and flexibility). Reported 
benefits of insulin therapy included perceived immediate improvements in blood 
glucose levels, energy and health, and increased satisfaction with diabetes 
management. Participants were mostly receptive to the possibility of future insulin 
intensification but cited inconvenience and perceived risk of hypoglycaemia as their 
greatest barriers to intensifying their regimen. These findings suggest that clinician 
counselling may be beneficial and evidence-based interventions are needed, in which 
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concerns about insulin are acknowledged, strategies for overcoming them identified, 
and benefits highlighted.  
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Chapter 10: Discussion 
10.1. Major Findings  
The aim of this thesis was to undertake a program of research to investigate: a) 
the measurement of insulin appraisals among Australians with T2D, b) the 
occurrence of, and factors associated with, PIR and intention to begin insulin therapy 
among adults with non-insulin-treated T2D within national population level and 
clinical settings, c) the demographic, clinical and psychological predictors of actual 
insulin uptake, and d) attitudes toward insulin post-initiation, perceptions of benefits 
and consequences of insulin, and attitudes to further treatment intensification. The 
following sections summarise the findings of this thesis with reference to these four 
objectives.  
10.1.1. Measuring insulin appraisals among Australians with T2D  
As highlighted in Chapter 2, with the exception of a single interview study 
(Furler, Spitzer, Young, & Best, 2011) and the international DAWN study (Peyrot et 
al., 2005), which used unvalidated single items, there has been no research 
investigating attitudes towards insulin therapy among Australians with T2D and, thus 
the Australian perspective is largely unknown. Further to this, the acceptability, 
validity and reliability of insulin appraisal measures has not been explored among 
Australians with T2D. Therefore, the first objective of this thesis was to conduct 
psychometric validation of a commonly used measure of insulin appraisals, the ITAS 
(Snoek, Skovlund, & Pouwer, 2007), among Australians with T2D. In addition, 
validation was conducted separately by treatment type to ensure the scale 
demonstrated satisfactory psychometrics across both insulin-treated and non-insulin-
treated populations. In the first Australian study employing the ITAS (see Chapter 4, 
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Study 1a), the measure was found to be acceptable and psychometrically sound 
among a national sample of adults with T2D. However, items in the Positive 
subscale did not load on a forced single factor, and the internal consistency of the 
single factor was low. Thus, computation of a Total scale score was not supported 
and the two ITAS subscales (Negative and Positive) were recommended for future 
use. Further analyses presented in this thesis used the two subscale scores in 
preference to the Total score, and where the Total score was used, the rationale was 
to enable comparison with international data.  
10.1.2. Attitudes to and willingness to begin insulin therapy  
The second objective of this thesis was to measure, and identify factors 
associated with PIR and receptiveness to insulin therapy among Australian adults 
with non-insulin-treated T2D. The mean Total and ITAS Negative scores among 
participants in Diabetes MILES – Australia (see Chapter 4; Study 1a) were similar to 
those reported internationally (Bahrmann et al., 2014; Chen et al., 2011; Hermanns, 
Mahr, Kulzer, Skovlund, & Haak, 2010; Snoek et al., 2007), whereby Total and 
Negative subscale scores were significantly higher, more negative, among those not 
yet using insulin in comparison to those using insulin. As observed elsewhere, 
positive insulin appraisals were highly endorsed among the non-insulin-treated 
sample (Chen et al., 2011; Larkin et al., 2008; Petrak et al., 2007; Snoek et al., 2007; 
Woudenberg, Lucas, Latour, & Scholte op Reimer, 2012). Among the current 
sample, the ITAS Positive subscale did not discriminate between treatment groups, 
and elsewhere results are inconsistent (Hermanns et al., 2010; Snoek et al., 2007).  
The breadth and depth of the Diabetes MILES – Australia dataset (Study 1) 
provided the opportunity to contribute to existing knowledge through the 
comprehensive investigation of the psychosocial correlates of negative insulin 
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appraisals among those with non-insulin-treated T2D. Chapter 5 (Study 1b) 
investigated the independent contributions of general and diabetes-specific emotional 
wellbeing and beliefs about medication in predicting ITAS Negative subscale scores 
among adults with non-insulin treated T2D. Consistent with prior research (Makine 
et al., 2009), diabetes-related distress was found to be a stronger independent 
predictor of insulin appraisals than depressive symptoms. Similarly, despite anxiety 
disorder recently being reported as a predictor of actual insulin uptake (Iversen et al., 
2015), anxiety symptoms did not contribute independently, after accounting for 
diabetes-related distress. This thesis examined, for the first time, the relationship 
between PIR and specific aspects of diabetes-related distress. The ‘emotional 
burden’ subscale of the Diabetes Distress Scale (Polonsky et al., 2005) was most 
strongly associated with negative insulin appraisals. ‘Regimen burden’ was 
moderately associated with the ITAS Negative, while a weak correlation was 
observed between ITAS Negative scores and ‘physician’ and ‘interpersonal’ distress. 
Beliefs about medications, in general, may play a role in attitudes to insulin therapy 
(Polonsky, Hajos, Dain, & Snoek, 2011), but the association had not previously been 
examined using validated measures, or measures that differentiate between general 
medication beliefs and diabetes-specific medication beliefs. In Study 1b, diabetes-
specific, but not general, medication beliefs were independently associated with 
ITAS Negative. Greater diabetes-related ‘emotional burden’ and ‘concern’ about 
current diabetes medications was associated with greater negative insulin appraisals. 
These findings suggest that negative attitudes toward future insulin use may be an 
extension of negative perceptions/experiences of current diabetes medications (i.e. 
OHAs) and experience of the emotional burden of living with diabetes.  
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In Chapter 6, ‘hypothetical willingness’ to begin insulin therapy was 
investigated among adults with T2D for whom insulin was clinically indicated (the 
Stepping Up sample; Study 2b): 22% reported being, hypothetically, ‘not at all 
willing’, and just 19% reported being ‘very willing’, to begin insulin therapy if 
recommended. In a study of PIR across eight Western countries, not including 
Australia, the average proportion of participants reported as unwilling to begin 
insulin was slightly lower (at 17%), although there was considerable variation 
between countries (from 6% in Spain to 37% in Italy) (Polonsky, Hajos, et al., 2011).  
Factors associated with hypothetical willingness to begin insulin were 
examined at the Stepping Up baseline using univariate analyses, which demonstrated 
no associations between willingness and: clinical variables (i.e. Hba1c, diabetes 
duration, number of co-morbidities, number of prescribed medications), current self-
management behaviours (i.e. daily SMBG and diabetes medication-taking 
behaviours (MARS)). Further, with the exception of socioeconomic status, no 
association was observed between willingness and demographic variables (i.e. age, 
gender). Significant associations were observed between willingness and emotional 
wellbeing (i.e. depressive symptoms and diabetes-related distress) and insulin 
appraisals (i.e. ITAS Negative and Positive subscales and single attitudinal measure). 
In multivariate analysis, after accounting for socioeconomic status and insulin 
appraisals, neither depressive symptoms nor diabetes-related distress contributed 
independently to the prediction of hypothetical willingness to begin insulin. The 
multivariate analysis demonstrated that socioeconomic status and both negative and 
positive attitudes towards insulin therapy were predictive of being ‘very willing’ to 
begin insulin therapy among adults with T2D in primary care for whom insulin was 
clinically indicated. Thus, interventions to increase willingness to initiate insulin 
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therapy must tackle negative attitudes towards insulin therapy and improve positive 
insulin appraisals. 
10.1.3. Individual-level predictors of actual insulin uptake 
In Chapter 6, factors associated with ‘hypothetical willingness’ to begin insulin 
were identified, but whether this reflects actual refusal rates has not been verified 
previously. Furthermore, at the time of commencing this thesis, little prospective 
research had comprehensively explored the demographic, clinical and psychological 
factors associated with actual insulin uptake. Therefore, the third objective of this 
thesis was to identify demographic, clinical, and psychosocial predictors of actual 
insulin uptake among people with T2D for whom insulin was clinically indicated and 
assess the predictive validity of the ‘hypothetical willingness’ item (Chapter 7; Study 
2b). Univariate analyses demonstrated that insulin use at 12 months among Stepping 
Up participants was associated with socioeconomic status and HbA1c at baseline. 
Consistent with recent studies, baseline ITAS Positive and Negative scores 
differentiated insulin users from non-insulin users at follow up (Keij, Ismail, & 
Winkley, 2016; Odawara, Ishii, Tajima, & Iwamoto, 2016), as did willingness to 
begin insulin. Depressive symptoms were not associated with insulin uptake, also 
consistent with prior research (Iversen et al., 2015; Nefs, Pop, Denollet, & Pouwer, 
2013). In contrast to the only other study which has assessed the relationship 
between diabetes-related distress and insulin use (Keij et al., 2016), univariate 
analysis demonstrated no association between diabetes related-distress and insulin 
use at 12 months. Using a multilevel logistic regression model, after controlling for 
study arm allocation, willingness to begin insulin therapy was predictive of insulin 
use at 12 months, negating the contribution of negative and positive insulin 
appraisals. Those who were hypothetically ‘very willing’ to begin insulin were more 
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likely to have switched to insulin therapy at 12 months, compared to those who were 
‘not at all’ willing. Higher baseline Hba1c was also an independent predictor of 
insulin use at 12 months. These results are consistent with a recent longitudinal study 
of Japanese adults with T2D, which identified that those who initiated insulin 
reported significantly higher HbA1c and less negative/more positive insulin 
appraisals, at baseline, compared with those who remained on OHAs (Odawara et al., 
2016). However, in that study, insulin appraisals were assessed using a study-specific 
unvalidated measure and hypothetical willingness to begin insulin therapy was not 
measured. 
10.1.4. Attitudes to insulin therapy after insulin initiation 
The fourth aim of the current thesis was to examine attitudes towards insulin 
post-initiation. This included examination of: a) change in attitudes towards insulin 
after initiation, and among those with insulin-treated T2D, b) factors associated with 
negative attitudes towards insulin, and c) perceived benefits and consequences of 
insulin and attitudes towards future insulin intensification. Data from all three studies 
were relevant to this objective.  
Participants in the Stepping Up trial (Study 2b) completed the ITAS at baseline 
and 12 months follow-up; enabling comparison of attitudes towards insulin over time 
as a function of insulin uptake and trial randomisation. The findings presented in 
Chapter 7 demonstrate a significant reduction in negative insulin appraisals overall at 
12 months. Further, there was a significant main effect of insulin initiation, whereby 
those who initiated insulin therapy reported a significantly greater improvement in 
ITAS Negative scores at follow-up, compared to participants who remained on 
maximum daily OHAs. This is consistent with prior research (Hermanns et al., 
2010). The Stepping Up study also provided the opportunity to compare change in 
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insulin appraisals by model of care received (usual care versus Stepping Up model of 
care) and identify any interaction effect with insulin uptake. A main effect of model 
of care was identified, whereby those in the intervention arm reported significantly 
greater improvements in ITAS Negative scores than those in the control arm, but no 
interaction was found. It is likely that the significant main effect of the study arm 
allocation is accounted for by the higher proportion of intervention participants who 
initiated insulin compared to the control arm, rather than any effect of the 
intervention itself. These results support the theory that uptake of and experience 
with insulin may mitigate negative perceptions of insulin therapy. In contrast to 
negative insulin appraisals, ITAS Positive scores did not change over time overall, or 
by insulin uptake. Elsewhere, the sensitivity of the ITAS Positive subscale to 
treatment change has varied (Hermanns et al., 2010; Liebl et al., 2013).  
Despite average reductions in negative insulin appraisals, certain negative 
attitudes or consequences of insulin use may be endorsed after insulin initiation. 
Little research has explored the possible impact of ongoing PIR among adults with 
insulin-treated T2D. As shown in Chapter 8, in the Diabetes MILES –Australia 
sample (Study 1c), approximately half the participants with insulin-treated T2D 
endorsed negative ITAS statements relating to insulin symbolising disease 
progression, and causing weight gain. The negative ITAS item ‘insulin makes life 
less flexible’ discriminated most between those with lower and higher ITAS 
Negative scores. Those with more negative insulin appraisals were younger and more 
likely to be in paid work, which is consistent as this group are more likely to 
perceive the need for a treatment that fits into their lifestyle. In contrast to prior 
research (Chen et al., 2011), those with greater negative insulin appraisals were more 
likely to have been using insulin therapy for one year or less, compared to those with 
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less negative insulin appraisals. However, the majority of those with negative insulin 
appraisals had been using insulin for more than one year, indicating that negative 
attitudes towards or experience of insulin may be common regardless of insulin 
treatment duration.  
Among Diabetes MILES – Australia participants, those with more negative 
insulin appraisals were more likely to perceive daily insulin injections as a greater 
burden, than those with less negative insulin appraisals, but they were injecting 
insulin a similar number of times per day and were also significantly more likely to 
report ‘always’ taking their insulin as prescribed, compared to those with less 
negative insulin appraisals. These results suggest that negative insulin appraisals 
alone are not associated with insulin omission; in fact, negative insulin appraisals 
may be the consequence of optimal, yet burdensome, insulin-taking behaviours.  
Despite reporting always taking their insulin as recommended, participants 
with insulin-treated T2D with higher ITAS Negative scores reported significantly 
lower diabetes-specific self-efficacy and reported less satisfaction with their glucose 
levels over the previous two weeks in comparison to those with lower ITAS 
Negative scores. Similarly, perceived social acceptability of, and satisfaction with, 
insulin delivery and perceived glycaemic control over the previous 4 weeks has been 
found to be associated with self-efficacy with insulin therapy in a 36-week clinical 
trial of insulin initiation (Hayes et al., 2013). It may be that negative insulin 
appraisals among people with insulin-treated T2D are related to perceptions of 
insulin therapy as ineffective, as evident from less satisfaction with glucose levels, 
despite optimal insulin-taking behaviours. This may, in turn, reduce diabetes-specific 
self-efficacy and increase diabetes-related distress. Indeed, those with insulin-treated 
T2D and more negative insulin attitudes were also more likely to report diabetes-
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related distress and increased depressive and anxiety symptoms. In contrast, an 
alternative explanation may be that those with a more negative outlook (evidenced 
by increased depression and diabetes-related distress) may be more susceptible to 
negative beliefs about their diabetes treatment and their ability to self-manage their 
condition effectively, and greater dissatisfaction with their treatment. Longitudinal 
studies are needed to more fully understand the nature of these relationships.  
Thus, the results presented in Chapter 8 provide quantitative evidence that 
negative insulin appraisals persist among people with insulin-treated T2D, while 
Chapter 9 presented qualitative data from an in-depth interview study (Study 3) with 
adults with insulin-treated T2D. Participants discussed their perceptions of the 
negative impact of insulin therapy, including adverse physical effects (i.e. weight 
gain, hypoglycaemia, injection-related pain) and emotional wellbeing (i.e. injection-
related fear or distress), personal control (i.e. sense of loss of control over treatment 
and health), lifestyle freedoms (i.e. having to consider insulin therapy when 
travelling and eating out, reduced sense of spontaneity), and other people’s 
perceptions of them (i.e. familial concerns, general public’s negative reactions to 
insulin therapy, injecting in public). The foremost-perceived benefit of insulin 
therapy was the observed improvement in glycaemic outcomes, which for some 
extended to more tangible improvements in general health. An additional identified 
benefit of insulin use, which is not covered within the ITAS but has been reported 
elsewhere (Morris, Povey, & Street, 2005; Phillips, 2007a), concerns an increase in 
perceived control over diabetes management and one’s health. This included better 
understanding of diabetes and control over outcomes and, in turn, for some it meant 
greater flexibility in their self-management (for example, ability to adjust insulin 
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doses according to glucose patterns, food intake or physical activity), with beneficial 
consequences for their quality of life.  
In addition to investigating psychological receptiveness and resistance to 
insulin uptake and maintenance, this thesis set out to investigate these issues in 
relation to insulin intensification. A recent systematic review (Polinski et al., 2012) 
highlighted the lack of research examining rates of, attitudes towards, and factors 
associated with timely insulin intensification among those with T2D already using 
insulin therapy. In one of the only qualitative studies to explore attitudes toward 
insulin intensification to date, people with T2D were found to be largely receptive to 
insulin intensification (Jenkins, Hallowell, Farmer, Holman, & Lawton, 2011). 
Consistent with this, the qualitative findings presented in Chapter 9 indicate that 
people already using insulin are receptive to intensification. However, some reported 
a desire to avoid additional injections, appearing more receptive to increasing their 
current insulin dose(s). The main reported barrier to insulin intensification was the 
perceived inconvenience and inflexibility of additional injections (i.e. having to 
change daily routine). In addition, participants discussed the possible negative 
consequences of fast-acting insulin, such as increased risk of hypoglycaemia and the 
need for carbohydrate counting, as barriers to insulin intensification.  
10.1.5. Summary  
This thesis extends significantly on previous knowledge of the measurement, 
experience, and correlates, determinants and consequences of PIR and receptiveness 
among adults with T2D including among those currently, and not yet, using insulin 
therapy. Specifically, Study 1a (Chapter 4) confirmed the psychometric reliability 
and validity of the ITAS among those with insulin-treated and non-insulin-treated 
T2D separately. Chapter 5 (Study 1b) reported comprehensive cross-sectional 
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analyses of the demographic, clinical and psychosocial factors associated with 
negative insulin appraisals among a national sample of Australians with non-insulin-
treated T2D; identifying diabetes-related distress and concerns about current diabetes 
medication as the strongest independent correlates. Chapters 6 and 7 reported on 
baseline and 12-month findings from a primary care sample of adults with T2D for 
whom insulin therapy is clinically indicated. Among this group, attitudes toward 
insulin therapy were associated with hypothetical willingness to begin insulin 
therapy (Study 2a, Chapter 6), and willingness, but not insulin appraisals, was 
associated with actual insulin uptake at 12 months (Study 2b, Chapter 7). Study 2b 
also demonstrated that change in negative, but not positive, insulin appraisals at 12-
month follow-up was associated with insulin uptake. Chapters 8 and 9 confirmed the 
persistence of negative insulin appraisals following uptake of insulin therapy. 
Among people with T2D already using insulin therapy, those with more negative 
insulin appraisals also reported worse emotional wellbeing and lower diabetes self-
efficacy and satisfaction with blood glucose (Study 1c, Chapter 8). Finally, Chapter 9 
(Study 3) reported on the experience of insulin use and identified receptiveness, and 
barriers to, future insulin intensification. 
10.2. Implications for Assessment, Clinical Practice and Future Research 
The following section discusses the implications of the studies presented in this 
thesis for the measurement of PIR and receptiveness, and for clinical practice, both 
before and after insulin initiation. Embedded in this discussion are implications of 
the findings in relation to theory, strategies for reducing negative insulin appraisals 
and improving receptiveness to insulin therapy initiation and intensification, and 
suggestions for further research.  
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10.2.1. Defining and measuring psychological insulin resistance and 
receptiveness 
PIR and receptiveness were defined in this thesis as negative and positive 
attitudes to insulin therapy, which may act as barriers to or enablers of insulin 
initiation, ongoing insulin use and insulin intensification. These concepts were 
operationalised in this thesis through the measurement of insulin appraisals (negative 
and positive attitudes) (Polonsky, Hajos, et al., 2011; Snoek et al., 2007), as well as 
through the related measurement of ‘hypothetical willingness’ to begin (or intensify) 
insulin (intention) (Polonsky, Hajos, et al., 2011), and actual acceptance or refusal of 
insulin therapy (behaviour) (Jenkins, Hallowell, Farmer, Holman, & Lawton, 2010; 
Jenkins et al., 2011).  
10.2.1.1. The value of measuring insulin appraisals 
Refusal or acceptance of treatment intensification, as well as optimal use of 
any prescribed treatment, by people with T2D is of primary clinical importance due 
to the necessity of establishing and maintaining glycaemia within target and, in turn, 
preventing/delaying the development of diabetes-related complications (U.K. 
Prospective Diabetes Study Group, 1998). In Chapter 7 (Study 2b), it was 
demonstrated that actual insulin uptake was predicted by higher HbA1c, being 
allocated to the intervention arm (i.e. receiving the Stepping Up model of care), and 
importantly by intention to begin insulin, but not insulin appraisals. This poses the 
question of whether it is useful to assess insulin appraisals if intention (assessed with 
just a single question of ‘willingness’) is a better predictor of the desired behaviour. 
The stronger association between intention and behaviour, in comparison to attitudes, 
is likely due to intention encapsulating both negative and positive insulin appraisals 
(as shown in Chapter 6) as well as other unmeasured factors. For example, the 
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clinical decision-making dynamic suggests that some people with diabetes may 
accept their HCP’s authoritative recommendation regardless of their own 
reservations (Jenkins et al., 2011). However, to understand the reasoning behind 
intention, HCPs need to understand attitudes towards insulin therapy (in addition to 
other possible factors), including both negative insulin appraisals (PIR) and positive 
insulin appraisals (receptiveness). Furthermore, in clinical practice, it may be more 
appropriate to explore attitudes to guide ‘decisional balancing’ about the prospect of 
using insulin (Miller & Rollnick, 2002) rather than simply asking the potentially 
confronting and blunt question of willingness.  
In addition to understanding attitudes that may lead to delays in insulin 
initiation, the measurement of insulin appraisals among those already using insulin 
therapy may also be used to identify new or ongoing barriers to insulin use, and 
explore their potential impact. For example, in Chapter 8 (Study 1c), negative insulin 
appraisals were identified among those already using insulin therapy, and this group 
also experienced worse general and diabetes-specific emotional wellbeing, lower 
diabetes self-efficacy and satisfaction with blood glucose levels compared to those 
with more positive insulin appraisals.  
10.2.1.2. Measuring insulin appraisals over time or between treatment groups 
As described in Chapter 2, several validated measures of insulin appraisals 
exist (Fu, Wong, Chin, & Luk, 2016; Martinez et al., 2007; Petrak et al., 2007; Snoek 
et al., 2007), in addition to other unvalidated measures (Odawara et al., 2016; 
Polonsky, Fisher, Dowe, & Edelman, 2003; Polonsky, Hajos, et al., 2011). When 
selected for use in this thesis, the ITAS was (and remains) the only measure to be 
developed and validated for use among both insulin and non-insulin using T2D 
populations (Snoek et al., 2007), and had demonstrated responsiveness (Hermanns et 
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al., 2010; Liebl et al., 2013). Thus, if assessing PIR over time or between treatment 
groups (both done in this thesis), the ITAS may be the most relevant measure. 
However, the limitations of this scale need to be considered. First, as described in 
Chapter 4, 8% of the non-insulin-treated participants (but none with insulin-treated 
T2D) skipped the entire scale within the Diabetes MILES – Australia survey. The 
first sentence of the ITAS instructions reads, “The following questions are about 
your perceptions of taking insulin for your diabetes”, which may have prompted non-
insulin-treated participants to skip the questionnaire entirely. After accounting for 
this, no particular items were skipped more commonly by either group, and all items 
appeared acceptable to both groups. Future researchers using the ITAS with non-
insulin using participants might consider modifying the instructions to better 
emphasise the questionnaire’s relevance to maximise completions.  
Second, as the ITAS was designed to be relevant to both insulin-treated and 
non-insulin-treated groups, it is possible that the items do not comprehensively 
capture the diversity of appraisals within both groups. In Chapter 9, a qualitative 
study identified negative experiences of insulin therapy among adults with insulin-
treated T2D; some of which are not assessed within the ITAS. For example, 
participants reported the need to more carefully consider additional negative 
consequences, relating to their lifestyle (physical activity, dietary choices and meal 
times), and the nuisance of having to carry insulin/monitoring supplies. While the 
ITAS includes the statement ‘...insulin means my diabetes had become much worse’, 
people with T2D already using insulin also report increasing insulin dose(s) as an 
additional indicator of worsening health. Further, there are no items in the ITAS 
concerning attitudes towards insulin adjustment, different insulin regimens, or 
insulin intensification. Thus, the ITAS may have limited sensitivity to appraisal of 
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once-daily or biphasic insulin regimens compared with intensive insulin therapy 
(multiple daily injections or insulin pump). Future research should investigate 
differences in insulin appraisals among people with insulin-treated T2D using 
various insulin regimens. Among adults with insulin-treated T2D, negative 
experiences of insulin therapy may be better assessed through the use of a measure of 
insulin treatment satisfaction (e.g. Anderson et al., 2004) and/or experience (e.g. 
Moock, Hessel, Ziegeler, Kubiak, & Kohlmann, 2010) specifically designed for use 
among this treatment group. Future research needs to examine the overlap between 
the ITAS and measures of insulin treatment experience or satisfaction, and identify 
which are more strongly associated with insulin-taking behaviours (i.e. insulin 
omission) and willingness to intensify insulin regimen. 
To protect the validity of ITAS for assessing change over time (and change in 
treatment), a balance must be struck between comprehensiveness and applicability 
across treatment groups. Indeed, items that require knowledge or experience of 
actual insulin therapy are of limited relevance to those not yet using insulin. This is 
evidenced by the inclusion of the item ‘insulin causes weight gain’, which, in both 
the original validation sample (Snoek et al., 2007) and in the Australian validation 
sample (Chapter 4), did not load on either the negative or the positive subscales 
(regardless of insulin use), and was the only negative item that was significantly 
more likely to be endorsed among the insulin-treated than the non-insulin-treated 
group. This suggests that people with non-insulin-treated T2D may be unaware of 
the association between insulin therapy and weight gain and, therefore, this item may 
not be relevant to this group. However, retaining the item may prompt HCPs to 
discuss this important potential side effect within care in the interests of informed 
decision making. 
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In contrast to the ITAS Negative, the ITAS Positive subscale scores did not 
discriminate between treatment groups cross-sectionally (Chapter 4) and did not 
change following insulin initiation (Chapter 7), consistent with prior research 
(Hermanns et al., 2010). This lack of sensitivity may be due to the ITAS Positive 
items referring mainly to knowledge of the physiological benefit of insulin use, 
which could be applied to any pharmacological treatment of diabetes, rather than to 
the consequences of insulin specifically. For example, items refer to insulin helping 
to ‘maintain good control of blood glucose’ and ‘prevent complications of diabetes’, 
which might be said of any glucose lowering agent when used appropriately. In 
Chapter 9, other benefits of insulin therapy were identified including: increased 
dietary flexibility due to the ability to adjust insulin, feeling more positive about 
health in general, relief over the ease of using insulin devices/injecting, and insulin 
use fostering personal control over diabetes. Thus, while it is recommended that the 
positive items of the ITAS are retained, this subscale may benefit from revision, with 
the development and testing of items referring to additional, and perhaps more 
immediately salient, benefits of insulin therapy. 
10.2.1.3. Measuring psychological insulin receptiveness 
The findings of this thesis suggest that PIR and receptiveness are not two ends 
of a single continuum, but may be parallel concepts. Statistically, the ITAS Positive 
perform quite differently to the ITAS Negative subscale: there was a weak 
association between subscales (rather than a strong negative correlation), positive 
items loaded weakly on the forced one-factor solution and reduced the internal 
consistency reliability of the Total ITAS score (Chapter 4). In Chapter 6, both 
Negative and Positive subscales were found to be independent predictors of intention 
to begin insulin therapy among Stepping Up participants. This suggests that the 
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initiation of, or intention to initiate, insulin would require the perceived necessity of 
insulin therapy (positive insulin appraisals) to outweigh the perceived concerns 
(negative insulin appraisals). This is consistent with the Necessity and Concerns 
framework (Horne, Weinman, & Hankins, 1999), which hypothesises that the 
decision to engage in treatment is based on both the perceived need for treatment 
(Necessity) and concerns about the consequences of the treatment (Concerns). While 
this framework has most commonly been applied to actual medication adherence in a 
range of chronic conditions (Horne et al., 2013), Patel and colleagues (2015) have 
recently suggested its relevance in predicting acceptance or refusal of insulin therapy 
among people with T2D. Therefore, it is recommended that both positive insulin 
appraisals (receptiveness) and negative insulin appraisals (PIR) are measured.  
10.2.1.4. Short-form measures of insulin appraisals 
Short-form measures of insulin appraisals may be preferred in clinical and 
research settings but the advantages (e.g. reduced participant burden) need to be 
weighed carefully against disadvantages (e.g. reduced validity). In Chapter 6, the 
ITAS was compared with a short, unvalidated measure of attitudes toward insulin, 
which asks participants to choose two of six statements (three positive and three 
negative) that best represent their feelings about insulin (Polonsky, Hajos, et al., 
2011). There was a weak-to-moderate correlation between this single attitudinal 
measure and the ITAS Positive and Negative subscales, and it contributed 
independently, alongside ITAS subscales, to the prediction of willingness to begin 
insulin. This suggests that the single attitudinal measure assesses a concept related to, 
but not precisely the same as, that assessed by the ITAS. The 20-item ITAS provides 
a more complete profile of attitudes towards insulin therapy. However, it may also be 
that the predictive validity of the Total and Negative subscale scores is diluted by the 
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scale length, as items of less relevance or concern to the actual uptake of insulin may 
be creating noise in the total scores. In contrast, responses to the single attitudinal 
measure represent the two most salient attitudes to insulin within a short list of six, 
though it is unclear whether these six items capture the most salient negative and 
positive aspects of insulin therapy for all people with T2D. For example, the second 
most highly endorsed negative ITAS item among Australians with T2D using OHAs 
to manage their condition was ‘taking insulin makes life less flexible’ (65%). The 
perceived impact of insulin therapy on lifestyle flexibility is not captured within the 
single attitudinal measure. Thus, further work is needed before a short-form 
instrument can be recommended. 
10.2.2. Reducing psychological insulin resistance among adults not using 
insulin therapy 
Among people with non-insulin-treated T2D, this thesis has demonstrated the 
correlational pathway between attitudes to intention (Chapter 6), and intention to 
change in behaviour (Chapter 7), as proposed in the theory of planned behaviour 
(Ajzen, 1991). Importantly, the association between intention to begin insulin 
therapy and actual insulin uptake was independent of the model of care highlighting 
that, in addition to successful practice-based/HCP level interventions to reduce 
clinical inertia, interventions need to target change in attitudes towards insulin 
therapy in order to increase intentions to begin insulin therapy among people with 
T2D.  
At the commencement of this thesis, many commentaries and perspectives on 
PIR and techniques to reduce negative attitudes had been published (Clark, 2007; 
Davis & Renda, 2006; Meece, 2006; Polonsky & Jackson, 2004). However, it is only 
in more recent years that interventions have been developed specifically to reduce 
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negative insulin appraisals (Brod, Alolga, & Meneghini, 2014; Patel, Stone, 
Hadjiconstantinou, et al., 2015) and to improve understanding of insulin therapy as a 
treatment option (Hassali et al., 2013; Mathers et al., 2012). These interventions have 
been evaluated to varying degrees, but none, to the PhD candidate’s knowledge, in 
terms of their association with actual insulin uptake, which needs to be the focus of 
future research.  
Patel and colleagues (2015) have developed an intervention for South Asian 
people with T2D living in the UK, which is designed to reduce myths and 
misconceptions about insulin therapy commonly reported among this community 
(Patel, Stone, Chauhan, Davies, & Khunti, 2012; Patel, Stone, McDonough, et al., 
2015). The intervention is delivered via DVD, designed to be viewed by the person 
with T2D within clinic and followed by a discussion of the content with a HCP. 
Despite positive feedback regarding the DVD and associated resources, the time 
required to provide the intervention was perceived to be a limitation by the HCPs. 
This has implications for the feasibility of applying such an intervention within real-
world care. It is already known that HCPs find insulin initiation a time-consuming 
exercise (Furler et al., 2011). If the DVD was found to be effective, an alternative 
implementation strategy may be required to extend the reach and acceptability of this 
intervention. Alternatively, the tool may be reformatted into a medium that could be 
viewed by people with T2D at home. For example, Brod et al (2014) recently 
developed an educational brochure that presents ten negative barriers to insulin 
therapy followed by an “unbiased, medically informative” response. This tool has 
undergone cognitive debriefing with people with T2D, but no further evaluation has 
been conducted. Thus, further research is needed to investigate whether this this tool 
may be effective in reducing PIR or is associated with actual insulin uptake. Future 
     289 
research needs also to the investigate the medium of delivery (i.e. DVD, brochure, 
website) within this context to identify the most acceptable, suitable, and effective 
way to challenge the insulin appraisals of people with T2D and increase intentions to 
use insulin when it is clinically indicated. 
Patel and colleagues (2015) also reported difficultly engaging people with non-
insulin-treated T2D to take part in the evaluation of their DVD. People with T2D 
were hesitant to take part due to their concern that consenting may mean that they 
would subsequently have to begin insulin therapy. As a consequence, the evaluation 
of this intervention was severely curtailed (N=3). Therefore, those with most 
negative attitudes towards insulin may be least inclined to engage with an 
intervention that explicitly aims to reduce negative attitudes towards insulin therapy. 
An alternative approach may be to re-frame the intervention as being more broadly 
about diabetes self-management, and present the strengths and weaknesses of various 
treatment options, rather than insulin in isolation. Mathers and colleagues (2012) 
have taken this approach in designing a decision aid tool, which provides evidence-
based information about several treatment options (no change, lifestyle 
modifications, or insulin therapy) and aims to help adults with non-insulin-treated 
using T2D to make an informed decision about their treatment. The decision aid 
takes a “balanced approach”, highlighting both positive and negative aspects of 
insulin therapy and other treatment options (Ng, Mathers, Bradley, & Colwell, 2014). 
The decision aid was designed for completion by the person with T2D prior to 
consulting with the HCP, followed by in-practice discussion within usual 
consultation time constraints. Therefore, this type of tool may be more acceptable to 
HCPs employing the intervention and people with T2D experiencing PIR. The 
decision aid has shown encouraging results in reducing decisional conflict and 
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improving insulin knowledge and expectations, but did not demonstrate change in 
willingness to begin insulin therapy following the intervention (Mathers et al., 2012). 
This may be due to the decision aid’s focus, mainly on the practical aspects of insulin 
therapy, such as pain, weight gain, hypoglycaemia and risk of complications. 
Chapters 4-6 of this thesis highlight other salient negative attitudes towards insulin 
therapy among those with non-insulin-treated T2D, for example, those referring to 
the symbolism of insulin (‘insulin means I have failed…’) and inter-personal impact 
(‘insulin causes family and friends to be more concerned about me’). However, as 
insulin appraisals were not evaluated in the decision aid trial it is not possible to 
ascertain whether there was change in negative and positive insulin appraisals after 
completing the decision aid. 
Each of the above-mentioned interventions were developed for use at the point 
of treatment intensification being required. Thus, interventions to reduce negative 
attitudes, and improve receptiveness, to insulin therapy have been designed typically 
to be reactive in nature. However, attitudes towards treatment progression may 
develop from diagnosis onwards (or may be formed pre-diagnosis). Indeed, the 
findings of this thesis indicate that insulin appraisals are not associated with diabetes 
duration among Australians with non-insulin-treated T2D (Chapters 5 and 6). Insulin 
initiation recommendations have highlighted the need for proactive within-care 
discussion of insulin therapy from diagnosis to increase awareness and acceptance of 
insulin therapy as a potential treatment option (Meneghini et al., 2010).  
Attitudes towards insulin therapy are associated with other diabetes-specific 
psychosocial processes and outcomes. For example, in Chapter 5, it was identified 
that those with more negative attitudes toward insulin therapy also reported more 
negative beliefs, or ‘concerns’, about their current diabetes medications (OHAs) and 
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greater diabetes-related distress. Furthermore, diabetes-related distress and beliefs 
about medications have previously been shown to be associated with diabetes 
medication-taking behaviours (Aikens, 2012; Aikens & Piette, 2009), and diabetes-
related distress is prospectively and positively associated with HbA1c (Fisher et al., 
2010). Thus, proactively identifying and addressing negative beliefs about current 
diabetes medications and diabetes-related distress from an early point in the person’s 
journey with diabetes may help to improve their receptiveness to further treatment 
intensification, as well as current medication-taking behaviours, which, in turn, is 
likely to improve glycaemic outcomes (Aikens & Piette, 2013).  
Recommendations for tackling PIR also highlight the need to reframe the need 
for insulin therapy through clarifying any inaccurate illness perceptions and 
misconceptions (e.g. Clark, 2007; Polonsky, 2007; Polonsky & Jackson, 2004; Reid, 
2007). For example, the belief that ‘insulin means I have failed’ may be a 
consequence of a broader belief that the they themselves are to blame, or at fault, for 
their diagnosis and/or their subsequent inability to maintain optimal blood glucose 
levels (Beverly et al., 2012; Broom & Whittaker, 2004; Browne, Ventura, Mosely, & 
Speight, 2013; Krall et al., 2014). Although not assessed in the current thesis, this 
suggests that attitudes towards insulin therapy may be, in part, a consequence of 
broader illness perceptions. Education received at diagnosis of diabetes, and 
reinforced thereafter, may play an important role in the development of illness 
perceptions and, consequently, medication beliefs and receptiveness to treatment 
progression. Indeed, illness perceptions have been found to be tenacious. A three-
year follow up of the ‘DESMOND’ structured T2D education program delivered at 
diagnosis revealed benefits of the intervention were maintained in terms of illness 
perceptions but not in terms of bio-medical outcomes (Khunti et al., 2012). It would 
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be useful to examine attitudes towards current and future medications among the 
DESMOND participants (intervention versus control) to understand whether an 
intervention to improve diabetes education and illness perceptions at diagnosis may 
be effective, over the long-term, at minimising negative attitudes towards insulin 
therapy and improving receptiveness to treatment intensification.   
The experience of hyperglycaemia, diabetes-related complications, and 
“engagement in disease progression” have been identified as facilitators of insulin 
receptiveness in qualitative research (Bogatean & Hâncu, 2004; Chin, Polonsky, 
Thomas, & Nerney, 2000; Jenkins et al., 2010; Phillips, 2007b). In addition, higher 
HbA1c is associated with insulin uptake in quantitative research (Odawara et al., 
2016; Xiong et al., 2014). Thus, education provision to improve recognition and 
understanding of prolonged hyperglycaemia may be an avenue for future 
intervention development. Indeed, undertaking SMBG was reportedly associated 
with greater belief in the efficacy of insulin therapy in the DAWN study (Peyrot et 
al., 2005). Corroborating prior research, HbA1c was found to be an independent 
predictor of actual insulin use at 12 months among Stepping Up participants (Chapter 
7). However, this finding should be interpreted with caution. A probable explanation 
for the association between baseline HbA1c and 12-month insulin use is that the 
likelihood of insulin prescription by HCPs increased as the perceived clinical need 
for insulin rose, regardless of study arm allocation. This is consistent with prior 
research that some HCPs prefer to delay insulin initiation until absolutely necessary 
(Peyrot et al., 2005). Neither baseline HbA1c, nor SMBG (at least once a day versus 
less than once per day), was found to be associated with willingness to begin insulin 
therapy among Stepping Up participants (Chapter 6), suggesting that engagement 
with disease progression was not a facilitator of receptiveness to insulin for people 
     293 
with T2D. However, HCP-led discussion of out-of-target HbA1c (which occurred as 
a result of the intervention, or at the request of control clinics to undertake a clinical 
review of participants) may, in itself, have acted as an intervention to improve 
receptiveness to insulin therapy. Intention to begin insulin therapy was measured 
prior to this initial consultation. Therefore, the association between HbA1c and 
insulin uptake is unclear. Future research needs to examine whether an educational 
intervention to improve understanding of diabetes progression and, in particular, 
recognition and understanding of hyperglycaemia is associated with improved 
receptiveness to treatment intensification. The use of a ‘structured’ approach to 
SMBG has been shown to increase insulin uptake and reduce HbA1c compared to 
usual SMBG (Polonsky, Fisher, et al., 2011). A qualitative investigation would be of 
interest to examine how the structured approach to SMBG affects understanding and 
visibility of diabetes progression, and attitudes towards treatment intensification.  
This thesis aimed to investigate factors associated with attitudes towards 
insulin and the relationship between insulin appraisals and intention to commence, or 
actual uptake of, insulin therapy among people with T2D. However, other factors, 
not investigated within this thesis, may also be relevant in the predicting intention or 
actual behaviour change. For example, according to the theory of planned behaviour, 
normative beliefs may add to the prediction of intention, or willingness, to begin 
insulin therapy (Ajzen, 1991) and it has been proposed that the most important 
determinant of intention to initiate insulin is the ‘subjective norm’ (Wolffenbuttel, 
Drossaert, & Visser, 1993). Indeed, qualitative literature (discussed in Chapter 2) has 
identified the role of others, including HCPs, family, friends and peers, in facilitating 
either PIR or receptiveness. Furthermore, HCPs may play a role in boosting diabetes-
specific self-efficacy and improving experience of insulin therapy at the time of, and 
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beyond, insulin initiation (discussed in Section 10.2.3). However, none of the studies 
included in this thesis specifically examined the role of the others (HCPs, family, 
friends or peers) in the development of insulin appraisals, intention to begin insulin 
therapy, or actual insulin uptake. Thus, future research is needed to quantitatively 
examine the association between these variables.   
A small number of longitudinal studies have reported change in insulin 
appraisals post insulin initiation, suggesting that uptake may be an effective 
intervention to reduce PIR in and of itself (Hermanns et al., 2010; Liebl et al., 2013; 
Odawara et al., 2016). Corroborating those findings, the results from this thesis 
showed that negative insulin appraisals were endorsed by significantly fewer adults 
with insulin-treated compared to non-insulin-treated T2D (Chapter 4), and significant 
reductions in negative insulin appraisals following insulin uptake (Chapter 7). 
Furthermore, in the qualitative study reported in Chapter 9, people with T2D 
reported their relief after injecting insulin for the first time, observed improvements 
in their blood glucose levels, and felt more satisfied that they were doing everything 
they could to manage their diabetes. Therefore, one way to improve attitudes towards 
insulin therapy may be an ‘insulin trial’, as previously suggested by Polonsky and 
Jackson (2004). This involves the individual trying an insulin injection in the safety 
of the clinic, or using insulin at home for a defined short-term period. This approach 
is clearly limited by the fact that the person with T2D must be willing to trial/use 
insulin therapy, which as evidenced by prior research (Polonsky, Hajos, et al., 2011) 
and in the current thesis, is not always the case. Thus, it is likely that various 
approaches are needed to reduce PIR and improve receptiveness to insulin therapy, 
as a ‘one size fit all’ approach will not work.  
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10.2.3. Psychological insulin resistance beyond insulin uptake  
Experience of insulin therapy alone does not result in universal mitigation of 
negative attitudes, and negative experiences/consequences of actual insulin therapy 
may contribute to negative attitudes. The results presented in Chapter 8 highlight that 
negative insulin appraisals are reported among people with insulin-treated T2D, with 
only 10% not endorsing any negative aspect of insulin therapy. While ‘insulin 
causing weight gain’ was the only ITAS Negative item to be endorsed by 
significantly more insulin-treated participants than non-insulin-treated participants, 
symbolic and social consequences of insulin use were also commonly endorsed 
among those using insulin therapy (Chapter 4). Likewise, the in-depth qualitative 
interview study (Chapter 9) identified negative consequences of insulin therapy use 
in terms of perceptions of personal control, emotional well-being, lifestyle flexibility 
and others' (family, friends, general public) negative reactions, in addition to the 
physical impact of insulin therapy. Thus, despite insulin initiation, or experience, 
being associated with a reduction in negative insulin appraisals overall (Chapter 7), 
negative attitudes to insulin therapy may be salient for some people with T2D using 
insulin. However, to the PhD candidate’s knowledge, no intervention has been 
developed to date to reduce PIR among those with insulin-treated T2D. 
This thesis (Chapter 8) demonstrated that negative attitudes towards insulin 
therapy are not associated with duration or intensity of insulin therapy, suggesting 
that additional familiarisation with, or experience of, insulin injections does not 
necessarily reduce negative attitudes towards insulin therapy or barriers to insulin 
intensification beyond initiation. Longitudinal research is needed to confirm this 
finding. In addition, negative attitudes towards insulin therapy (i.e. relating to 
inconvenience and perceived seriousness of using fast-acting insulin therapy) may be 
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barriers to insulin intensification among those using insulin therapy (Chapter 9) and, 
elsewhere, negative consequences of insulin therapy have been identified as barriers 
to self-titration (McBain, Begum, Rahman, & Mulligan, 2016). It is, therefore, 
important to consider the impact of negative attitudes toward, and experiences of, 
insulin therapy at all stages of care (i.e. prior to and after insulin initiation).  
In addition to the actual physical experience of insulin administration and its 
consequences (e.g. reduction in blood glucose levels, reactions of others), it may be 
that education and support received from HCPs at the time of, and immediately 
following insulin initiation, partially accounts for the observed reduction in negative 
insulin appraisals after insulin initiation. Thus, enhanced education and support from 
HCPs may result in less negative insulin appraisals after insulin initiation. Prior 
research has demonstrated associations between insulin uptake and information 
provision from HCPs being perceived as adequate (Karter et al., 2010), and between 
patient-provider relationship/interactions and PIR, measured using the BIT 
questionnaire (Nam, Chesla, Stotts, Kroon, & Janson, 2010). The perceived patient-
provider relationship, and its association with PIR, was not the focus of the current 
thesis. However, Study 2b (Chapter 7) examined the association of the model of care 
received (i.e. study arm allocation) on change in insulin appraisals among Stepping 
Up participants. The Stepping Up model of care was found to have no relative 
advantage in improving insulin appraisals over and above insulin uptake (experience) 
alone. This might be due to HCPs in the intervention arm providing limited 
additional support at the time of insulin initiation over and above HCPs who 
prescribed and initiated insulin therapy within usual care. Indeed, the main focus of 
the Stepping Up HCP training and specialist support was to reduce the primary care 
team’s clinical inertia, not necessarily to reduce PIR among patients. HCPs did not 
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receive comprehensive training in identifying and addressing concerns about insulin 
therapy (either before or after insulin uptake). It would be worthwhile to assess 
whether provision of comprehensive training in identifying and addressing barriers to 
insulin therapy for HCPs would be associated with a) improved insulin uptake, and 
b) further reductions in negative insulin appraisals among those who initiate insulin 
therapy, compared to the original Stepping Up model and usual care.  
Nam et al. (2010) previously identified diabetes-specific self-efficacy as a 
mediator of the relationship between patient-provider relationship/interactions and 
PIR. Among Diabetes MILES – Australia participants with T2D already using 
insulin therapy, those with more negative insulin appraisals also reported lower 
diabetes self-efficacy (Chapter 8). Support and education received from the HCPs at 
the time of, and beyond, insulin initiation may help to reduce the negative 
experiences of insulin use through boosting diabetes self-efficacy. For example, 
those with insulin-treated T2D reporting more negative insulin appraisals, and lower 
diabetes self-efficacy, commonly endorsed that injecting insulin is painful, requires a 
lot of time and energy, and is difficult (Chapter 8). These types of negative 
experiences of insulin therapy or low insulin-related self-efficacy may suggest the 
need to trial a different insulin device or regimen, and/or review the person’s insulin 
administration technique. The association between diabetes self-efficacy and PIR 
may also relate to the perceived effectiveness of insulin therapy (Hayes et al., 2013). 
As discussed in Chapter 8, people with T2D whose blood glucose levels remain 
suboptimal despite using insulin therapy, or those experiencing hypoglycaemic 
episodes as a result of insulin therapy, may consequently feel that they are unable to 
manage their diabetes effectively (i.e. low diabetes self-efficacy). This highlights the 
need for timely titration or intensification of insulin therapy by the HCP. However, 
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large-scale cohort studies suggest that titration/intensification of insulin therapy, like 
insulin initiation, is also commonly delayed (Fulcher, Roberts, Sinha, & Proietto, 
2015; Grant, Buse, & Meigs, 2005; Khunti et al., 2016; Polinski et al., 2014).  
Consistent with clinical guidelines for the management of T2D, which 
advocate for person-centred care (Inzucchi et al., 2012; The Royal Australian 
College of General Practitioners and Diabetes Australia, 2014), identifying and 
addressing negative insulin appraisals or barriers to optimal insulin use should 
recognise the needs, concerns and context of the individual with T2D, providing an 
appropriate level of training, support and problem solving. For example, life stage 
and lifestyle may be related to barriers to optimal insulin use. Diabetes MILES – 
Australia participants with insulin-treated T2D who reported more negative attitudes 
to insulin therapy were typically younger and in paid employment, compared to 
those with less negative insulin appraisals, and the majority of the subgroup agreed 
that insulin made life less flexible (Chapter 8). Elsewhere, young adults (aged 18-39 
years) with T2D have reported time constraints as a major barrier to optimal self-care 
(Browne, Scibilia, & Speight, 2013), and are significantly less likely to take their 
insulin injections as recommended compared to older adults with T2D (Browne, 
Nefs, Pouwer, & Speight, 2015). Furthermore, in another sub-analysis of Diabetes 
MILES – Australia participants with T2D, being employed was significantly 
associated with sub-optimal self-care (O'Neil et al., 2014). Younger people with 
insulin-treated T2D may have additional competing demands on their time, which 
need to be anticipated and acknowledged by clinicians.  
Emotional wellbeing should also be considered. For example, Australians with 
T2D already using insulin therapy and reporting more negative insulin appraisals 
were almost twice as likely to report moderate-to-severe depressive and/or anxiety 
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symptoms, than those reporting less negative appraisals (Chapter 8). Elsewhere, the 
presence of depressive symptoms has been shown to be associated with requiring 
significantly more time, and visits, with HCPs to receive insulin administration 
training, compared to those without depressive symptoms (Dzida, Karnieli, 
Svendsen, Sølje, & Hermanns, 2015). Depressive symptoms are also associated with 
suboptimal medication-taking, including insulin omission among adults with T2D 
(Mashitani et al., 2015), and this relationship has been shown to be mediated by 
diabetes self-efficacy and diabetes-specific social support (including support 
received from HCPs) (Tovar, Rayens, Gokun, & Clark, 2015). Therefore, people 
with insulin-treated T2D who have concurrent depressive symptoms may require 
additional support and education from HCPs in order to bolster diabetes self-
efficacy, reduce negative insulin appraisals, and consequently reduce the likelihood 
of insulin omission. 
Quantitative research examining reasons for insulin omission has highlighted 
the role of negative insulin experiences and attitudes among adults with insulin-
treated T2D (Davies et al., 2013; Farsaei, Radfar, Heydari, Abbasi, & Qorbani, 2014; 
Peyrot, Barnett, Meneghini, & Schumm-Draeger, 2012b; Peyrot, Rubin, Kruger, & 
Travis, 2010). In the current thesis, suboptimal insulin-taking behaviour (i.e. insulin 
omission) was not associated with PIR (Chapter 8). However, these findings are 
limited in that an unvalidated single-item measure of insulin-taking behaviours was 
used to quantify insulin-taking behaviours. Future research needs to explore the 
association between PIR and insulin omission using a more sensitive measure. For 
example, the MARS (used in the Stepping Up study), has been previously used in 
diabetes research (Barnes, Moss-Morris, & Kaufusi, 2004). The instructions 
normalise sub-optimal medication-taking behaviours in order to promote honest, 
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rather than socially desirable, responses. Another option is the recently published 
Morisky Insulin Adherence Scale, a validated measure designed specifically to 
assess insulin-taking behaviours among people with diabetes (Osborn & Gonzalez, 
2016). 
In addition to support from HCPs within usual care, people with T2D may 
benefit from insulin-specific structured education. The Global Guideline For Type 2 
Diabetes (International Diabetes Federation, 2012) recommends that structured 
diabetes self-management education is an integral part of care from diagnosis and 
ongoing. However, the Diabetes MILES – Australia survey demonstrated that less 
than half of Australians with type 1 diabetes or T2D have received structured 
education, and the majority of those were offered education only at the time of 
diagnosis (Speight et al., 2011). In the Stepping Up study, the median diabetes 
duration of participants who initiated insulin was nine years and, thus, structured 
education received at baseline is unlikely to remain effective at the time of insulin 
uptake. Furthermore, initial structured diabetes education may not comprehensively 
cover insulin therapy use (e.g. insulin types, administration techniques, self-titration), 
let alone the psychosocial barriers to insulin initiation or intensification discussed in 
this thesis. However, such programs may be expanded to include treatment-specific 
modules. For example, the structured T2D self-management education program, 
DESMOND (Davies et al., 2008), was recently expanded to include the Injectable 
Therapy Toolkit, which includes core and topic-specific education sessions on 
insulin therapy. However, its effectiveness has not yet been published. Existing 
structured education programs that focus on insulin therapy have been developed to 
provide training in the skills needed for flexible, intensive insulin therapy, and are 
generally restricted to those with type 1 diabetes (i.e. Dose Adjustment For Normal 
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Eating program (DAFNE) (DAFNE Study Group, 2002)). However, the 4-day 
Newcastle Empowerment program, which combines the principles of DAFNE 
(flexible insulin management to enable dietary freedom) with an empowerment 
approach, is available to people with type 1 diabetes and those with insulin-treated 
T2D who are willing to engage in an intensive basal bolus insulin regimen (Lowe, 
Linjawi, Mensch, James, & Attia, 2008). Flexible insulin therapy structured 
education programs have demonstrated improvements at follow up in diabetes 
knowledge and diabetes self-efficacy (Lowe et al., 2008) as well as diabetes-related 
distress and general emotional wellbeing (Hopkins et al., 2012; Speight et al., 2016). 
However, this type of program may not be appropriate for those with T2D using 
‘simple’ insulin therapy regimens recommended for first-step insulin initiation (i.e. 
once-daily basal or pre-mixed insulin injections) (The Royal Australian College of 
General Practitioners and Diabetes Australia, 2014). This suggests an existing gap in 
the availability of structured education for those with T2D using insulin. 
Furthermore, no structured education program for people with T2D has assessed the 
impact of the intervention on attitudes towards insulin therapy (i.e. PIR).  
10.3. Limitations of the Research  
The specific limitations of each of the six empirical research studies included 
in this thesis are described in Chapters 4-9. In addition, broad limitations of the 
Diabetes MILES – Australia study are published elsewhere (Speight, Browne, 
Holmes-Truscott, Hendrieckx, & Pouwer, 2012). The following section summarises 
limitations across the thesis as a whole, with reference to the design, the measures 
used, and the sample representativeness of each study (1: Diabetes MILES – 
Australia, 2: Stepping Up Study, 3: Qualitative Interview Study). 
  
     302 
10.3.1. Study design 
One objective of this thesis was to examine attitudes towards insulin therapy 
held by Australians with T2D longitudinally, and how attitudes differ by insulin use. 
Data collected from the Diabetes MILES – Australia 2011 national cross-sectional 
survey were used to compare insulin appraisals among adults with insulin-treated 
and non-insulin-treated T2D. A longitudinal follow-up survey of this national 
sample, allowing for the assessment of change in insulin appraisals over time, and 
treatment, would have been ideal. However, due to the small proportion of people 
with T2D initiating insulin at any given time-point and the potential loss to follow-
up, it was not possible to guarantee in advance a sufficiently sized longitudinal 
sample who would initiate insulin within the require time period. This is supported 
by unpublished insights from the recently conducted (2015) second Diabetes MILES 
– Australia survey. In total, longitudinal data were collected from 168 participants 
with T2D who reported not using insulin therapy in 2011, of whom 16 reported now 
using insulin therapy. Thus, a prospective, observational, population-level study of 
change in insulin appraisals over time was not possible within this PhD.  
The Stepping Up Study provided the opportunity to investigate change in 
insulin appraisals over time and after insulin initiation, with participants with T2D 
completing psychosocial survey booklets, including the ITAS, at baseline and 12-
month follow-up (Furler et al., 2014). However, participants may have initiated 
insulin at any point within the 12-month trial period. Significant change in negative 
insulin appraisals was demonstrated among those who initiated insulin. However, it 
is unclear when the change in insulin appraisals occurred and whether it preceded 
insulin initiation or followed experience with insulin. This is because the study 
design did not allow for repeated measurement of insulin appraisals, or any other 
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psychosocial measures, throughout the follow-up period or even at the time of, or 
immediately after, insulin initiation. Such additional measurement would have 
increased participant burden and potentially increased attrition rates and, arguably, 
would have been an intervention in itself.  
Study 3 provided opportunity for qualitative investigation of the impact of 
insulin therapy among those already using insulin. Instead of recruiting a separate 
sample, it may have been preferable to conduct a mixed-methods study, through the 
inclusion of qualitative interviews in the Diabetes MILES – Australia or Stepping Up 
studies. This may have reduced the recruitment period as well as enabling purposive 
sampling of participants with more and less negative insulin appraisals. However, 
this was not possible for the following reasons. First, Diabetes MILES – Australia 
participants had provided consent to participate in future research, but this was 
limited to a) completion of another similar survey in 4 or 5 years, and/or b) an 
interview or focus group within the next year. Study 3 was conducted in 2013-14, 
outside of the ethically approved time period for which consent to be contacted for 
an interview study was provided. The Stepping Up sample was also deemed 
unsuitable for the qualitative study. Interviews would need to have been conducted at 
the conclusion of the trial in order to capture those who had initiated, and 
‘experienced’, insulin therapy, as well as avoiding contamination of the results of the 
RCT. The trial concluded in April 2015 and did not fit within the timeline of this 
PhD. Furthermore, the experience of insulin use among Stepping Up intervention 
participants may differ considerably from the experience of the general population of 
adults with T2D in primary care, and the control arm included only a small pool of 
participants. Therefore, the decision was made to recruit a separate sample to 
qualitatively explore the impact of insulin therapy use among people with T2D.  
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10.3.2. Representativeness and generalisability of the samples 
A key limitation of this thesis concerns the representativeness, and therefore 
generalisability, of the study samples. The recruitment methods and actual response 
rates suggest the study samples are skewed towards more empowered participants, 
which may not represent the general Australian population with T2D. With regard to 
Diabetes MILES – Australia (Study 1), the majority of participants were recruited 
through invitations sent to a random sample of 15,000 NDSS registrants who had 
previously consented to being contacted about research opportunities (Speight et al., 
2012). Approximately half of the one million NDSS registrants with T2D (National 
Diabetes Services Scheme, 2016) have indicated consent to be contacted about 
research participation opportunities. However, it is estimated that one in five 
Australians with T2D are undiagnosed and therefore not registered with the NDSS 
(Australian Bureau of Statistics, 2013). Furthermore, the response rate for this large-
scale mail-out was just 18%. Online survey participation was also made available 
nationally to eligible Australians regardless of the NDSS registration, and attracted 
~1000 participants. However, the study was advertised only through relevant 
diabetes media, including the NDSS and Diabetes Australia (national and state-
based) websites, and a range of diabetes or health specific newsletter/e-newsletters, 
and therefore may not have been seen by individuals who do not regularly review or 
subscribe to such sites. This limitation applies also to Study 3, which similarly 
recruited participants through advertisements placed on websites, social media and e-
newsletters of Diabetes Victoria and the Australian Centre for Behavioural Research 
in Diabetes. 
It has been suggested that adults with T2D with negative insulin appraisals 
may be hesitant to participate in studies about insulin therapy due to concern that 
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they may subsequently have to use insulin (Patel, Stone, Hadjiconstantinou, et al., 
2015). In the Stepping Up study, an invitation letter was sent to 521 potentially 
eligible adults with T2D, which stated that the aim of the study was to make sure that 
patients get the best available treatment which “may involve different or additional 
medicines or even starting insulin”. It may be that the 19% who did not respond to 
the study invitation (Furler et al., 2015) were more likely to report PIR or be less 
engaged in their health in general. Indeed, those who did participate displayed, on 
average, lower rates of diabetes-specific distress and depressive symptoms, and 
lower ITAS Negative scores at baseline (Chapter 6) compared with the Diabetes 
MILES – Australia 2011 sample (Chapter 4). Therefore, while the Stepping Up trial 
identified all eligible adults with T2D in the primary care practices for whom insulin 
was clinically indicated, it may under-represent those who are hypothetically 
unwilling to begin insulin therapy, and consequently the proportion of people with 
T2D who might refuse insulin therapy.  
Finally, it is important to note the lack of cultural and linguistic diversity in the 
studies presented in this thesis. Given the nature of the sample, it is not possible to 
comment on the specific barriers to the insulin initiation and ongoing use faced by 
people from specific culturally and linguistically diverse backgrounds within 
Australia. All three studies required participants to be able to communicate in 
English. There was no funding to support the translation of study materials (i.e. 
survey booklets) or to provide translators for interactions with participants with T2D 
(i.e. Stepping Up consultations, qualitative interviews). While a small proportion of 
participants in Diabetes MILES – Australia (3%) and the Stepping Up (6%) studies 
reported a primary language other than English, this is considerably lower than the 
19% of Australians who speak a language other than English at home (Australian 
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Bureau of Statistics, 2012). While linguistically concentrated among English-
speaking participants, between 28% and 38% participants with T2D in the three 
studies included in this thesis report being born overseas, which is representative of 
the broader Australian population (Australian Bureau of Statistics, 2012). The rate of 
insulin-treated T2D is three times as higher among Indigenous Australians (i.e. of 
Aboriginal or Torres Strait islander descent) compared to non-indigenous Australians 
(Australian Institute of Health and Welfare, 2016). However, this group were under-
represented in all three studies. As the study of PIR and receptiveness among 
Indigenous Australians was not the primary aim of this thesis, the included studies 
were not designed to capture issues of particular relevance to, or follow best practice 
principle for conducting research among (Jamieson et al., 2012), this community and 
therefore, Indigenous Australians were not recruited actively.  
10.3.3. Measurement issues  
The ITAS is the principal measure of insulin appraisals used within this thesis. 
The psychometric validation of the scale using national survey data (Study 1) 
confirmed that the measure was psychometrically robust and acceptable among 
Australian adults with T2D, although slightly less so for those not using insulin 
therapy (Chapter 4). However, the scale was developed for use in the USA and the 
exploratory work underpinning its development is not described in detail (Snoek et 
al., 2007). The scale has not undergone cognitive debriefing among its target 
population within Australia, beyond the general debriefing of the full Diabetes 
MILES – Australia questionnaire prior to the national survey (Speight et al., 2012). 
In the qualitative study with people using insulin, the negative and positive aspects of 
insulin use were explored beyond those included in the ITAS (Study 3). However, 
this thesis did not explore qualitatively whether the ITAS adequately identifies all 
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positive and negative aspects of insulin use among Australians with non-insulin-
treated T2D.  
Studies 1b and 1c (Chapters 5 and 8) both explored the association between 
insulin appraisals and diabetes-related distress in insulin-treated and non-insulin 
treated samples. However, different measures of diabetes-related distress were used 
in each study, and therefore the associations between diabetes-related distress and 
insulin appraisals are not comparable across treatment groups. Specifically, the DDS 
was completed by participants with the non-insulin-treated T2D, while the PAID was 
completed by insulin-treated participants. The reason for this is that two different 
diabetes-related distress measures, DDS and PAID, were included in alternate 
versions of the Diabetes MILES – Australia survey, with the broader aim to conduct 
a psychometric comparison of the established PAID with the novel DDS (reported 
elsewhere (Fenwick et al., 2016)). Appendix C (Methods) provides a detailed 
description of the measures included in each survey version.  
Investigation of PIR was not the primary aim of the Diabetes MILES – 
Australia study, and the single item assessing hypothetical willingness to begin 
insulin was not included in the survey. Its inclusion in the survey would have 
characterised receptiveness to insulin therapy nationally and perhaps enabled a more 
concise exploration of the predictors of, and the association between, insulin 
appraisals and receptiveness within a single sample. Furthermore, it would have been 
useful to understand how those with non-insulin-treated T2D who skipped the ITAS 
questionnaire responded to the willingness item. It was hypothesised (in Chapter 4) 
that those who skipped the ITAS questionnaire completely did so because they 
thought it was irrelevant to them. Thus, it would be interesting to understand whether 
this group were more likely to also skip the willingness item or respond to it more 
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negatively (e.g. ‘not all willing’ to begin insulin therapy) in comparison to the rest of 
the non-insulin-treated sample, perhaps due to the perception of insulin as an 
inappropriate treatment option for them at this time. Finally, the inclusion of 
hypothetical willingness would have enabled the opportunity to examine 
receptiveness by treatment type among adults with non-insulin-treated T2D: lifestyle 
modifications only compared to those using OHAs. However, a key limitation of the 
Diabetes MILES – Australia data is the absence of objective clinical data (e.g. 
HbA1c, prescribed treatment doses), and therefore any sub-analysis by treatment 
type would be unable to differentiate between those using entry level versus 
maximum dose OHAs or identify those who would benefit clinically from insulin 
initiation, as was possible in Stepping Up (Study 2).  
Study 1b and 1c findings, regarding the correlates of negative insulin 
appraisals, could not necessarily be followed up in the Stepping Up study. For 
example, beliefs about current diabetes medications were found to be predictive of 
insulin appraisals in Study 1b (Chapter 5), but were not assessed in the Stepping Up 
study. Therefore, we cannot determine whether current medication beliefs were 
predictive of insulin receptiveness or actual insulin uptake. The reasons for this were, 
first, the assessment of PIR and known correlates was of secondary importance in the 
trial and reducing participant burden was a study priority. Second, Stepping Up 
practices were recruited from October 2012 (Furler et al., 2014) and, therefore, the 
questionnaires included in the patient participant survey booklets were confirmed 
prior to completing the sub-analysis of correlates of negative insulin appraisals 
discussed in Studies 1b and 1c.  
Study 3 offered the opportunity to undertake a qualitative exploration of 
attitudes towards insulin use and intensification among those already using insulin 
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therapy. Participants were asked how many injections they were currently taking, 
followed by enquiry about how they thought they would feel if they needed to take 
more injections each day (see Appendix C, Table 2). Participants discussed the 
possibility that additional injections might involve introducing fast-acting insulin 
into their treatment regimen, and the negative consequences of this (Chapter 9). 
However, participants were not specifically asked about the use of fast-acting 
insulins and, therefore, it is difficult to distinguish barriers to intensification 
associated with frequency of injections from type of insulin. Similarly, prior 
quantitative research has investigated attitudes to additional injections without 
exploring the influence of change in insulin type on responses (Martinez et al. 2007; 
Zambanini et al. 1999). Future research is needed to understand the barriers to 
increasing total daily insulin injections versus changing the type of insulin used 
among adults with T2D.  
10.4. Strengths of the Research 
This section summarises the key strengths of this thesis and its contribution to 
the current body of research in the area of PIR and receptiveness to insulin therapy 
among adults with T2D. The general strengths of the Diabetes MILES – Australia 
and Stepping Up studies are reported elsewhere (Furler et al., 2014; Speight et al., 
2012), and strengths specific to each of the six empirical research studies included in 
this thesis are discussed in Chapters 4-9. Broadly, the strengths of this thesis lie in 
the fact that the research questions were addressed using a mixed-methods approach 
(including a large-scale national population-level survey, a fully powered, cluster 
randomised clinical trial in primary care, and a qualitative study in which data 
saturation was achieved), with comprehensive assessment of relevant psychological 
constructs using validated measures. 
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A broad definition of PIR and receptiveness was applied in this thesis, 
including psychological barriers to or enablers of insulin initiation, ongoing insulin 
use and insulin intensification. This definition facilitated a comprehensive program 
of research that investigated PIR and/or receptiveness throughout diabetes 
progression and treatment intensification. The ITAS was chosen to assess insulin 
treatment appraisals in Study 1 and Study 2 as it had been designed for use in non-
insulin-treated and insulin-treated T2D. However, psychometric validation had not 
been conducted separately for each intended user group. In Study 1a (Chapter 4), 
data from the large-scale national survey were used to examine, for the first time, the 
psychometric properties of the ITAS in both insulin-treated and non-insulin treated 
T2D populations, with samples of sufficient size (n=249 and n=499) to enable 
appropriate subgroup analyses.  
The extensive number of validated questionnaires, and study-specific clinical 
and self-care items, assessed in the Diabetes MILES – Australia study allowed for 
comprehensive investigation of factors associated with insulin appraisals among 
adults with non-insulin-treated T2D in Study 1b (Chapter 5). Factors investigated 
included both known correlates of insulin appraisals (i.e. diabetes-related distress 
(Makine et al., 2009)), as well as concepts not previously assessed in relation to PIR 
(i.e. anxiety symptoms, diabetes-related distress subscales), or those not previously 
measured using validated measures (i.e. beliefs about medications). 
It has been suggested that PIR may not be as common as previously 
documented (Jeavons, Hungin, & Cornford, 2006), and that receptiveness may be a 
more common experience when insulin initiation is clinically indicated (Jenkins et 
al., 2010). However, research identifying hypothetical (un)willingness to begin 
insulin therapy has most commonly been undertaken in convenience samples of 
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adults with non-insulin-treated T2D with varying diabetes durations and treatment 
progressions. Thus, the Stepping Up study (Study 2a, Chapter 6) provided important 
and timely insight into rates of receptiveness and PIR, operationalised as 
hypothetical willingness, at a clinically relevant timepoint, as well as a 
comprehensive assessment of the factors associated with receptiveness to insulin 
therapy among this specific clinical cohort. Furthermore, for the first time, the 
predictive validity of the hypothetical willingness single item in determining actual 
insulin uptake among adults with T2D was examined (Study 2b, Chapter 7). The 
Stepping Up study also offered the opportunity to assess insulin appraisals, 
depressive symptoms and diabetes-related distress in the prediction of actual insulin 
uptake in a single prospective study. Previously these relationships have been 
examined separately (Iversen et al., 2015; Keij et al., 2016; Nefs et al., 2013).  
Studies examining insulin omission show negative insulin appraisals among 
those with T2D already using insulin (Peyrot, Barnett, Meneghini, & Schumm-
Draeger, 2012a; Peyrot et al., 2010). However, with the exception of one study 
(Chen et al., 2011), which examined the association between ITAS scores and insulin 
mode and duration, no previous quantitative research had explicitly investigated 
factors associated with negative insulin appraisals among adults with insulin-treated 
T2D. Using data from Diabetes MILES – Australia, Chapter 8 (Study 1c) presented 
the first comprehensive assessment of demographic, clinical, self-care and 
psychological factors associated with negative insulin appraisals among those with 
T2D already using insulin therapy. Extending on this work, the qualitative study 
(Study 3, Chapter 9) provided the opportunity to conduct an in-depth exploration of 
the perceived impact of insulin therapy use among adults with T2D, capturing any 
positive or negative insulin experiences that may not have been captured adequately 
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in the quantitative assessment with the ITAS. Further, Study 3 responded to the call 
for additional research into receptiveness to insulin intensification (Polinski et al., 
2012) and corroborated the findings of the few other qualitative studies undertaken to 
examine receptiveness to, and barriers of, insulin intensification among adults with 
insulin using T2D (Jenkins et al., 2011; Simon, Gude, Holleman, Hoekstra, & Peek, 
2014). 
In addition to contributing to the rapidly growing body of research globally, as 
described above, this thesis has advanced PIR and receptiveness research in 
Australia. Only two published studies had explicitly examined PIR among 
Australians with T2D at the commencement of this thesis: a multi-national survey 
using unvalidated items (Peyrot et al., 2005) and a qualitative investigation of 
barriers and enablers of insulin uptake among adults with T2D within Australian 
primary care (Furler et al., 2011). Thus, little was known about PIR and 
receptiveness within the Australian context. This thesis provides a comprehensive 
understanding of the barriers to insulin initiation, use, and intensification among 
Australians with T2D which may be used to inform strategies and interventions to 
reduce the impact of PIR and encourage receptiveness within the Australian context 
in the future. 
10.5. Conclusion 
The collective findings of this thesis extend significantly on previous 
knowledge of the measurement, experience, and correlates, determinants and 
consequences of PIR and receptiveness among adults with T2D throughout treatment 
progression.  
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The psychometric reliability and validity of the widely-used ITAS was 
confirmed among Australians with insulin-treated and non-insulin-treated T2D 
separately, and the use of the subscale scores were recommended in preference to the 
use of Total scale. The findings suggested that receptiveness to insulin therapy is not 
merely the absence of negative attitudes towards insulin therapy (PIR), but a parallel 
concept, and therefore both concepts need to be assessed. However, the ITAS 
Positive subscale may benefit from future review through the development and 
testing of additional items.  
 This thesis demonstrates the impact of PIR and receptiveness on actual insulin 
uptake: negative and positive attitudes to insulin therapy are associated with 
intention to begin insulin therapy and, in turn, intention was an independent predictor 
of actual insulin uptake. This suggests that interventions or strategies to increase 
timely insulin initiation for T2D should aim to reduce PIR and improve receptiveness 
to insulin initiation. In addition to assessing and addressing PIR at the time of insulin 
initiation, the findings from this thesis suggest that negative attitudes towards insulin 
therapy may develop early in diabetes duration and that concerns about oral diabetes 
medications and diabetes-related distress may contribute to their development. 
Therefore, identifying and addressing negative beliefs about diabetes medications 
and diabetes-related distress early, and in an ongoing manner throughout diabetes 
progression, may help to improve receptiveness to future treatment intensification. 
Future research needs to investigate the impact of interventions and structured 
education to promote appropriate beliefs about diabetes and medications and/or 
reduce diabetes-related distress on attitudes towards treatment progression.    
Finally, the findings of this thesis corroborated previous research that actual 
insulin use is associated with a reduction in negative insulin appraisals but identified 
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the existence of negative insulin appraisals for some Australians using insulin 
therapy, and demonstrated that PIR among those already using insulin is associated 
with impaired emotional wellbeing, diabetes-specific self-efficacy and satisfaction 
with blood glucose. Furthermore, barriers to and enablers of insulin intensification 
were identified. These findings highlight the impact of PIR and receptiveness beyond 
insulin uptake and the need to identify ongoing, or new, concerns about insulin use 
beyond insulin initiation.   
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Appendix C: Methods 
Chapter 3 introduces the three studies from which data is analysed within this 
thesis, and the associated research questions. This appendix presents a detailed 
description of the methods for each study, as they relate to this thesis. Specific 
methods of each empirical paper are described in Chapters 4 to 9.  
1. Diabetes MILES – Australia Study, 2011 
1.1. Background 
Diabetes MILES (Management and Impact for Long-term Empowerment and 
Success) is an international collaborative led by Professor Jane Speight (Deakin 
University, Australia) and Professor Frans Pouwer (Tilburg University, The 
Netherlands). Diabetes MILES explores the psychosocial and behavioural aspects of 
living with diabetes in a series of large-scale, cross-sectional national surveys. The 
first Diabetes MILES survey was undertaken in Australia in 2011(Speight, Browne, 
Holmes-Truscott, Hendrieckx, & Pouwer, 2012), and others have been completed 
since in Australia (Hagger et al., 2016) and overseas (Nefs, Bot, Browne, Speight, & 
Pouwer, 2012).  
1.2. Ethics approval  
The Diabetes MILES – Australia (2011) study received ethics approval from 
the Deakin University Human Research Ethics Committee (ref number: 2011-046). 
1.3. Research design  
Diabetes MILES – Australia (2011) was a national cross-sectional survey of 
adults with type 1 diabetes or T2D, undertaken in July 2011. Detailed descriptions of 
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the study rationale, design, methods, and sample characteristics for the study have 
been published elsewhere, co-authored by this PhD candidate (Speight et al., 2012).  
1.4. Participants 
Eligibility criteria for the Diabetes MILES – Australia study included: living 
with type 1 diabetes or T2D, currently residing in Australia, aged between 18 and 70 
years, and able to complete the survey without help from others. As it was not 
possible for the Diabetes MILES – Australia survey to be made available in other 
languages, participant eligibility included the ability to read and write in English. 
The final eligible sample consisted of 3,338 participants, including 1,962 (59%) 
adults with T2D (age 58.5±8.7 years; 49% women; T2D duration: 9±7 years) 
(Speight et al., 2012; Speight et al., 2011).  
This thesis focused on data collected from those who self-reported a diagnosis 
of T2D and completed questionnaires of specific relevance to this thesis (see below). 
The participant group was further broken down to explore three overarching research 
questions, which are described in Chapter 3. Additional details regarding participant 
eligibility and demographics for each overarching research question are provided 
within the corresponding published manuscript (Chapters 4, 5 and 8). 
1.5. Measures  
A comprehensive list of all the measures included in the Diabetes MILES – 
Australia 2011 survey has been published (Speight et al., 2012).The primary 
questionnaire of relevance to this thesis is the Insulin Treatment Appraisal Scale 
(ITAS) (Snoek, Skovlund, & Pouwer, 2007), and several others are of secondary 
interest. These are described below. 
     369 
1.5.1. Attitudes towards insulin 
The ITAS (Snoek et al., 2007) was developed and validated in the US for use 
with people with T2D regardless of treatment type, enabling assessment of insulin 
appraisals both before and after insulin initiation. For people with T2D not yet using 
insulin therapy, the ITAS is used to explore participants’ beliefs and expectations 
regarding future insulin therapy use. For those already using insulin, the ITAS 
assesses the participants’ experience of insulin therapy.  
The ITAS includes 20 items, which were generated through literature searches 
and informed by diabetes healthcare providers (Snoek et al., 2007). Respondents are 
asked to indicate their level of agreement with each statement on a five-point scale 
from ‘strongly disagree’ to ‘strongly agree’ (scores ranging from 1 to 5). The ITAS 
was conceptualised as two-dimensional, including a negative insulin treatment 
appraisal score (scored as the sum of 16 items) and a positive insulin treatment 
appraisal score (the sum of four items). Higher scores indicate more negative or 
positive insulin appraisals respectively. In addition, a single underlying construct 
(appraisal of insulin therapy) is computed by summing all 20 items after reverse 
scoring the positive items. Higher scores indicate more negative insulin appraisals 
overall.  
The developers of the ITAS (Snoek et al., 2007) report that the scale has sound 
psychometric properties overall. Exploratory factor analysis supports a two-factor 
structure and good internal consistency reliability is demonstrated (Cronbach’s 
α=0.89, 0.90, 0.68 for the Total, Negative and Positive scales respectively), 
indicating homogeneity of the items within the total and subscales. Concurrent 
validity was also assessed, with low to moderate associations in the expected 
direction found between the ITAS Total score and measures of diabetes-related 
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distress (PAID scale: r=0.35) and general wellbeing (WHO-5 scale: r=-0.14). The 
ITAS has demonstrated sensitivity to change following insulin initiation (Hermanns, 
Mahr, Kulzer, Skovlund, & Haak, 2010). The psychometric properties of the ITAS in 
the current Australian sample were investigated as part of this thesis, and are 
reported in Chapter 4.  
1.5.2. Beliefs about oral medications  
For participants not using insulin, beliefs about current medications were 
assessed using the Beliefs about Medications Questionnaire (BMQ) General and 
Specific (Horne, Weinman, & Hankins, 1999). The BMQ Specific (11 items) 
includes two subscales representing the perceived ‘necessity’ (five items) of 
condition-specific medications in maintaining health, and ‘concerns’ (six items) 
associated with having to take those medications in the long term. The BMQ Specific 
items are tailored to the respondent group, in Diabetes MILES – Australia survey the 
questions referred to “your diabetes medicines”. The BMQ General (8 items) 
includes subscales addressing perceived ‘harm’ (four items) and ‘overuse’ (four 
items) of prescription medications in general.  
All items are rated on a 5-point Likert scale from ‘strongly disagree’ to 
‘strongly agree’ (scores ranging from 1 to 5). Subscale scores are calculated by 
summing item scores and dividing by the number of items. Higher scores indicate 
stronger beliefs in the subscale concept.  For the BMQ Specific, a necessity-concerns 
differential score can be obtained by subtracting the ‘concerns’ score from the 
‘necessity’ score, enabling assessment of whether concerns outweigh beliefs in the 
necessity of taking the medications (Horne & Weinman, 1999). 
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BMQ items were formulated through literature searches and interviews with 
people living with, and taking medications for, a chronic illness. The questionnaires 
were validated in a multi-condition sample, including a subsample (n=99) of adults 
living with diabetes (Horne et al., 1999). Each of the subscales in the General and 
Specific questionnaires were shown to have good internal consistency (ranging from 
α=0.66-0.80).  
In the current sample of Australian adults with non-insulin-treated T2D, the 
BMQ Specific subscales had satisfactory internal consistency reliability (‘necessity’ 
α=0.85; ‘concern’ α=0.83). Previously, an equally balanced (4-items per subscale) 
two factor structure was recommended for the BMQ General (Horne et al., 1999). 
However, Horne has since suggested (personal communication) that item four 
(“natural remedies are safer than medicines”) may perform better in the ‘harm’ 
subscale than the originally proposed ‘overuse’ subscale. To investigate scale 
structure, a forced two-factor solution with direct oblimin rotation exploratory factor 
analysis was conducted (Costello & Osborne, 2005). Consistent with Horne’s 
recommendation, the two-factor structure accounted for 64.5% of the total variance 
and, after rotation, a 3-item ‘overuse’ and five-item ‘harm’ scale was apparent, with 
all items loading >0.4 and no double loadings >0.3. Further, the three-item ‘overuse’ 
and 5-item ‘harm’ subscales produced better Cronbach’s alpha values (both α=0.82) 
in comparison to the two four–item subscales (α=0.80 and α=0.78, respectively). As 
such, the current study utilises the modified BMQ General subscale structure.  
1.5.3. Diabetes-related distress  
At the time of undertaking Diabetes MILES – Australia 2011, two measures of 
diabetes-related distress, or the emotional distress associated with living with 
diabetes, were widely used clinically and in research, However, no study had directly 
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compared the scales. With the broader study aim of comparing the scales (Fenwick et 
al., 2016), both scales were included in the Diabetes MILES – Australia survey, in 
alternate versions, and both measures are of relevance to this thesis.   
The Problem Areas In Diabetes (PAID) questionnaire (Polonsky et al., 1995) is 
a 20-item scale, in which respondents rate the extent to which each item, or issue, is 
a problem for them on a five-point scale (0=‘not a problem’ to 4=‘serious problem’). 
Item scores are summed and standardised to a score out of 100, where higher scores 
indicate greater distress and scores ≥40 indicate severe diabetes distress (Snoek et al., 
2011). The PAID was developed through item generation by diabetes healthcare 
providers, focusing on their clinical experience with people living with diabetes 
(Polonsky et al., 1995). Early drafts of the questionnaire were piloted among people 
with diabetes using insulin and a psychometric validation was undertaken on the 
final 20-item version, demonstrating good internal reliability consistency (α=0.95) 
(Polonsky et al., 1995). The PAID has been translated into more than 20 languages, 
each shown to have satisfactory reliability and validity (Polonsky et al., 1995; Snoek, 
Pouwer, Welch, & Polonsky, 2000). Within the Diabetes MILES – Australia 2011 
dataset, all 20 items of the PAID scale loaded well (>0.3) for participants with 
insulin and non-insulin treated T2D, and internal consistency reliability was strong 
(both samples α=0.96). 
  The Diabetes Distress Scale (DDS) is a 17-item scale that was developed in 
response to the reported limitations of the PAID (Polonsky, Fisher, Earles, et al., 
2005). Perceived limitations included a lack of items addressing respondents’ 
feelings about healthcare providers, reported participant confusion over the exact 
meaning of some items, and the inability to differentiate between different types of 
diabetes-related distress (Polonsky, Fisher, Earles, et al., 2005). With these perceived 
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limitations in mind, the DDS was developed through discussion with people with 
diabetes, diabetes healthcare specialists and psychologists. A 50-item pool was 
developed and tested among people with diabetes, resulting in the deletion of items 
that were ambiguous or repetitive. Items were categorised into four distress domains, 
which were decided a-priori based on focus group findings. The final item reduction 
and scale validation resulted in a 17-item questionnaire. Respondents indicate the 
degree to which each item has been a problem for them over the past month on a 6-
point scale (‘not a problem’=1, ‘very serious problem’=6). A composite score is 
derived by summing scores and dividing by the number of completed items. A score 
of  ≥2 is considered indicative of moderate-to-high distress, and ≥3 indicative of high 
distress (Fisher, Hessler, Polonsky, & Mullan, 2012). The DDS also includes four 
subscales: emotional burden (5-items), physician-related distress (4-items), regimen-
related distress (5-items), and diabetes-related interpersonal distress (3-items). 
Satisfactory internal consistency has been shown previously for the DDS total score 
(α=0.93) and the 4 subscales (α=0.88-0.90) (Polonsky, Fisher, Earles, et al., 2005). In 
the current sample of Australian adults with T2D, internal consistency reliability was 
satisfactory for participants who are insulin-treated (total score α=0.94, subscales 
α=0.89-0.91) and among those non-insulin-treated (total score α=0.93, subscales 
α=0.89-0.90).  
1.5.4. General emotional wellbeing  
The presence and severity of depressive and anxiety symptoms was assessed 
using the 9-item Patient Health Questionnaire (PHQ-9) (Kroenke, Spitzer, & 
Williams, 2001) and the 7-item General Anxiety Disorder (GAD-7) questionnaire 
(Spitzer, Kroenke, Williams, & Löwe, 2006). For each measure, respondents rate the 
frequency with which they have experienced symptoms over the past two weeks on a 
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4-point scale (‘not at all’=0 to ‘nearly every day’=3). Item scores are summed to 
form a total score (PHQ-9 range: 0-27; GAD-7 range: 0-21), where higher scores 
reflect greater depressive/anxiety symptoms and a cut-off score of ≥10 indicates 
moderate-to-severe symptoms.   
Psychometric studies have demonstrated both scales to be valid and reliable in 
general population samples (Kroenke et al., 2001; Spitzer et al., 2006). The PHQ-9 
and GAD-7 have both been validated in Australian samples (Carey, Boyes, Noble, 
Waller, & Inder, 2015; Dear et al., 2011; Reddy, Philpot, Ford, & Dunbar, 2010) and 
used with people living with diabetes, (Reddy et al., 2010; Stoop, Spek, Pop, & 
Pouwer, 2011; van Steenbergen-Weijenburg et al., 2010). In the current sample of 
Australian adults with T2D, both scales show good internal consistency, regardless 
of treatment regimen (PHQ-9 α=0.90; GAD-7 α=0.93). While these scales are not 
diagnostic tools, they can be used to identify the presence of depressive and anxiety 
symptoms (with follow-up clinical interview for those screening positively), as the 
scale items reflect the DSM criteria for Major Depression Disorder and General 
Anxiety Disorder (American Psychiatric Association, 2013). The PHQ-9 has also 
shown good psychometric properties against gold standard diagnostic Major 
Depressive Disorder tests (Gilbody, Richards, Brealey, & Hewitt, 2007). However, 
due to the nature of somatic depressive symptomology, the PHQ-9, like other 
depressive symptom questionnaires, may overestimate depressive symptom severity 
in people with T2D due somatic symptom overlap (Reddy et al., 2010). For example, 
changes in sleeping behaviours, energy and appetite, may be symptoms of both 
depression and T2D.  
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1.5.5. Diabetes-specific self-efficacy 
Diabetes-specific self-efficacy was measured using the 8-item Diabetes 
Empowerment Scale – Short Form (DES-SF) (Anderson, Fitzgerald, Gruppen, 
Funnell, & Oh, 2003). The DES-SF was developed through the identification of 
items best representing each of the eight domains of the original scale (Anderson, 
Funnell, Fitzgerald, & Marrero, 2000), i.e. those with the highest item-total 
correlation (Anderson et al., 2003). Respondents indicate the extent to which they 
agree/disagree with each item on a 5-point scale (0=‘strongly disagree’ to 
5=‘strongly agree’). A composite score (range 0-5) is calculated by summing item 
scores and dividing by eight, where higher scores reflect greater diabetes-specific 
self-efficacy. The DES-SF is sensitive to change over time (Anderson et al., 2005), 
and has been shown to be valid and reliable (Anderson et al., 2003). In the current 
sample of Australian adults with T2D, all items loaded on a single scale (>0.30), 
which had satisfactory internal consistency reliability (insulin-treated: α=0.88; non-
insulin-treated: α=0.91). 
1.5.6. Self-management behaviours 
The Diabetes MILES – Australia 2011 survey included a number of 
questionnaires exploring general and specific self-management behaviours. Of 
specific interest to this study were single items from the Diabetes Self Care 
Inventory-Revised (DSCI-R) (unpublished), regarding insulin injections, tablets, diet 
and exercise, the duration of insulin therapy, the number of injections taken per day, 
and the average number of blood glucose checks performed per day over the past two 
weeks and satisfaction with these checks (0=’very dissatisfied’ to 6=’very satisfied’). 
Further to this, participants taking insulin injections were asked questions regarding 
whether they take their required number of injections (1=‘never’ to 5=‘always’), the 
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perceived importance of taking their injections (1=‘not at all’ to 4=‘very’) and the 
burden associated with these injections (1=‘not at all’ to 4=‘a great burden’). The 
calculation of total scores is not recommended and item scores are used 
independently. 
The DSCI-R was selected for inclusion in the 2011 Diabetes MILES – 
Australia survey in preference to previously validated self-care measures (e.g. 
Summary of Diabetes Self-Care Activities measure (Toobert, Hampson, & Glasgow, 
2000)) for several reasons: due to the limitations and lack of responsiveness of other 
measures, due to the DSCI-R’s brevity, its relevance for participants with type 1 
diabetes or T2D and, specifically, for its novel inclusion of importance and 
burdensomeness ratings for each self-care behaviour.  
1.5.7. Socio-demographic and clinical characteristics 
Socio-demographic and clinical characteristics were all self-reported by 
Diabetes MILES – Australia participants. Demographic data included: age; gender; 
relationship status (in relationship/single); employment status 
(employed/unemployed); education level (no formal qualifications, intermediate 
certificate/completed year 10, high school/year 12 completion certificate, 
trade/certificate/diploma, undergraduate university degree, higher university degree); 
and socioeconomic status (imputed based on participants post-code using published 
Socio Economic Index For Area - Index of Relative Socioeconomic Advantage and 
Disadvantage (IRSAD) decile values designated by the Australia Bureau of Statistics 
(Australian Bureau of Statistics, 2011). Clinical data included: diabetes type (type 1 
or type 2); diabetes duration (years); treatment type (insulin injections, insulin pump 
therapy, oral medications, diet and exercise, other: free-text response box); and 
treatment duration (years). After inspecting the ‘other’ free text responses, an 
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additional treatment regimen was included: non-insulin injectables (i.e. glucagon-like 
peptide-1 (GLP-1)). For the purposes of this thesis, treatment type was used to 
categorise and differentiate between participants with T2D who were using insulin 
and those not using insulin. Other clinical characteristics captured were Body Mass 
Index (BMI) (through the self-report of weight (kg) and height (cm)) and the 
presence of diabetes-related complications (including kidney damage, albuminuria, 
retinopathy, neuropathy, heart disease, stroke and vascular disease). Diabetes related-
complications were summed (total possible score = 7) to allow for examination as a 
continuous variable.  
1.6. Recruitment 
Diabetes MILES – Australia survey booklets were posted to 15,000 randomly 
selected NDSS registrants9 with type 1 diabetes or T2D, aged 18-70 years who had 
previously consented to being contacted regarding diabetes research opportunities. 
The NDSS register includes 1.2 million Australians living with diabetes, of whom 
86% have T2D (National Diabetes Services Scheme, 2016). The random sample of 
NDSS registrants contacted for the Diabetes MILES – Australia 2011 survey was 
stratified to ensure significant sub-samples of respondents with type 1 diabetes and 
insulin-treated T2D. Of interest to this thesis, 60% (N=9,000) of the NDSS 
                                               
9The NDSS is an initiative of the Australian Government administered with the 
assistance of Diabetes Australia. Registration enables people with diabetes to access 
subsidised products (e.g. blood glucose test strips, insulin pump consumables) and 
support services (e.g. structured education programs, telephone helpline). For a 
person to become registered with the NDSS, an accredited HCP must authorise a 
registration form on behalf of the person with diabetes, providing the individual’s 
contact details, date of birth, diabetes type and treatment, as well as whether they 
consent to receiving information about future research studies. Over time, personal 
and medication information should be updated to ensure subsidised access to 
relevant products and services.  
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registrants sampled had T2D and half of these were registered as using insulin to 
manage their condition.  
In addition to the postal survey, the survey was also made available online and 
advertised nationally. Advertisements for the online study were promoted by 
Diabetes Australia and its associated state/territory member organisations via e-
newsletters, websites and social media sites, as well as national, state and local e-
newsletters administered by diabetes consumer groups (e.g. Type 1 Network), HCPs 
and community health (e.g. Primary Health Bulletin), and diabetes 
pharmaceutical/device companies (e.g. Medtronic, Sanofi).  
1.7. Procedure and survey 
In addition to the survey, the postal and online survey versions both included a 
plain language statement form (see Appendix D) and a contact details form. The 
contact details form provided participants with the opportunity to enter a prize draw 
and/or be contacted for participation in future research. The completion of this form 
was separate from the survey and was not linked to survey data. The hard copy 
differed from the online survey in that it also included a reply paid envelope for 
survey return. 
In order to maximize the relevance of questions for particular subgroups and 
minimize respondent burden, six versions of the Diabetes MILES – Australia survey 
were developed (Speight et al., 2012). The surveys were categorised as specific to: 
type 1 diabetes, T2D using insulin, or T2D non-insulin. For each of these three 
participant groups, two survey versions (A/B) were developed (see below). NDSS 
registrants, who received a hard copy survey invitation, received a survey booklet 
matched to their recorded diabetes diagnosis and treatment (type 1 diabetes, T2D 
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using insulin, or T2D non-insulin). The appropriate survey version was allocated to 
online participants after they self-reported diabetes type and treatment.  
All surveys included core measures and demographics, as well as questions 
specific to respondents’ diabetes type. In addition, questionnaires of secondary 
interest were included in either version A or B, to reduce overall respondent burden. 
Each of the survey versions was piloted with 20 Victorian adults (12 participants 
with type 1 diabetes and eight with T2D) followed by a cognitive debriefing 
interview to explore the relevance and suitability of content for the broader study 
population (Speight et al., 2012).  
Several questionnaires of relevance to the current thesis were included in 
opposing A/B survey versions, or in a limited number of survey versions (see Table 
1). Of particular relevance, the ITAS was included in opposing A/B versions: survey 
version A for those with non-insulin-treated T2D and survey version B for those with 
insulin-treated T2D. The inclusion of the ITAS in opposing A/B versions means that 
questionnaires of secondary interest to this thesis may not be available for both 
subsamples of interest in this thesis (adults with insulin-treated or non-insulin-treated 
T2D). For example, two measures of diabetes-related distress were used (see 1.5.3), 
with the DDS included in survey version A and the PAID included in survey version 
B. The BMQ General and Specific were included only in survey version A. A 
complete list of the questionnaires included in each Diabetes MILES – Australia 
survey version has been published elsewhere (Speight et al., 2012). 
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Table 1  
Inclusion of questionnaires of interest in T2D survey versions  
Measure/variable 
T2D participant group (survey version) 
Insulin     
(A) 
Insulin     
(B) 
Non-
insulin 
(A) 
Non-
insulin 
(B) 
Insulin treatment appraisals: ITAS  X X  
Beliefs about medications: BMQ 
General  
X  X  
Beliefs about medications: BMQ 
Specific 
X  X  
Diabetes distress: PAID  X  X 
Diabetes distress: DDS X  X  
Depressive symptoms: PHQ-9 X X X X 
Anxiety symptoms: GAD-7 X X X X 
Diabetes-specific self-efficacy: 
DES-SF 
 X  X 
Self-management (study-specific 
items) 
X X X X 
Demographics (study-specific 
items) 
X X X X 
ITAS: Insulin Treatment Appraisals Scale (Snoek et al., 2007); BMQ: Beliefs about 
Medications Questionnaire (Horne et al., 1999); PAID: Problem Areas in Diabetes 
(Polonsky et al., 1995); DDS: Diabetes Distress Scale (Polonsky, Fisher, Earles, et 
al., 2005); PHQ-9: Patient Health Questionnaire (Kroenke et al., 2001); GAD-7: 
General Anxiety Disorder (Spitzer et al., 2006); DES-SF: Diabetes Empowerment 
Scale – Short Form (Anderson et al., 2003). 
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1.8. Response rate 
Data collection took place over two months, starting from 1st July 2011. In 
total, 3,833 people responded to Diabetes MILES – Australia 2011. One quarter 
(N=987) of the surveys were completed online, including 220 participants who 
indicated that they had received the postal survey but instead opted to complete the 
survey online. A further 2,095 participants returned hard copy surveys. Thus, 2,351 
invited NDSS registrants completed the survey, which equates to a 17% response 
rate. After adjusting for the 541 surveys returned to sender, the final response rate 
was 18% (Speight et al., 2012).  
1.9. Data entry, cleaning and analysis 
Upon receipt, completed surveys were de-identified and forwarded to a 
contract research organisation (CRO) for survey scanning and data entry. The data 
were then merged with the online survey data by the CRO. The CRO supplied a 
spreadsheet including all data (online and print survey), as well as scanned images of 
all hard copy surveys.  
The data were transferred to Statistical Package for Social Sciences (SPSS) 
version 17.0 for data cleaning. Cleaning of the full Diabetes MILES – Australia 2011 
dataset was co-performed by this PhD candidate and research fellow, Dr Jessica 
Browne. This included: 
 confirmation of participants’ eligibility requirements; the data of 495 
respondents were removed due to ineligibility (i.e. did not have type 1 
diabetes or T2D, age outside the specified range, or self-reported that they 
completed the survey with assistance from others) 
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 validation of diabetes type and treatment against survey version and reported 
self-management characteristics 
 inspection of hard copy surveys where the CRO was unable to decipher 
participant responses 
 review and coding of qualitative responses  
 missing data inspection and imputation, as appropriate, and computation of 
total or subscale scores to create a usable database for collaborative work 
going forward.  
Data cleaning and analysis specific to the current studies was undertaken solely 
by this PhD candidate. Analysis of the Diabetes MILES–Australia dataset was driven 
by three overarching research questions (Chapter 3) and are presented as three 
empirical studies (Study 1a, 1b and 1c). These details can be found in relevant 
Chapters (4, 5 and 8).   
2. Stepping Up Study  
2.1. Background  
The ‘Stepping Up’ study is a multidisciplinary research study, led by Professor 
John Furler (University of Melbourne), which trialled an intervention to facilitate 
insulin initiation in primary care for adults with non-insulin-treated T2D. The trial 
protocol was registered on the Australian and New Zealand Clinical trials registry 
(ACTRN12612001028897) and has been published elsewhere (co-authored by this 
PhD candidate) (Furler et al., 2014).  
     383 
2.2. Ethics approval 
The Stepping Up study obtained ethics approval from the University of 
Melbourne Human Research Ethics Committee (HREC 1237406). In addition, the 
Deakin University Human Research Ethics Committee provided ethics approval for 
the PhD candidate’s involvement within the study (2012-180).  
2.3. Research design  
Stepping Up is a two-armed, 12-month cluster randomised controlled trial 
testing a new model of care, compared to usual care, to facilitate timely and 
evidence-based initiation and up-titration of insulin in primary care for eligible adults 
with non-insulin-treated T2D. While the main unit of analysis was the individual 
with T2D, the complex nature of intervention (and potential for contamination) lent 
itself to cluster-randomisation at the practice-level. The Stepping Up intervention 
involves two key elements: a) supportive education for the general practitioner (GP) 
and practice nurse (PN), addressing inter-professional culture and clarifying roles 
and; b) practice systems change, tailored to meet the local practice and funding 
context and the needs of patients. The control arm practices were requested to 
provide usual care. Survey data were collected at baseline and at 12-month follow-up 
from participants (patients and health care professionals) and biomedical data were 
collected from all participants with T2D.  
The primary outcome of Stepping Up was change in HbA1c at 12 months. The 
results of the primary analysis have been presented elsewhere (co-authored by this 
PhD candidate) (Furler et al., 2015; Furler et al., 2014). The primary outcomes for 
the purposes of this thesis were: a) hypothetical willingness to begin insulin 
(assessed at baseline), b) attitudes towards insulin therapy (at baseline and at 12 
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months), and c) the proportion of participants who were using insulin therapy (at the 
conclusion of the 12-month study).  
2.4. Participants 
Eligible Victorian primary care practices were those employing at least one 
consenting GP and one PN, and were able to identify at least one eligible patient with 
T2D. Patient eligibility requirements include: aged 18 to 80 years; diagnosed with 
T2D; non-insulin using; taking maximum oral hypoglycaemic agents; stability of 
current treatment for at least 3 months prior to enrolment; willingness to monitor 
blood glucose at least twice daily; and HbA1c ≥7.5% (58mmol/mol) in the past 6 
months. In addition, a current HbA1c was assessed at baseline for all potential 
participants to confirm their eligibility for the study. Potential participants were 
excluded if they had previously used insulin, did not speak English or had any 
current physical or psychiatric condition that could impair their ability to inject 
insulin or monitor their blood glucose.  
Sample size calculations, detailed elsewhere (Furler et al., 2014), were 
undertaken by the study statistician based on the Stepping Up study primary 
outcome: change in HbA1c. A minimum of 224 participants (an average of three 
participants per practice) from 74 general practices was required. The final sample 
consisted of 266 patients with T2D from 74 Victorian clinics. Clinics from metro, 
regional and rural areas of Victoria were represented, but the majority were located 
in major cities (64%). 162 GPs and 103 PNs took part and the median (IQR) number 
participating per clinic were 5 (4,9), and 2 (1,4), respectively. On average, the mean 
(SD) age of GPs was 49 (11) years, 62% (n=101) were male, and they had a median 
(IQR) of 20 (8,30) years clinical experience. All PNs were women with a mean (SD) 
age of 45 (10) years and median. The majority of participants with T2D were men 
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(n=163, 61%), with a mean (SD) age of 62 (10) years and a median diabetes duration 
of 8.5 (5,13) years. This thesis focuses primarily on the data collected from 
participants with diabetes. 
2.5. Measures 
The Stepping Up study included a number of measures for each participant 
group, involving practice surveys, GP and PN surveys, and T2D participant surveys, 
as well as the collection of biomedical data.  
Of relevance to this thesis were data collected from participants with T2D, at 
several timepoints in the trial. At baseline, the following data was collected from 
patient participant screening questionnaires and medical records: demographics 
(including: age; gender; country of birth; primary language; residential postcode), 
clinical data and medical history (including: BMI; diabetes duration; number of co-
morbid conditions (Barnett et al., 2012); and current medications prescribed). 
Participants were also asked to report their frequency of blood glucose self-
monitoring per day. In addition to the baseline assessment, HbA1c was assessed at 6 
and 12 months follow-up. All HbA1c was assessed at DCCT-aligned10 pathology 
laboratories and communicated to clinicians and patients as part of routine clinical 
care; the data were retrieved from the clinic records or, with permissions in place, 
directly from pathology laboratory records.  
Participants received a survey booklet for completion at baseline and at 12 
months. The survey booklet included a number of scales relevant to the broader 
objectives of the Stepping Up study but not relevant to this thesis. Measures of 
                                               
10Pathology laboratories conduct DCCT-aligned HbA1c so that assays are 
standardised and an individual’s risk of complications can be inferred from the 
result. 
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relevance to the current study, and already described in Appendix C (Section 1.5), 
include: the ITAS (Snoek et al., 2007), PHQ-9 (Kroenke et al., 2001), and PAID 
(Polonsky et al., 1995). In addition, the following relevant measures are described 
below: the Medication Adherence Rating Scale (MARS) (Horne & Weinman, 1999), 
and single items assessing willingness to initiate insulin and attitudes towards insulin 
(Polonsky, 2007). 
2.5.1. Medication Adherence Rating Scale 
Medication-taking behaviour was assessed using the 6-item Medication 
Adherence Report Scale (MARS) (Horne & Weinman, 1999). Each item refers to a 
parameter relating to suboptimal medication-taking behaviour, and participants 
indicate the frequency with which they behaved accordingly on a 5-point scale (1 
‘always’, 2 ‘often’, 3 ‘sometimes’, 4 ‘rarely’, 5 ‘never’). The scale was designed to 
be specific to particular medical conditions with minimal modification (Horne & 
Weinman, 1999). Thus, with the developer’s permission, was adapted to refer to 
diabetes-specific medications. A total score (from 6 to 30) is calculated by summing 
all 6 item scores, with higher scores indicating more optimal medication-taking 
behaviours.   
The MARS was developed by Horne and colleagues in response to the 
limitations of other self-report measures, which may overestimate medication-taking 
behaviours through self-presentational and recall biases (Horne & Weinman, 1999). 
The MARS does not ask participants to recall the exact number of days on which, or 
the time each day at which, they took their medications. Further, the design of the 
MARS attempts to normalise sub-optimal medication-taking behaviours by stating 
that the list of behaviours included “are some ways in which other people have said 
they use their diabetes medicines”, thus promoting a honest, rather than socially 
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desirable, response. The MARS has been used in samples of people with various 
conditions, including diabetes (Barnes, Moss-Morris, & Kaufusi, 2004).  In the 
Stepping Up sample, the MARS had good internal consistency reliability (α=.86).  
2.5.2. Willingness to begin insulin  
‘Hypothetical willingness’ to begin insulin therapy has been assessed to date 
using a single item to identify the proportion of people with T2D who are unwilling 
or willing to begin insulin therapy (Larkin et al., 2008; Nur Azmiah, Zulkarnain, & 
Tahir, 2011; Polonsky, Fisher, Guzman, Villa-Caballero, & Edelman, 2005; 
Polonsky, Hajos, Dain, & Snoek, 2011; Wong et al., 2011; Woudenberg, Lucas, 
Latour, & Scholte op Reimer, 2012). This question asks individuals to indicate their 
willingness (very, moderately, not very, not at all) to begin insulin if it was 
recommended by their HCP. This item has been scored inconsistently across prior 
research, including the use of all four categories or recoding to dichotomous or 
trichotomous variables using various cut points (Polonsky, Fisher, Guzman, et al., 
2005; Polonsky et al., 2011). Given previous scoring inconsistencies, this thesis uses 
the original response options.  
2.5.3. Attitudes toward insulin 
Two measures of attitudes toward insulin were included to enable greater 
comparability of the insulin appraisals of the current sample to national samples 
(Chapter 4) and international samples (Larkin et al., 2008; Polonsky et al., 2011; 
Snoek et al., 2007; Woudenberg et al., 2012). In addition to the ITAS, described in 
Appendix C Section 1.5 (Snoek et al., 2007), a single question tool was used which 
asks respondents to identify two out of six statements that best match how they feel 
about the possibility of starting insulin (Polonsky et al., 2011). Half of these 
statements are positively worded (‘help to feel better’, ‘opportunity to have better 
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control’ and ‘logical next step in treatment’); and half are negatively worded 
(‘feeling of personal failure’, ‘fear linked to injections’, and ‘feeling that the disease 
is getting worse’). The number of positive and negative endorsements for each 
participant was summed to provide a 3-point score, where 0=no negative 
attitudes/two positive attitudes, 1=one positive and one negative attitude, 2=two 
negative attitudes/no positive attitudes). 
2.6. Recruitment 
Potential clinics were identified through direct contact and promotion via 
professional organisations (e.g. RACGP), University of Melbourne Department of 
General Practice database (the VicREN practice-based Research Network), through 
Medicare Locals,11 and through ‘snowballing’ from key clinicians identified as 
opinion leaders. Recruitment of patient participants began after clinic randomisation, 
stratified by practice size and type.  
Potentially eligible patients with T2D were identified through each practice’s 
electronic medical records database. Upon identification, patients received a letter 
from the clinic inviting them to participate and a follow up telephone call from the 
GP and/or PN. The invitation letter stated that participants might benefit from 
assessment and intensification of diabetes treatment, which may involve insulin 
injection therapy. The invitation letter, plain language form and consent forms are 
provided in Appendix D. 
                                               
11Medicare Locals were primary health care organisations established to coordinate 
primary health care delivery. They were a key feature of the Australian 
Government’s National Health Reform. From July 2015, they were replaced with 
Primary Health Networks. 
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Recruitment of clinics and patients took place between October 2012 and 
January 2014 and was led by the University of Melbourne Stepping Up study team. 
Each participant was enrolled in the Stepping Up study for 12 months. 
2.7. Procedure and intervention 
The study protocol has been published elsewhere (Furler et al., 2014). Provided 
here is a brief description of the intervention, with emphasis on particular aspects 
considered relevant to this thesis. 
  Practices randomised to the intervention group received 1-2 hours training, 
and an accompanying educational booklet, delivered by the study team during a 
practice visit. The training included evidence for timely insulin initiation, common 
barriers to insulin initiation within primary care and how to deal with them, and 
familiarisation with insulin delivery systems and insulin titration tools. Of specific 
relevance to this thesis, the training included a brief outline of motivational 
interviewing and a list of eight common concerns about insulin therapy among 
people with T2D and how to respond to them. Participants received ‘Patient Packs’ 
including information and fact sheets about insulin therapy as well as a diary and 
phone record book for use in dose adjustment consultations. Practices were 
supported by practice visits, telephone and email contact from the study Diabetes 
Nurse Educator (DNE) as required during the 12-month follow-up period. 
Management options included referral to an endocrinologist, DNE or other HCP, if 
required.  
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Control arm practices were provided with a copy of the latest guidelines for the 
management of T2D (The Royal Australian College of General Practitioners and 
Diabetes Australia, 2014) and offered training in the Stepping Up model of care once 
the 12-month follow-up was completed. During the trial, control practices were 
asked to undertake clinical review of their eligible participating patients, as part of 
ongoing usual clinical care. 
Following recruitment and baseline data collection, participants in the 
intervention arm were invited to attend their GP for a diabetes assessment. The GP 
discussed possible treatment intensification, recommended and prescribed insulin 
therapy commencement, and referred the participant to the PN. Immediately 
following this, the participant saw the PN for an insulin initiation assessment, during 
which time the PN worked through the patient pack with the participant. At this time, 
if the patient was agreeable, the PN gave the participant their first insulin injection. 
The Stepping Up study DNE attended the clinic to support the PN for the first 
participant at each intervention clinic. If insulin was initiated, the participants were 
asked to telephone the PN every three days to discuss blood glucose levels and adjust 
insulin dose and, after four weeks, attend an appointment for a clinical review. The 
role of the GP was to initiate and prescribe insulin, while the insulin adjustment was 
led primarily by PN and participating patient in discussion with the GP as necessary. 
If participants did not commence insulin at the first GP/PN visit, they continued to 
see the PN and GP as clinically appropriate with the aim of commencing insulin. 
GPs and PNs saw participants on as many occasions as was clinically necessary over 
the 12-month period. 
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2.8. Response and attrition rate 
The recruitment period (from first to last practice/patient enrolment) took 16 
months, during which 93 practices expressed interest in participation and identified 
521 potentially eligible patients with T2D. After exclusion of non-responding 
potential participants with T2D (n=99) and those found to be ineligible at screening 
(n=156), the final eligible participating Stepping Up sample included 266 adults with 
T2D (51% of the potential population) across 74 practices. Of the total sample, 248 
(93%) completed 12-month follow-up for the primary endpoint (HbA1c). As 
reported elsewhere (Furler et al., 2015), there were no differences in baseline 
characteristics observed between study completers and non-completers, except for 
gender, where women were more likely to be non-completers than men (n=11, 11% 
and n=7, 4%, respectively). 
2.9. Data entry, cleaning and analysis 
The completed demographic, baseline and follow-up questionnaires were 
checked for completeness before being scanned and processed by a CRO. Clinical 
data (e.g. HbA1c, medications and co-morbid conditions) were extracted from clinic 
records and entered by study research assistants. Pathology data were extracted, as 
required, by the study pathology provider. All data were uploaded into Stata 12 for 
further cleaning led by Dr Jo-Anne Manksi-Nankervis (project manager), with 
advice from the Stepping Up data management team (including this PhD candidate). 
Syntax was written to enable ongoing automated assessment of missing data and 
questionnaire scoring, following monthly update of databases by the CRO. The PhD 
candidate advised on the scoring (Appendix C, Section 2.5) and data management 
expectations, and reviewed the relevant syntax, for all questionnaires and 
measurements included in the current study. 
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Upon baseline and follow up database closure the PhD candidate exported the 
patient de-identified data into SPSS version 22. The raw and scored data were then 
reviewed, missing data identified and scale scores re-calculated to ensure accuracy. 
Using baseline and 12-month data, the PhD candidate created change scores for the 
ITAS.  
Analysis of the Stepping Up baseline and follow up datasets was driven by two 
overarching research questions (Chapter 3) and are presented as two empirical 
studies (Study 2a and 2b). Data cleaning and statistical analysis undertaken for each 
study are detailed in Chapters 6 and 7 respectively.   
3. Qualitative Study of Insulin Appraisals among Adults with Insulin-
Treated Type 2 Diabetes 
3.1. Background  
A qualitative interview study was conducted with the broad aim of eliciting an 
in-depth narrative of the experience of diabetes and treatment progression among 
people with T2D using insulin therapy, from diagnosis to present day. This thesis 
examines a subset of the collected data with reference to the lived experience of 
adults with T2D already using insulin, including perceived consequences of insulin 
use and attitudes towards future insulin intensification (e.g. additional insulin 
injections). 
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3.2. Ethics approval  
The qualitative study received ethics approval from the Deakin University 
Human Research Ethics Committee (ref number: 2013-048). 
3.3. Research design 
A semi-structured face-to-face interview study was conducted. A semi-
structured approach was used to ensure interviews included discussion of the 
predefined objective or study focus, while allowing participants to express 
themselves freely “to offer new meaning to the study focus” (Galetta, 2013).  
3.4. Participants 
Eligible participants included English-speaking Australian adults (18+ years of 
age) with T2D who had been using insulin therapy for no more than three years. 
They needed to be able to attend a face-to-face interview in Melbourne or in Geelong 
(Victoria). The participant group is detailed in Chapter 9.  
3.5. Materials 
The semi-structured interview schedule was developed by the PhD candidate, 
in conjunction with the primary supervisor. The schedule was designed to elicit a 
narrative from participants about their lived experience of diabetes and attitudes to 
treatment intensification, and was informed by existing literature (Gherman et al., 
2011; Snoek et al., 2007; Wang & Yeh, 2012). The schedule included a series of 
open-ended questions regarding the participant’s experiences and feelings at various 
stages or their diabetes duration, ordered by approximate chronological timing from 
diagnosis, to insulin initiation, to current day. A series of follow-up questions or 
prompts were developed to obtain further details following the main questions if the 
interviewee had not elaborated sufficiently. In addition to the interview questions, 
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the interviewer (this PhD candidate) read aloud items from the Insulin Treatment 
Appraisal Scale (ITAS) (Snoek et al., 2007) and interviewees were asked to reflect 
on whether each item was true for them now or in the past. The ITAS was not 
scored, but rather individual items were used to prompt discussion of concerns and 
perceived benefits of insulin therapy prior to initiation and the extent to which these 
concerns were alleviated or persisted. The tool was introduced mid-interview, after 
participants were given the opportunity to freely express (unprompted) specific 
barriers and benefits to going on to insulin. The focus of this thesis is the experience 
of insulin use and attitudes towards insulin intensification. Table 2 presents the 
questions from the interview schedule that are most relevant to the current study.  
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Table 2  
Interview schedule topics and questions of relevance to this thesis 
Topic Interview questions 
Experience of insulin 
initiation 
1) How long after being recommended insulin did you 
begin using insulin?  
2) What was it like the first time you/your GP/nurse 
injected insulin? 
3) How did you feel about using insulin to manage your 
diabetes, at first?   
4) What did your family and friends think about the idea of 
you using insulin? 
Satisfaction with and 
consequences of 
insulin therapy use 
1) Now that you’ve been using insulin for X years/months, 
how do you feel about using insulin to manage your 
diabetes? 
2) Do you feel insulin has made any difference to:  
a) your diabetes outcomes overall? 
b) how you manage your diabetes? (e.g. lifestyle 
changes, glucose monitoring)  
c) how you feel? (e.g. more/less energy?) 
3) Compared to before insulin therapy, are you more or 
less satisfied with your diabetes management now?  
4) For you, what is/are the greatest benefit(s) of using 
insulin? 
5) Are there any negative aspects of using insulin?  
a) How do these negative aspects of insulin use make 
you feel? 
b) Do these negative aspects interfere with your ability 
to manage your diabetes? 
6) Do these negative aspects interfere with any other 
aspects of your life? 
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Topic Interview questions 
Insulin taking 
behaviours 
1) Some people with diabetes miss an insulin injection or 
change their dosage of insulin. Do you ever miss or skip 
an insulin injection?  
a) How often do you miss injections? What are your 
reasons for missing a dose? 
2) Do you ever take a reduced dose of insulin? 
a) How often do you reduce your insulin dose? What 
are your reasons for reducing your dose? 
Insulin treatment 
intensification 
1) How many injections do you take each day?  
2) Has this changed over time, if so how have you felt 
about this change? 
3) How do you think you would feel if you needed to take 
more injections each day? 
 
 
Each participant also completed a one-page demographics questionnaire (see 
Appendix E). Questions included gender, age, country of birth, primary language, 
education level, employment status, diabetes duration, insulin treatment duration, 
and HbA1c (%).  
3.6. Recruitment 
Participants were recruited through volunteer sampling using study 
advertisements placed on the Diabetes Victoria and The Australian Centre for 
Behavioural Research in Diabetes (ACBRD) websites, social media sites (Twitter, 
Facebook) and e-newsletters from June 2013 to February 2014. The study 
flyer/advertisement promoted the study as an interview study “to understand how 
people with T2D think about managing their diabetes and cope with beginning new 
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and more advanced treatments”. The flyer invited participants to attend a one-hour 
interview in Melbourne or Geelong, indicating that participants would receive a $20 
gift voucher as a token of appreciation for their participation. Interested potential 
participants were invited to contact the research team by phone or email to obtain 
detailed information about the study and confirm eligibility. 
 Purposive sampling was used with the aim of achieving an approximately 
equal gender split and a broad range of ages. The aim was to interview a minimum of 
20 participants with the possibility of conducting further interviews, if necessary, to 
achieve data saturation. Guidelines for qualitative research propose minimum sample 
sizes from as few as five to hundreds of participants depending on the theoretical 
framework underpinning the research, the research topic, the objective of the study 
(i.e. is it a comparative study), as well as the homogeneity of the sample (Guest, 
Bunce, & Johnson, 2006). Despite inconsistent sample size recommendations, 
guidelines consistently recommend that data saturation be reached. This can be 
demonstrated through a lack of new insights on the research topic emerging in later 
interviews, and therefore the collection of additional data, through increased sample 
size, would not provide novel data on the topic of interest.  
Overall, 52 participants enquired about the study: 20 were ineligible (e.g. not 
insulin-treated or using insulin for more than 4 years), 12 declined the invitation or 
made no further contact after receiving study information, and 20 proceeded to 
interview. Due to an over-representative initial response from male participants, 
more men than women took part in the study overall, and in order to achieve a 
reasonable data-split, men were excluded from taking part from September 2013.   
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3.7. Procedure 
Upon contacting the PhD candidate, via phone or email, potential participants 
were asked to provide their first name, contact details, diabetes type, treatment and 
treatment duration, age, gender, and preferred interview location for screening 
purposes. These data were stored separately from participant interview recordings 
and transcripts. Eligible participants were sent a plain language statement (PLS) and 
consent form (Appendix D) via email or post, according to their preference. Eligible 
participants were asked to read the PLS and contact the PhD candidate if they wished 
to proceed with an interview or had any further questions. An appointment time was 
made at a convenient time to the participant.  
All interviews were undertaken in a meeting room in a non-clinical setting 
(Deakin University or Diabetes Victoria) between June 2013 and February 2014. 
Interviews lasted on average 42 minutes (range: 20-69 minutes). Upon consent, the 
interviews commenced and were audio-recorded for transcription and analysis. 
Immediately following the interview, participants were asked to complete the 
demographic questionnaire and were provided with a $20 department store gift 
voucher. 
3.8. Data Entry 
On completion of the interviews, the first 10% (n=2) were transcribed 
verbatim by the PhD candidate. The remaining 90% (n=18), the audio-files were sent 
to a professional and confidential transcribing company where they were transcribed 
verbatim. All transcripts were then checked against the audio recording by the PhD 
candidate and loaded into QSR NVivo Version 10, a qualitative data analysis 
software package.  
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3.9. Data Analysis  
 Inductive thematic analysis was undertaken to identify themes relevant to the 
general aim of the current study. Thematic analysis is a broad and flexible method 
used to identify, analyse, interpret and report patterns stemming from the original 
data (Braun & Clarke, 2006). Thematic analyses may be undertaken from a 
theoretical or inductive context. Inductive analysis refers to the analysis of themes 
being driven by the data rather than by a priori hypotheses, theory, or an existing 
coding framework (Braun & Clarke, 2006). A non-linear iterative process informed 
by Braun and Clarke’s (2006) six-phase process for undertaking thematic analysis 
was used to guide analysis. The PhD candidate (EHT), primary supervisor (JS) and 
another health psychology researcher with experience in diabetes and qualitative 
research (co-author JB), were all involved in analysis, enabling reflective analysis 
involving multiple revisions of the coding framework, double coding a portion of 
transcripts and checking for inter-coder agreement, and broad theme agreement 
amongst the team.  
EHT read and re-read all transcripts, meanwhile generating initial data codes 
and categories from a subset of transcripts. The coding framework, along with 
coding definitions and rules, were reviewed by the full authorship team, and minor 
iterative revisions were made. Following this, EHT and JB independently coded two 
transcripts, and collaboratively reviewed their coding decisions and reflected upon 
when and how the coding framework was and was not adequate. Upon revising the 
framework so that it better reflected the data, EHT and JB then independently coded 
five transcripts using the revised coding framework. Inter-coder agreement for each 
code was assessed by summing the percentage of content in each code identified by 
both coders. A mean agreement rating (average percentage across codes) of 99.5% 
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was reached, indicating a high level of consistency in coding. The remaining 
transcripts were coded by EHT.  
The data analysis was undertaken for the entire dataset generated by the 
interviews (not reported here). The final stage of thematic analysis was guided by the 
specific research questions of Study 3 (Chapter 3), and is described in Chapter 9.  
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Appendix E: Interview Study Demographics Questionnaire 
ABOUT YOU 
Below are some questions about you. Answering these questions will help us understand a little 
more about who took part in the interviews.  
1. What is your age?  __ __ __ __ 2. Are you:    Male  Female 
3. What is your postcode? __ __ __ __     
4. In which country were you born?   Australia  Other: ______________           
4a. If other, in what year did you first arrive in Australia to live here?  __ __ __ __  
5. What is the main language you speak at home?    English    Other:___________
6. How old were you when your type 2 diabetes was diagnosed?     __ __ years old
7. How do you treat your diabetes currently and how long have you been using this 
treatment? 
 Insulin injections   __ __ years
 Blood glucose-lowering tablets  __ __ years
 Diet & physical activity (lifestyle changes)  __ __ years
 Complementary and alternative medicines  __ __ years
 Other:   _________________________  __ __ years
8. What was your HbA1c the last time it was checked?   ________ % 
9. What is the highest qualification you have completed? 
 No formal qualifications 
 Primary school or intermediate       
certificate  
 High school or leaving certificate 
 Trade / apprenticeship
     (e.g. hairdresser, chef) 
        Certificate / diploma 
 University degree 
 Higher University degree 
     (e.g. Grad Dip, PhD) 
10. Which of the following best describes your current employment?
 Full time work 
 Part time work  
 Retired 
 Not working for another reason: 
______________ 
THANK YOU FOR TAKING PART IN THIS STUDY 
 
